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SUMMARY 
Background: Current literature reports the frequent co-occurrence of psychiatric disorders (PDs) in adults 
with Intellectual and Developmental Disorders (IDD), such as Intellectual Disability (ID) and Low-
Functioning Autism Spectrum Disorder (LF-ASD). Unfortunately, the adaptations of diagnostic criteria for 
PDs as well as the standardization of the psychiatric diagnostic process in this population still represent an 
unmet need, with relevant implications for both the management of mental health issues and the research in 
this field. In fact, the assessment of PDs in people with IDD requires appropriate modifications in respect to 
the general population, to adjust for cognitive dysfunctions, language and communication limitations, sensory 
impairments, skill deficits, impairment of adaptive behavior, and physical disabilities. Moreover, research and 
clinical experience highlight the interpretation of problem behaviors (PBs) to interfere with the psychiatric 
diagnostic process. Among PDs, depressive and bipolar disorders (DDs and BDs, respectively), seem to be 
very common and associated to a variety of behavioral, medical and treatment issues in these populations. 
Indeed, the prevalence rates of DDs and BDs in large ID population-based studies are estimated to be about 
5% and 2.5%, respectively. The prevalence rates are at least doubled in the overall ASD population and even 
higher rates can be found in clinical studies. These data indicate the co-occurrence of mood disorders (MDs) 
in intellectually disabled persons to be a relevant clinical issue, but some difficulties may arise as far as a 
certain number of patients, mostly those with lower cognitive and adaptive functioning, have atypical 
presentations. To implement the validity of clinical diagnosis and in order to operationalize the adaptations 
and descriptions of MDs in ID, the design and experimentation of specifically addressed assessing tools is 
required.  
Aim: The main objective of the present study was to develop and to validate the version for DDs and BDs of 
the Systematic Psychopathological Assessment for persons with Intellectual and Developmental Disabilities 
(SPAIDD-M). Secondary aims of the present study were the investigation of the prevalence and clinical 
features of MDs in people with ID and LF-ASD, including demographic, anamnestic, familial, and clinical 
variables as well as the course and clinical specificities of MDs in this population. 
Method: 233 adults with ID and with an eventual co-occurrence of ASD, aged 16-65 years, were recruited 
among those attending the residential and clinic-rehabilitative facilities of the San Sebastiano Foundation in 
Florence and of the wide network of the Research and Clinical Center (CREA). The sample underwent a 
complex anamnestic evaluation implying the collection of demographics, psychosocial, familial, medical and 
psychiatric information via a semi-structured interview developed ad hoc. The SPAIDD-M 1.2 was completed 
for all the participants. For the evaluation of concurrent validity, 197 participants (85.3%) were administered 
with the Diagnostic Assessment for the Severely Handicapped (DASH-II), and 141 (68.4%) were assessed 
with DSM-5 criteria for Major Depressive Episode, Mania and Hypomania, adapted according to the definition 
of DM-ID-2. Mixed features of major depressive episode (MDE) and (hypo)manic episode were evaluated in 
110 probands. The overall sample was stratified based on ID severity as described by the following three 
groups: 1. Borderline intellectual functioning (BIF) and mild ID; 2. Moderate ID; 3. Severe and profound ID. 
The test-retest reliability was evaluated in reference to three study participants (one for each ID level) through 
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the administration of the tool to the same informants at baseline and after two-to-three months. The inter-rater 
reliability was evaluated through a special session which included eight different professionals rating for the 
same study participant. χ² for categorical variables, ANOVA and F-variance for continuous variables tests 
were used for comparisons between groups. The psychometric properties evaluated were: internal consistency, 
inter-rater reliability, face validity, criterion validity, test-retest reliability, concurrent validity. To explain the 
variance, a factorial analysis was performed. For other clinical variables, stepwise backward procedure logistic 
regression models were elaborated. 
Results: SPAIDD-M 1.2 showed good psychometric properties. The face validity, which underwent two 
revisions, resulted to be comprehensible for most evaluators. Some difficulties remained about the completion 
of the items relative to mixed features. The internal consistency was very good, with a Cronbach’s  of .937, 
as well as an acceptable inter-rater reliability expressed by a Cohen’s K coefficient ranging from .870 to .575. 
Criterion validity was also good for both the major depressive and the (hypo)manic episodes. The concurrent 
validity was found to be high with moderate correlations between SPAIDD-M and DASH-II scores, and strong 
correlations between SPAIDD-M and DSM-5 diagnoses. A factor analysis identified four main factors 
explaining about the 38% of the score variance. The sample was very homogeneous regarding all the 
demographic, socio-economic, familial, medical and psychiatric variables explored. The comparisons of the 
psychiatric diagnoses indicated the rates of MDs to be equally distributed across the three ID groups, whereas 
this homogeneity was not evident before the assessment provided in the study protocol. Indeed, before the 
study, the severe/profound group had been correctly diagnosed only in the half of the cases as well as other 
participants in the other groups had to be diagnostically reviewed. In our sample, MDs were associated to a 
higher number of mental health issues in the personal and family history as well as a higher use of 
psychotropics. LF-ASD resulted to be at higher risk for MDs, mostly BD type I, and the affective illness was 
more frequently associated to catatonia, mixed features and rapid cycling. The analyses of differences between 
DDs and BDs as presented in ID did not identify any statistically significant feature, and both clinical 
conditions resulted to be equally associated to high rates of psychotic, catatonic and mixed symptoms in a 
more frequent way than it is reported in the general population. The diagnosis of BD was associated to a 
complex pattern of comorbidities including ADHD, impulse control disorders, binge eating and the presence 
of a familial psychiatric burden. By the contrary, DDs were associated to anxiety disorders and family history 
of ASD. 
Limitations of the study: Sample size, selection, referral and recall biases. Concerns regarding the use of 
behavioral equivalence. Difficulties in the differential diagnosis with other psychiatric and iatrogenic 
conditions beyond DDs and BDs. 
Conclusions: The study provides preliminary information regarding the psychometric properties and the 
effectiveness of specifically addressed assessment in the ID and LF-ASD population. The prevalence data are 
not generalizable to the overall ID population. Some clinical information has been drawn regarding the peculiar 
presentations of MDs in persons with ID pointing towards a pathoplastic effect of the basal 
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neurodevelopmental condition. Further research is needed to operationalize the assessment of DDs and BDs 
in ID and LF-ASD. 
 1 
 
CHAPTER 1 
 
1.1 INTRODUCTION TO THE ISSUE 
In the last decades, the interest towards psychopathology of Intellectual Disability (ID) and Autism Spectrum 
Disorder (ASD) has significantly raised within the neuroscientific community, although research activity and 
clinical advances have been limited. One of the most urgent need is to overcome significant gaps in the 
identification of psychiatric disorders (PDs) in ID and ASD people with severe cognitive and communication 
impairment in order to develop reliable and evidence-based guidelines for management strategies and 
psychopharmacological treatments.  
Diagnosing PDs in persons with ID (PwID) constitutes a challenge from different points of view, including 
the fact that the diagnosis is generally made starting from the psychopathological knowledge derived from the 
general population, upon which neuroscientists have been debating for the last 50 years. Until the 1980s, there 
was a generalized belief that PwID could not suffer from mental health issues and all the eventually thought, 
speech, mood, psychomotor, perceptual and behavioral abnormalities were somehow attributed to the 
neurodevelopmental condition. There are memories of my oldest colleagues remembering their oldest 
colleagues saying “well, he’s oligophrenic, what else?”. Similar considerations were made upon people with 
ASD, especially those with low-functioning ASD (LF-ASD) or co-occurring ID, with few studies focusing 
only on developmental age. Afterwards, some pioneer clinicians claimed that PwID and LF-ASD may present 
the full range of PDs, and a body of literature was produced in support to this view (Moss and Goldberg, 1991, 
Sovner and Hurley, 1982, Sovner and Hurley, 1983).  
Significant problems are intrinsic to the psychiatric diagnostic process in ID and LF-ASD people, and most of 
them remain not completely solved (Bertelli et al., 2012, Bertelli, 2015, Underwood et al., 2015). In fact, in 
PwID and LF-ASD psychiatric manifestations may be difficult to detect and correctly framed according to the 
currently used standardized categorical diagnostic systems that have been designed for people with typical 
neurodevelopment. This problem is directly proportional to the increasing severity of cognitive, 
communicative and language impairment. As a fact, subjects with a restricted behavioral and communicative 
repertoire may express any kind of distress through a limited span of manifestations. A strong effort is needed 
to interpret these manifestations and to find time after time the correct solution among a broad range of 
etiological issues. Transient behavioral abnormalities might be the main or most evident expression of distress, 
including reactions to incident physical problems, pain, environmental stressors, psychological needs but also 
co-occurring PDs. Moreover, it is not a secondary aspect that the research on genetic syndromes associated to 
ID demonstrated that specific behavioral disturbances and/or psychiatric manifestations are related to a variety 
of complex interactions between environment and specific neurobiological underpinnings (Tunnicliffe and 
Oliver, 2011). This may imply that the same behavior (e.g. self-injury) may be related to different biological, 
psychological and behavioral mechanisms which may require differentiated approaches. Unfortunately, the 
attitude of care-givers and professionals frequently consists of applying urgency-based strategies rather than a 
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scientific, evidence- and observation-based approach. The final effect is a widespread inequal access to optimal 
sanitary and psychological care for people with ID and LF-ASD. 
A vicious circle affects advances in research. The peculiar presentations of PDs in PwID and LF-ASD raise 
perplexities about the full applicability of standardized diagnostic criteria, thus in the last years the scientific 
community have made significant efforts to provide adaptations to those criteria encompassing a broad range 
of behavioral and atypical manifestations commonly associated to specific PDs in this population. By the 
contrary, some researchers tried to develop independent criteria specifically designed for PwID. The lack of a 
unitary perspective inevitably lowered the quality of most research: population-based studies accounting for 
official administrative records usually failed to detect the actual prevalence and features of PDs because of the 
poor sensitivity of standardized criteria. Otherwise, the clinical research often omitted to clarify the criteria 
applied for the diagnosis of both PDs and ID with the final result of interesting but often poorly generalizable 
data and, sometimes, overestimation of psychiatric comorbidity. These issues are also strictly connected with 
the substantial lack of reliable assessing instruments, to support the clinicians in this complex diagnostic 
process and to allow full generalizability of research results regardless the level of ID.   
Affective Disorders are highly prevalent in PwID and LF-ASD, although data derived from epidemiological 
and clinical studies vary with a very broad range of prevalence. This disparity may be due to significant 
differences across studies in the methodology and the clinical definitions used to make the diagnoses.  The co-
occurrence of Mood Disorders (MDs) has several implications. From a clinical point of view, it is associated 
with both a significant worsening in cognitive and pragmatic functioning as well as with a substantial reduction 
of the functional and health-related outcomes comparing to the expected potential of the individual. 
Noteworthy, especially in subjects with substantial cognitive, communicative and language deficits, both 
mania and depression are significantly associated to challenging behaviors, such as increased stereotypic 
behavior and movements, oppositional-defiant behaviors, aggressiveness, self-injury (Matson and Smiroldo, 
1997, Matson et al., 1999). Such behavioral abnormalities may become prominent in the clinical picture and 
shadow other symptoms, which are clearly referable to MDs. For example, restlessness, temper tantrums, 
defiant behavior and aggression are counterintuitively common in PwID during depression and, at first sight, 
it can be difficult to draw the correct conclusion. Unfortunately, inappropriate psychopharmacological 
interventions, whose administration is frequently based on the urgency to suppress abnormal and challenging 
behaviors, often exert further diagnostic difficulties. A diagnosis based on the cross-sectional observation can 
be particularly misleading as the main characteristic of MDs consists in cyclicity and recurrent course.  
Although it is generally accepted that in PwID and LF-ASD depression and mania may present with atypical 
and peculiar features, especially in persons with lower cognitive and communication skills, there is no full 
agreement regarding which symptoms, behaviors and course features actually characterize depressive and 
bipolar disorders in this heterogeneous population. Beside the diagnostic issues shared with the other PDs in 
PwID and LF-ASD, MDs show specific issues that are quite common in clinical practice but poorly explored, 
such as the differential diagnosis from medication side effects or negative symptoms of schizophrenia, the 
distinction between mania and hypomania, the differential diagnosis between bipolar disorder and 
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schizophrenia spectrum disorders mostly in the presence or suspect of psychotic symptoms, and the 
identification of mixed and rapid cycling features.  
In this perspective, advances in the diagnostic procedure of MDs are needed as an essential starting point for 
the improvement of the research regarding interventions and equity to the access to optimal treatments. Current 
standardized diagnostic manuals, namely the International Classification of Disorders (ICD) of the World 
Health Organization and the Diagnostic and Statistical Manual for Mental Disorders (DSM) of the American 
Psychiatric Association, have been used as basis for manuals providing the adaptations of PDs to ID and LF-
ASD. The adaptations for MDs mainly consist in offering a variety of descriptions and examples to encompass 
the range of atypical symptoms and behaviors that have been associated in the literature to depression and 
mania. However, given the limitations of most studies in this field, further research is needed to produce proper 
standardized diagnostic criteria. In this desirable advancement, the development of valid assessing instruments 
may play a central role. 
The present study focuses on the development and first validation of a diagnostic tool for depressive and 
bipolar disorders as they are described in the fifth edition of the DSM. The instrument is part of a battery 
named Systematic Psychopathological Assessment for persons with Intellectual and Developmental 
Disabilities (SPAIDD), whose projecting was started in Italy 16 years ago (Bertelli et al., 2003, Bertelli et al., 
2012) with the aim of providing clinicians and other professionals working with ID/LF-ASD with a 
comprehensive set of tools to be used for all the different phases of the clinical intervention, such as the 
diagnostic screening, the diagnostic refinement, and the symptoms follow-up. All the tools belonging to the 
SPAIDD system can be used across the range of ID, but they have been designed for people with important 
communication and cognitive impairment. In fact, they include lists of observable symptoms (mainly 
behaviors) to be checked for presence or absence through an interview to a significant proxy. Nonetheless, the 
PwID can be involved in the assessment when able to integrate the information. The aim of this study was to 
evaluate the psychometric properties of the version for MDs of the SPAIDD (SPAIDD-M), but also to show 
preliminary results about the prevalence and presentation of depressive and bipolar disorders in PwID. 
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1.2 INTELLECTUAL DISABILITY (INTELLECTUAL DEVELOPMENTAL DISORDER) 
1.2.1 DEFINITION AND DIAGNOSTIC CRITERIA  
The conceptualization of ID is controversial as it cannot be considered a disease but a complex and 
heterogeneous group of conditions characterized by deficit in cognitive functioning prior to the acquisition of 
abilities through learning (Salvador-Carulla and Bertelli, 2008). A disruption of typical neurodevelopment 
with various degree of functional alterations and/or structural abnormalities of the Central Nervous System 
(CNS) underlies the conditions falling under the label of ID. They can be related or caused by a variety of 
etiopathological factors that in half of the cases are not identifiable. As ID involves the neurodevelopment, it 
occurs early in life and has to be considered a life-long condition and deficits in intellectual functioning tend 
to remain stable ((APA), 2000), while improvements in adaptive behavior can occur ((APA), 2013). The final 
presentation of the individual clinical picture may include differential impairments of intelligence, learning, 
language and communication, adaptive behaviors, and abilities.  
Before the early nineteenth century the terms used to label intellectually disabled persons included idiocy, 
deficiency, oligophrenia, mental deficiency, mental handicap, mental sub-normality etc (Schalock et al., 2007).  
The term mental retardation  (MR) has been the label of diagnostic categorical systems used until now (ICD-
10 and DSM-IV-TR) even if in the last decade the research community, professionals of this field and disability 
rights movements made an attempt to replace it with other terms with the double purpose of removing negative 
connotations and stigma and to stress that ID belongs to neurodevelopmental disorders. Indeed, both ICD and 
DSM in their latest versions (ICD-11 and DSM-5) completely abandoned MR and chose intellectual disability 
or intellectual developmental disorder (IDD) ((APA), 2013, (WHO), 2018). Comparing to the label MR, ID 
refers to a significant reduction of global and/or specific abilities to achieve certain targets considered 
appropriate for average IQ persons. More specifically, the words ID refer to intelligence and in particular to a 
deficit of the logical-deductive process with a reduced ability to learn new skills with consequent impairments 
of adaptive functioning, in line with current definition of intelligence (Bertelli et al., 2014).  
The history of the terminology is not merely a matter of words but represents the reflex of the evolution of 
different perspectives and conceptualizations. Differences have been supported by changes both in 
sociocultural and health policies frameworks, as well as the ever-expanding advances in the knowledge of 
neurobiological and genetic bases and causes of ID that dramatically changed the way we currently look at ID 
(Girimaji  and Pradeep, 2018). Some ambiguities are summarized by the position of MR in the different 
editions of the DSM. Both the DSM ((APA), 1952)and II ((APA), 1968) included MR in a section separated 
from other psychiatric diagnoses. The DSM III ((APA), 1980) moved MR in the Axis I, among the disorders 
with onset usually occurring in childhood and adolescence. Then the DSM III-R ((APA), 1987) and DSM IV 
((APA), 1994) moved RM back on Axis II along with the personality disorders and pervasive developmental 
disorders (PDD), or just with personality disorders, respectively. The above-mentioned repositioning 
movements reflected uncertainties regarding the nature of ID as health condition or disability, but also 
regarding the concept of ID with respect to psychiatric disorders: the concept that intellectually disabled 
persons may suffer from mental health illness equally to the general population is relatively new and before 
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the last four decades most researchers claimed that a co-occurrence would not be possible (Earl, 1961). Finally, 
IDD has moved back again in Axis I with acceptance of the concept of dual diagnosis; this change created the 
prerequisite to the implementation of adapted criteria for PD in this population. 
In the DSM-IV-TR and ICD-10 ((APA), 2000, (WHO), 2010), the key feature of MR was a general intellectual 
functioning impairment qualified by an IQ significantly below the average (criterion A).  Significant 
limitations in adaptive functioning areas had to be present in at least two of the following performance 
domains: communication, personal care, family life, social/interpersonal abilities, use of community resources, 
self-determination, scholastic skills, work, leisure, health, and safety (Criterion B). Onset must be before the 
age of 18 years (Criterion C). 
The IQ defines general intellectual functioning or equivalent, obtained by assessment with one or more of the 
standardized, individually administered intelligence tests (e.g. The Wechsler Intelligence Scale (WAIS), 
Stanford–Binet Intelligence Scale, or the Kaufman Brief Intelligence Test). Significant subaverage general 
intellectual functioning is defined by the APA ((APA), 2000) as an IQ of approximately 70 or below 
(approximately 2 standard deviations below the mean). 
• Mild mental retardation: IQ level 50-55 to approximately 70 
• Moderate mental retardation: IQ level 35-40 to 50-55 
• Severe mental retardation: IQ level 20-25 to 35-40 
• Profound mental retardation: IQ level below 20 or 25. 
Borderline Intellectual Functioning (BIF) is a mild cognitive developmental condition distinguished from ID 
by less extensive and severe cognitive impairments. BIF is defined as IQ between one and two standard 
deviations from the population IQ mean that is diagnosed by IQ test score of 70-85. BIF was included in the 
DSM-IV but omitted from DSM-IV-TR and DSM-5; neither it is included in ICD 10, and ICF (Hassiotis, 
2015). 
In the DSM-5 ((APA), 2013) the term MR was officially replaced by ID or IDD then adopted by the ICD-11 
((WHO), 2018), highlighting the convergence between the two classificatory systems.  
In order to make a diagnosis according to DSM-5, the following 3 criteria must be satisfied: 
A. Deficit of intellectual functions, such as reasoning, problem solving, planning, abstract thinking, 
judgment, academic learning or learning from experience, and confirmed by both individual clinical 
assessment and standardized intelligence testing. 
B. Deficits in adaptive functioning that failure to meet developmental and socio-cultural standards for 
personal independence and social responsibility. Without ongoing support, the adaptive deficits limit 
functioning in one or more activities of daily life, such as communication, social participation, and independent 
living, across multiple environments, such as home, school, work, and community. 
C. Onset of intellectual and adaptive deficits during the developmental period. 
Although ID/IDD is usually a stable diagnosis, there can be significant variability in cognitive functioning and 
abilities across different clinical severity levels throughout the life cycle. Therefore, ID is considered a dynamic 
health condition, and it should be reassessed at key developmental stages, life transitions (e.g. at school entry 
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age, puberty and early and later adulthood), and in case of traumatic events or other life events, mostly in order 
to recalibrate the severity and, subsequently, the supports needed. 
In the DSM-5, the specific age limit of 18 years was considered arbitrary. While ID does not require a specific 
age, individual’s symptoms must begin during the developmental period and are diagnosed based on the 
severity of impairments in adaptive functioning ((APA), 2013). This modification as well as the inclusion of 
ID in the first chapter of DSM-5 encompassing all the neurodevelopmental disorders represents one of the 
major advances of the new classification, indicating that ID is nowadays considered as the outcome of 
pathophysiological mechanisms affecting the developing brain and influencing its functioning along the entire 
life-span (Girimaji  and Pradeep, 2018).  
The subaverage general intellectual functioning (Criterion A) is defined by an IQ score of approximately two 
standard deviations or more below the mean of the general population. When extremely low (under 60), IQ 
measures are no longer valid. This concept found a form in the ICD-11 definition of IDD as “a group of 
etiologically diverse conditions originating during the developmental period characterized by significantly 
below average intellectual functioning and adaptive behavior that are approximately two or more standard 
deviations (SDs) below the mean (approximately <2.3rd percentile), based on appropriately normed, 
individually administered standardized tests. Where appropriately normed and standardized tests are not 
available, diagnosis of DID requires greater reliance on clinical judgment based on appropriate assessment of 
comparable behavioral indicators” ((WHO), 2018). Therefore, the DSM-5 continues to distinguish four levels 
of severity (mild, moderate, severe, and very serious), but with different criteria from the DSM-IV and IV-TR. 
The range of deficits extends from very specific limitations of learning and control of executive functions to a 
global impairment of social skills or intelligence.  
The term adaptive behavior refers to the individual’s ability to cope with and meet environmental demands for 
personal independence and responsibility ((APA), 2013) according to the expectations of their chronological 
age and cultural group ((WHO), 2018, (WHO) and  2017, Schalock et al., 2010).   
Both DSM-5 and ICD-11 agreed that the definition of the severity levels had to rely more on adaptive 
functioning than on IQ scores, since the adaptive functioning in the areas of conceptualization, socialization, 
and practical skills determines the level of support required to maintain an acceptable condition of life.  
Measurable indicators of adaptive functioning include the following:  
• Conceptual skills: language, reading and writing, using money, understanding and using concepts such 
as time, numbers or measures, and problem solving. 
• Social skills: creating and maintaining mutually satisfying social relationships, interactions with 
others, social engagement and participation, emotional competence, social problem solving, self-direction, 
responsibility, gullibility and naïveté, and self-esteem.  
• Practical skills: instrumental and basic activities of daily living, work/vocational skills, domestic skills, 
and personal hygiene. 
The emphasis given to specific, peculiar and sometimes parcel deficits represents a further opening toward a 
new conceptualization of intelligence and its disorders, indicating research perspective for the next future: a 
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recent literature mapping indicates that in People with ID (PwID) the same IQ score may be associated with 
different cognitive profiles, which are also based on underlying etiopathogenetic factors (Bertelli et al., 2014). 
For example, subjects with Down’s syndrome usually manifest impairments in specific areas of language, 
long-term memory and motor performance while showing relative strengths in visuospatial construction 
(Edgin et al., 2010). Different cognitive profiles are related to the differential involvement of specific 
neurotransmitters and neuroanatomical circuits: differences may have impact on behavioral phenotypes 
(Tunnicliffe and Oliver, 2011), adaptive profiles and, possibly, specific vulnerability to PD. Going fast 
forward, it is also possible that specific dysfunctions of some neural circuitries may imply different responses 
to psychopharmacological treatments: the implications for management strategies and outcome estimation are 
very intriguing.  
In summary, the new approach gives more relevance to various behavioral and clinical indicators in 
supplementing, complementing or substituting formal IQ scores in diagnosing ID and quantifying the severity 
level (Girimaji  and Pradeep, 2018). Some differences between the two classificatory systems regard the 
emphasis given to the components of the diagnostic process. ICD-11 substantially equalizes intellectual 
functioning and adaptive skills in specifying the severity of IDD by means of comprehensive descriptions of 
behavior and impaired abilities associated to each degree of ID. This expedient is functional to broaden the 
possibility of clinical diagnosis not fully supported by standardized testing, often not available or not 
practically and routinely used in low- and middle-income countries (Girimaji  and Pradeep, 2018). This 
approach looks also forward to research and administrative utility of diagnostic criteria.  On the other hand, 
DSM-5 puts in first sight pragmatic requirements: determining ID level only through the quantification of 
adaptive functioning, especially in lower ranges of IQ, where the measure is less valid. 
Both classifications maintained the four levels of ID: mild, moderate, severe and profound. In ICD-11 the 
subcategory “provisional subtype” was added, whereas DSM-5 included global developmental delay (GDD) 
and unspecified IDD. The provisional subtype indicates the presence of some kind of disorder of intellectual 
development but the evaluation cannot be considered conclusive because the very early stage of the 
individual’s development (infants and children before the age of 4) or the assessment of functioning and 
adaptive behavior is not valid for a variety of reasons (sensory disabilities, severe locomotor impairment, 
severe problem behaviors or co-occurring mental and behavioral disorders (Rutter et al., 1975). GDD 
encompasses only cases of developmental delay in individuals below the age of 5 not able to participate to 
assessments ((APA), 2013), whereas other peculiar cases can be included into the unspecified subcategory.  
ICD-11 also mentioned BIF, defined as a reduction of mean scores in standardized assessments of intellectual 
and adaptive functioning of 1-2 SD comparing to the average IQ. ICD-11 does not consider BIF as a 
diagnosable disorder but as a “condition of interest”. Indeed,  the growing body of literature on BIF indicates 
on one hand the need of early interventions for this condition ((APA), 2013), and on the other hand the high 
prevalence of BIF among certain psychiatric populations and, by the contrary, the higher vulnerability of 
persons with BIF to develop psychiatric disorders, addiction, social, employment and legal problems across 
the lifespan (Deb et al., 2001a, Hassiotis, 2015). DSM-5 placed BIF in the section III, “Other Conditions that 
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may be a Focus of Clinical Attention,” under the subsection “Other Circumstances of Personal History”, not 
specifying diagnostic criteria for BIF. The DSM-5 code for BIF must be used when the condition may impact 
the clinical presentation, treatment and outcome of other diagnosable disorders.   
The debate on ID classification could have serious implications. Diagnostic categories are used throughout the 
world to specify the type of population eligible for specific health care, educational and social services. 
Therefore, the location of ID as disability or health condition has the potential of impacting health statistics, 
health policy, and the services available for this vulnerable population (Salvador-Carulla et al., 2011). ICD-11 
took a balanced position on this debate clearly conceptualizing ID as a health condition or a disorder rather 
than merely a disability: the basic condition may lead to various degrees of disability that can be evaluated and 
measured under the International Classification of Functioning Disability and Health (ICF). 
 
1.2.2 EPIDEMIOLOGY 
The prevalence of ID is estimated between 1 and 3%, and the incidence is estimated to be around 1.8% (Harris, 
2006, Heikura et al., 2003). In developed countries like Finland or the Netherlands, the prevalence of ID is 
currently less than 1%, while it may rise to 4–5% in more deprived regions of the world (Durkin, 2002) and 
can reach up to 6% in some countries in Eastern Europe. Among the four different severity degrees, 85% have 
mild ID, 10% moderate, 4% severe, and 2% profound (King et al., 2009).  
Mild ID is present in 80 to 85% of the world’s population (Schalock et al., 2010). 
The prevalence of BIF is estimated between 12.3%; for example Hassiotis et al. (Hassiotis et al., 2008) found 
that on a sample of 8.450 adults living as part of a family in UK, approximately one-eighth had BIF. 
The prevalence of ID is higher in males than females in both adults, children/adolescents. Among adults, the 
male-to-female ratio varies between 0.7 and 0.9 (Maulik et al., 2011).  
The lack of adequate and consistent epidemiological data was one of the main reasons for the exclusion of the 
last study conducted by the World Health Organization and the World Bank Burden of Disease. One 
consequence is that ID still occupies an important position among the ‘hidden problems’ of global health. 
Another consequence is that the gap between the offer of health services and the unmet needs of intellectually-
disabled people has become incalculable ((WHO), 2007). 
 
1.2.3 ETIOPATHOGENESIS 
IDs can result fromaa different combination of specific causative factors, both of genetic and environmental 
origin (Bertelli and Kishore, 2014). Historically, people with ID have been classified in two broad categories 
on the base of the etiology of ID. In the first category, accounting for about the half of the IDs, an organic 
insult is identifiable as the probable cause of delayed cognitive and emotional development. In this group are 
included those subjects with perinatal asphyxia or hypoxia or other pre-perinatal insults as in the case of 
cerebral palsy, documented substance/medication use during pregnancy, pre-, peri- or post-natal exposure to 
infections or toxins, but also genetically-based conditions as chromosomopathies, metabolic disorders, 
tuberosclerosis and neurofibromatosis. The second category is constituted by those subjects without an 
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identified cause of ID, at least according to current knowledge and available diagnostic procedures. The cause 
is unknown for up to 60% of cases (Rauch et al., 2006). It has been suggested that this group would include 
most people with mild ID (Volkmar et al., 2007). 
 
A. Prenatal causes 
Genetic factors 
Conventionally, genetic-related IDs are dividend in syndromic and non-syndromic forms: syndromic forms 
are characterized by specific constellations of clinical, radiological, metabolic or biological features. In non-
syndromic forms the cognitive impairment is the only manifestation of the disease. This distinction has been 
and continues to be useful in clinical approach; however, giving the never-ending expansion of knowledge in 
genetics and neurobiology, some forms previously considered non-syndromic are nowadays recognized as 
syndromic (Durkin, 2002, Frints et al., 2002, Ropers and Hamel, 2005). Current literature reports variable rates 
depending on the type of sampling: non syndromic ID is estimated around 30%-50% of the cases (Daily et al., 
2000), whereas a genetic disorder is identifiable with rates ranging from 17% to 50 (Rauch et al., 2006, 
Moeschler et al., 2006, Kaufman et al., 2010).  
More than a thousand of genes are involved in the etiopathogenesis of ID and more than 290 genes have been 
associated with specific clinical phenotypes, metabolic, and neurological disorders causing ID (Chelly et al., 
2006, Kahler and Fahey, 2003, Levy, 2009). Trisomy 21 is the chromosomopathy responsible for over 95% of 
Down's syndrome, which is the best-known genetic cause of ID (Patterson and Costa, 2005, Rauch et al., 
2006). Other relatively frequent genetic conditions include Fragile X syndrome (Leonard and Wen, 2002), 
Turner syndrome, Klinefelter's syndrome (Money, 1993), neurofibromatosis (or von Recklinghausen's 
disease), phenylketonuria, Williams’s syndrome, and Prader-Willi syndrome. ID can occur in other genetic 
syndromes like tuberous sclerosis, Huntington's disease (Mouridsen and Sorensen, 1995, Raznahan et al., 
2007), mucopolysaccharidosis, alcaptonuria, and porphyria (Kahler and Fahey, 2003, Levy, 2009). 
Consanguineous marriage produces a 5-fold increase of the risk of transmission and expression of genetic 
conditions associated to recessive genes (Ten Kate, 2012).  
Rare de novo point mutations, for example copy number variants (CNV) mutations, are related to an increasing 
amount of cases of Idiopathic ID (de Ligt et al., 2012). Microarray studies, and exome sequencing techniques 
found CNVs in approximately 15% of PwID (Ropers and Hamel, 2005, Pfundt and Veltman, 2012). 
Studies reported that recurrent CNVs involve the following genes: 1q21.1, 1q41-42, 2p15-q16.1, 3q29, 
7q11.23, 9q22.3, 12q14, 14q112, 15q13.3, 15q24, 16p11.2, 16p11.2-12.2, 16p13.1, 17p11.2, 17q21.31, 
19q13.11, 22q11.2, and Xq28 (Vissers et al., 2010, Morrow, 2010).  
For example, Berkel and colleagues (Berkel et al., 2010) found de novo CNVs of the SHANK2 gene in 184 
individuals with ID, and in 396 individuals with ASD. CNVs of the NLGN4 gene and 16p11.2 were identified 
both in ID and (Berkel et al., 2010, Cook and Scherer, 2008, Fernandez et al., 2010), while deletions of the 
1q21.1 region were detected also in schizophrenia (International Schizophrenia, 2008). 
 
 10 
 
Epigenetic mechanisms 
Epigenetic regulation has been implicated in the causation of several forms of ID: in some cases, gene 
imprinting may cause different phenotypes and syndromes as in the case, for example of Prader-Willi and 
Angelman syndromes, Silver–Russell syndrome and Beckwith–Wiedemann syndrome¸ Smith–Magenis 
syndrome and Potocki–Lupski syndrome (Badcock, 2011). According to the theory of the imprinted brain, the 
predominant expression of maternal or paternal genes in some specific chromosomal regions may cause 
functional imbalance. Some authors observed that the maternal/paternal imprinting of a mutated gene may 
cause clinical pictures and phenotypes with opposite features (Badcock, 2011). A similar mechanism has been 
hypothesized in the etiopathogenesis of some autistic forms, according to the idea that autism may represent a 
paternal bias in the expression of imprinted genes (Baron-Cohen, 2002).    
Mutations in Methyl CpG binding protein 2 (MeCP2) and ATP-dependent helicase X-linked (ATRX) protein 
gene is already well established in Rett syndrome, Down's syndrome and some cases of X-linked forms 
(Dragich et al., 2000, Gibbons et al., 2009, Nan et al., 2007, Sanchez-Mut et al., 2012). 
In most cases, modifications in the expression of genes can be related to environmental factors before and after 
birth via epigenetic mechanisms (Zahir and Brown, 2011). 
Biological and environmental factors 
Prenatal causes of ID include congenital infections such as cytomegalovirus, toxoplasmosis, herpes, rubella, 
influenza and human immunodeficiency virus (Strømme and Hagberg, 2007). The human foetus seems unable 
to produce an effective immunological response in early pregnancy; the ability of children to produce 
antibodies increases significantly only between the sixth and twelfth month of age. 
Exposure to pollutants, heavy metals, and harmful medications such as thalidomide, phenytoin and warfarin 
in early pregnancy,  to substances of addiction such as alcohol, nicotine and cocaine can also cause delays in 
the development or ID (Behnke et al., 2013, Daily et al., 2000, Ke and Liu, 2012, Sithisarn et al., 2012). 
Other prenatal risk factors are: maternal hypoglycaemia, diabetes and malnutrition (Groce et al., 2014, Mann 
et al., 2013). Evidences from experimental studies show that malnutrition in utero can impact on the brain 
development process leading to a reduction of nervous cells, protein synthesis deficits, and abnormal electrical 
activity (Nyaradi et al., 2013). 
 
B. Perinatal causes 
Perinatal causes include complications in delivery, severe prematurity, very low birth weight, birth asphyxia 
or hypoxia, and birth trauma. Furthermore, neonatal complications in the first 4 weeks of life including 
septicaemia, severe jaundice, and hypoglycaemia may severely impact the following development of the SNC 
(Nosarti et al., 2004, Kolevzon et al., 2007). The measure of this impact and its manifestations across the life-
span are not limited to ID, which may be considered one pole of the continuum including other 
neurodevelopmental conditions and several psychiatric disorders (i.e. ASD, ADHD, bipolar disorder and 
schizophrenia) (Owen, 2012, Owen and O'Donovan, 2017). 
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Low birth weight at delivery can be due to genetic causes as well as environmental factors encompassing poor 
nutritional contribution in uterus associated with placental insufficiency, or others damaging agents. Low-
weighting children for gestational age show retardation in foetal growth and subsequent neurological 
complications that are different from those related to shorter gestation period. True pre-term births before 26 
weeks of gestation and pre-term births after less than 36 weeks of gestation are those at greatest risk of 
developing neurological damage, which increases in inverse proportion to the degree of maturity and birth 
weight (<1500 grams) (Winter et al., 2002, Marlow et al., 2005). Low-weight at birth may also be caused by 
malnutrition. Recently, the issue of diet during pregnancy arose interest even in Western countries given the 
increasing percentages of vegetarian and vegan diet regimens among women, also during pregnancy and during 
breast-feeding. A vegan diet seems to be associated to lower birth weight comparing to vegetarians and 
omnivorous mothers (Ferrara et al., 2019). Long-term follow-up are lacking in this field to draw conclusions. 
Structural abnormalities of the CNS are more common among children born at lower limit of viability and 
weight, while learning disabilities affect more frequently children of lower socioeconomic status. This finding 
supports the idea of a further contribution of adverse childhood events to cognitive performance (Ritchie et al., 
2011). 
 
C. Postnatal causes 
During the postnatal period, which includes infancy and childhood, brain infections such as encephalitis, and 
bacterial meningitis are observed as causes of variable degrees of CNS maturation disruption (Noyola et al., 
2001). Furthermore, encephalic traumatism, severe and prolonged malnutrition can lead to some kind of ID 
(Anderson et al., 2005, Leonard and Wen, 2002). Malnutrition is a common cause of lower cognitive abilities 
(Durkin et al., 2000). The effects of malnutrition on the development of ID are almost always concomitant 
with negative socio-environmental conditions. Studies reported a significant association between ID and 
exposure to a wide range of environmental and psychosocial distress including infections, inadequate 
caregivers, low level of stimulation (Emerson and Hatton, 2007, Leonard and Wen, 2002). 
Neuroanatomical abnormalities  
Structural abnormalities of the CNS are the result of a multitude of insults that are primarily of prenatal origin. 
Primary malformations including neural tube defects, cerebral dysgenesis, and congenital hydrocephaly or 
hydranencephaly can be associated with moderate to profound ID.  
PwID may show a variety of damages in the integrity of the brain's structures (McDaniel, 2005, Plomin and 
Kosslyn, 2001). There are no alterations univocally associated to ID, on the contrary it is not uncommon to 
find no macroscopic SNC alterations in PwID. 
Cortical grey matter volumes are related to the integrity of circuitries involved in several executive functions 
such as planning, working memory, and attention. Several studies found negative correlations between low IQ 
and reduced total volume of the frontal grey matter (Reiss et al., 1996, Sowell et al., 2001), particularly in the 
orbitofrontal and medial frontal regions (Frangou et al., 2004).  
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Moreover, white matter tracts including the corpus callosum, cingulum, uncinate fasciculus, corticospinal tract 
and optic radiation, may be damaged in people with ID (Yu et al., 2008).  
The corpus callosum, connecting the right and left cerebral hemispheres, has been indicated by some studies 
as a vulnerable structure in ID: some studies found thinned or reduced size of the corpus callosum, particularly 
in anterior subregions (Njiokiktjien et al., 1994, Spencer et al., 2005). The thinning of the corpus callosum 
may be associated to impairments of sustained attention and adaptive skills during complex cognitive tasks 
(Colom et al., 2006). Other important structures possibly involved in the pathophysiology of IDs are the 
cingulum, uncinate fasciculus, and corticospinal traits. A significant left-greater-than-right asymmetry of the 
cingulum seems associated with impairment of executive functioning (Gong et al., 2005). Abnormalities of 
the uncinate fasciculus are related with deficits in verbal, visual memory, and executive performances (Levine 
et al., 1998), while the corticospinal tract plays a role in the control of discrete finger movements (Martin, 
2005). 
Sensory impairment in PwID are not infrequent. For example, optic radiation or geniculo-calcarine tract 
alterations are associated in PwID with visual impairments (Warburg, 2001), strabismus, loss of visual acuity, 
and amblyopia (Atkinson et al., 2001). 
 
1.2.4 PROBLEMS ASSOCIATED WITH INTELLECTUAL DISABILITY (INTELLECTUAL 
DEVELOPMENTAL DISORDER) 
Medical illnesses 
PwID may present a wide range of co-occurring pathologies with higher rates than the general population 
(Kwok and Cheung, 2007). The most frequent disorders are: epilepsy, gastro-oesophageal reflux disorder 
(GORD), constipation, visual impairments, hearing impairments, osteoporosis, respiratory infections, risk of 
aspiration and choking, and repeated accidents or falls. Diabetes is diagnosed in PwID more than twice as in 
the general population, and obesity is significantly associated with diabetes.  
Specific genetic conditions such as Down’s syndrome or William’s syndrome are associated with illnesses 
such as thyroid disorders, and cardiovascular disease, which may arise at different stages of life. Also, 
antipsychotic medications seem to contribute to physical diseases (Jansen et al., 2004, Prasher and Janicki, 
2008). 
Epilepsy is one of the most common chronic illnesses diagnosed in PwID, both in syndromic as in idiopathic 
forms. Shared neurobiological underpinnings are suspected in most cases. Associated problems include global 
skill deficits, wetting, soiling, walking problems, attention seeking, lack of empathy and mood swings 
(McGrother et al., 2006). Epilepsy and significant EEG alterations are common in ASD too (Mathewson et al., 
2012). The management of epilepsy in ID presents several issues and requires a holistic approach. In fact, 
psychiatric symptoms and communication impairment often complicate the diagnosis, as well as higher rates 
of resistance to usual anticonvulsant treatment regimens (McGrother et al., 2006). By the contrary, epilepsy 
and its treatment may negatively impact physical, mental and psychological health (Kerr and Espie, 2000). 
Behavioral disturbances are very frequent in ID-epileptic patients and the diagnostic process may be interfered 
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by seizure frequency, seizure severity, temporality of seizure occurrence, life events, and other socioeconomic 
indicators (Wilcox and Kerr, 2006).  
Gastrointestinal problems are common in persons with ID for a variety of reasons. The most obvious regard 
the lifestyle and poor physical activity often associated to motor disability and skeletal deformities. In the last 
few years there is a growing body of literature reporting functional alterations in ASD. Gastrointestinal 
symptoms are reported between the 22% and 84% in the paediatric population (Horvath and Perman, 2002b, 
Horvath and Perman, 2002a, Melmed et al., 2000, Nikolov et al., 2009). Gastrointestinal symptoms have been 
associated to greater severity of irritability, anxiety and social withdrawal (Nikolov et al., 2009). The 
exploration of the relationship between the physiopathology of ASD and alteration of intestinal microbiota and 
metabolomes, including neurotransmitter molecules, represent a new research frontier in this field.  
CNS ageing and dementia are another challenging issue in PwID. Some genetic syndromes are associated to 
certain types of dementia, for example it is well-known that persons with Down’s Syndrome are at very high 
risk to develop Alzheimer’s disease in their fifties (Holland et al., 2000, Prasher, 1995) reaching the 16.8% 
prevalence rate (Coppus et al., 2006). The onset of dementia dramatically contributes to a global decline in 
health status of these individuals including epilepsy, lung disease, mobility problems, visual and hearing 
impairment, cataract, fractures with increased need for hospitalizations and surgeries (McCarron et al., 2005, 
Patti et al., 2005). Dementia may also be associated to the onset or worsening of behavioral disturbances 
(Huxley et al., 2005) and psychiatric symptoms. 
Overweight and obesity are major health issues in PwID, especially in higher-income Countries (Fox and 
Rotatori, 1982, Janicki et al., 2002, Kelly et al., 1986, Rimmer et al., 1993, Rubin et al., 1998). Obesity 
prevalence is similar in ID as in the general population according to population-level surveys (Emerson, 2005, 
Yamaki, 2005). Prevalence rates range from 25% and 50% in females and 15% and 45% in males in USA, and 
slightly lower rates in European Countries and Australia (Rimmer and Yamaki, 2006). Extreme obesity 
(BMI>40) has been reported to be disproportionately more common in PwID too (Rimmer and Wang, 2005). 
Gender (female) , ageing, less severe degrees of ID and certain genetic syndromes (i.e., Down syndrome, 
Prader-Willi syndrome) are risk factors for obesity (Rimmer and Yamaki, 2006). Researches claim 
environmental factors as the major determinants of this comorbidity. It is possible that antipsychotic treatment, 
especially Second Generation Antipsychotics (SGAs), contribute to metabolic side effects in this population 
(Rummel-Kluge et al., 2010).   
Organic pathologies are often undetected especially in individuals with severe and profound ID. Indeed, 
impaired communication and language, reduced awareness of body schemata, altered perception of pain may 
make the diagnosis very difficult. Moreover, in patients with a restricted communicative repertoire, physical 
illness may be misinterpreted as apparent problem behaviors (PBs), or psychiatric symptoms. Therefore, in the 
complex evaluation of PwID it is essential to consider all factors that can influence behavior and affect 
vulnerability and symptom presentation. The exclusion of physical problems as the cause of behavioral 
disturbances is the first obligated step of the psychiatric and behavioral diagnostic process in PwID.  
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Problem behaviors  
PBs or challenging behaviors (CB) are very common in adults with ID with a prevalence ranging from 5 to 
60%, and a point prevalence of about 20%, depending on the exact definition of the terms used (Cooper et al., 
2007d, Deb et al., 2008, Emerson et al., 1999, Smiley, 2005). 
PBs may be defined as all those behaviors that for intensity, frequency, or duration threaten the physical safety 
of the person or others or restrict access to the community (Emerson et al., 2001b). This interferes with 
learning, development, and social participation. The most common types of PBs in this population are: 
physically aggressive behavior, verbally aggressive behavior, screaming, destructive behavior or aggression 
to property, self-injurious behavior, overly-demanding behavior, oppositional-defiant behavior, and sexually 
inappropriate behavior (Lowe et al., 2007, Smith and Matson, 2010a). Some authors also include stereotypies. 
Behavioral difficulties often persist, with relapse and remission periods, and the same individual may show 
multiple forms of challenging behavior (Lowe et al., 2007). 
PBs result from the complex interaction between biological, psychological, social and developmental factors 
(Griffiths and Gardner, 2002), whereas in some cases genetic causes underlie PBs and impacts directly on the 
phenotypic expression (O'Brien and Yule, 1995, Tunnicliffe and Oliver, 2011).  
In a quantitative perspective, a behavior is considered problematic basing on excessive intensity, frequency or 
duration. In fact, the same behaviors may be part of the communicative or symptomatic repertoire of the 
individual, mostly of those subjects with severe cognitive, language and communication impairment. 
Behaviors may achieve the significance of PB for a large variety of reasons: physical disorders, pain, 
psychological distress, attempts to achieve a secondary advantage with environmental reinforcements. In 
general, challenging behaviors may be considered the common final pathway of any kind of distress. CB could 
also occur as symptoms of psychiatric disorders (de Winter et al., 2011, Emerson et al., 2001a, Felce et al., 
2009, Hemmings et al., 2006, Kishore et al., 2005, Moss et al., 2000), especially in individuals with more 
severe impairment (Felce et al., 2009). In this case, before making a diagnosis is required to clarify the temporal 
relationship to the onset of the PBs (Charlot, 2005). 
Other risk factors for CBs are co-occurring ASD (McClintock et al., 2003), the level of ID (Emerson and 
Bromley, 1995, Emerson et al., 2001b), gender (male), young age ((Emerson and Bromley, 1995, Emerson et 
al., 2001b, McClintock et al., 2003), and overmedication  (Matson et al., 2000). The assessment of CBs should 
be very careful considering all the factors described above, as they are a major cause of misdiagnosis and 
inadequate treatment. Indeed, the general tendency of most caregivers and of not fully trained professionals is 
toward a “urgency-guided” management approach, often leading to over-prescription of sedatives and 
antipsychotics and not based on a solid and scientific diagnostic process.  
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1.3 AUTISM SPECTRUM DISORDERS 
1.3.1 DEFINITION AND DIAGNOSTIC CRITERIA  
Autism Spectrum Disorders (ASD) are a group of heterogeneous conditions sharing two key features: 
impairment of socialization and qualitative deficits of communication, (e.g. reluctance to make eye-contact, 
lack of appropriate peer relationships, lack of emotional reciprocity, delay in verbal responses, poor 
conversation skills, lack of pretend play), and restricted and/or repetitive behaviors or interests (e.g. repetitive 
motor movements, preoccupation with parts of objects, hyperfocused interests) (Briegel et al., 2009, Horovitz 
and Matson, 2010, Leung et al., 2010, Matson et al., 2009a, Matson et al., 2009b, Smith and Matson, 2010a, 
Smith and Matson, 2010b, Smith and Matson, 2010c).  
The term autism was coined by Eugen Bleuler to describe one of the four fundamental aspects of schizophrenia, 
the individuals ‘inward turning’ into his/her own world and thereby losing contact with the outer world. 
Bleuler’s overall conceptualisation of schizophrenia is focused on the loss of interpretative and relational skills, 
as summarised in the 4A theory: inappropriate or flattened Affect, Ambivalence towards others, loosening of 
thought Associations, and Autism, which was defined as ‘preference for living in a fantasy world’, a gap 
between the patient’s inner fantastic world, inaccessible to reality, and the unlovely environment (Bleuler, 
1911). More precisely, the Bleulerian “autism” had nothing to do with the later meaning of social isolation and 
its theoretical conceptualization of autism did not impact on later discussions about autism. 
There is large agreement that the “discover” of autism belongs to the separate works of Hans Asperger and 
Leo Kanner, who in 1943 and 1944 described some children with clinical picture fitting with the current 
descriptions of autism. The ‘Autistischen Psychopathen’ patients described by Asperger were different from 
those of Kanner in three aspects: 1) more fluent speech; 2) difficulty in carrying out large movements but not 
fine movements; 3) a different level of learning ability. He called his patients ‘abstract thinkers’, which, 
according to Kanner, have great problems with mechanical learning. Even with important common traits, two 
different clinical forms were determined - Kanner’s autism and Asperger’s syndrome. Subsequently, 
Asperger's syndrome became the term applied to the autistic people with a relatively high IQ. 
However, this view is quite inaccurate because by the 1920s the term autism had been definitely used in 
paediatric circles in Europe to label the social withdrawal that small children experienced (Shorter and 
Wachtel, 2013). In this perspective the transition from Bleulerian autism and the current term has its roots in 
a literature of clinical descriptions produced between the end of the 19th and the beginning of the 20th centuries. 
Children with a marked tendency to isolation, poor affective contact, and coldness toward significant others 
were described under the label of “hereditary insanity”. Many of them also had psychosis but a remarkable 
intelligence, as described in his textbook by Heinrich Schüle, a German physician (Schüle, 1886). By the 1880s 
similar features associated to catatonia were found in developmentally delayed children. For example, in 1887 
the English paediatrician J. Langdon Down associated autistic behavior with catatonia in ‘developmental 
idiocy’, although he used neither the term autism nor catatonia. He described those children as poorly 
reciprocate “he returns your kiss by a bite”, inflexibly mute, withdrawn and scarcely reactive regardless of the 
circumstances around them, and sometimes fascinated by peculiar sensorial stimulations, for example the 
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rhythm of music. He also described automatic movements of the fingers and rhythmical movements of the 
body, what now we would call stereotypies (Down, 1887). In 1913 Kraepelin describing a childhood onset 
form of dementia praecox, accounted for clinical pictures belonging to the current description of autism: he 
referred to these patients embracing the term autism coined by Bleuler (Kraepelin, 1913). In the following 
twenty years the term autism ran across the Europe. In that period a Russian paediatric neurologist, Grounia 
Soukhareva, gave autism its modern meaning of social isolation, she applied to children the Kretschmer’s ideas 
about autism and underlined the association with catatonia (Ssucharewa, 1932). Although she remained almost 
completely unknown to historians, she gave an important contribution as she had large sample of children to 
observe. Her work was then continued and expanded in Moskow by Ewa Grebelskaja-Albatz, who in 1934 
published a case series on 22 children with autism, psychosis and/or catatonia, but focusing on patients with 
lower functioning (Grebelskaja-Albatz, 1934, Grebelskaja-Albatz, 1935). Unfortunately, probably due to the 
language, this remarkable work was forgotten for long time. 
Even in USA, some authors had descriptions of young schizophrenic patients who can now be revised as 
catatonic and autistic, for example in 1930s Howard Potter, Lauretta Bender; Juliette Louise Despert imported 
this concept of autism in the context of schizophrenia of children (Grebelskaja-Albatz, 1934, Grebelskaja-
Albatz, 1935). In this context the credit of Kanner and Asperger was that of an afterthought more than prologue 
in definitely separating autism from schizophrenia giving to these syndromic pictures an autonomy. Currently, 
we are still questioning about the relationship between the former and a letter and the idea con a 
neurodevelopmental continuum has been hypothesized (Insel, 2010, Owen, 2012, Owen and O'Donovan, 
2017).   
 Further advances in the clinical conceptualization of autism is due to Lorna Wing, a British psychiatrist born 
in 1928, mother of an autistic child and founder of the National Autistic Society in the UK. She distinguished 
three types of social interaction: 
• CONFIDENTIAL: individuals indifferent to other people, detached, characterized by the presence of motor 
stereotypes, good mechanical skills and visual-spatial abilities, and medium-severe cognitive impairments 
(autistic disorder). 
• PASSIVE: autistic disorder with fewer symptoms that are detected later in life. 
• STRANGE: people who are a bit ‘naïve’, but with good cognitive abilities (high-functioning autism). 
During the 1950s and 1960s, autism was still considered an early manifestation of schizophrenia, which was 
thought of as an emotional disorder caused by pathological parent-child interaction.  
In the first two editions of the DSM, autism was classified under the terms ‘schizophrenic reaction, childhood 
type’ ((APA), 1952) and ‘childhood schizophrenia’ ((APA), 1968), respectively. 
During the 1970s, the psychogenic paradigm was abandoned and the scientific community started thinking 
that autism is a biological disorder, and is not caused by cold parents. Autism was also no longer considered 
incompatible with ID. Even in the 1960s children showing several signs of autism, co-occurring mild ID, and 
childhood psychosis were rediscovered. 
 17 
 
In the 1960s and 1980s there was still a clear controversy over the definition of autism between the international 
nosographic systems. The International Classification of Diseases - Ninth Revision, ICD-9 ((WHO), 1980) 
considered autism a diagnostic subcategory of the childhood schizophrenia. The DSM-III ((APA), 1980) 
introduced 6 diagnostic criteria for infantile autism including early onset within 30 months of age, 
communication and language disorders, narrow interests and fear of change. For the first time the distinction 
between schizophrenia and autism was emphasized by international classifications and the definition of 
Pervasive Developmental Disorder (PDD) was introduced. Five disorders belonged to PDD category: infantile 
autism, residual infantile autism, childhood onset pervasive developmental disorder, residual childhood onset 
pervasive developmental disorder, and atypical autism. Bringing forward the concept of ‘syndrome’, possible 
symptoms including the bizarre movements, problems of affectivity, abnormal speech, hyper- or 
hyposensitivity, self-harming behaviors, anti-social behaviors, and lack of empathy were mentioned. 
The DSM-III-R ((APA), 1987) provided a more complex definition and the diagnosis required that an 
individual had to exhibit at least 8 of these 16 criteria in the three areas of social interaction, 
communication/imagination and interest/activity. The age of onset was revised and shifted to ‘within the first 
36 months of life’. A new diagnostic category under the term of PDD-Not Otherwise Specified (PDD-NOS) 
was introduced. PDD-NOS was defined by subthreshold symptoms, too mild to allow a diagnosis of real autism 
that should be considered if a child does not meet the diagnostic criteria for a specific PDD. Revisions made 
in the DSM-III-R included changing infantile autism to autistic disorder, while childhood onset pervasive 
developmental disorder and residual infantile autism were dropped. 
The DSM-IV ((APA), 1994) further refined the diagnostic criteria and increased the number of PDD to  
five: autistic disorder, Asperger’s disorder, Rett’s disorder, childhood disintegrative disorder and PDD-NOS. 
The DSM-IV adds autism to the general chapter ‘global alterations of psychological development’ and 
particularly to ‘generalized developmental disorders’.  
In the DSM-IV-TR ((APA), 2000) the diagnostic categories and criteria remained consistent from the earlier 
edition.  
According to the revision of the IV edition of DSM (DSM IV-TR) valid until May 2013, the diagnosis of autism requires 
the following criteria:  
A. A total of six (or more) items from (1), (2), and (3), with at least two from (1), and one each from (2) and (3): 
(1) qualitative impairment in social interaction, as manifested by at least two of the following: 
a) marked impairments in the use of multiple nonverbal behaviors such as eye-to-eye gaze, facial expression, body 
posture, and gestures to regulate social interaction 
b) failure to develop peer relationships appropriate to developmental level 
c) a lack of spontaneous seeking to share enjoyment, interests, or achievements with other people, (e.g., by a lack 
of showing, bringing, or pointing out objects of interest)  
d) lack of social or emotional reciprocity  
(2) qualitative impairments in communication as manifested by at least one of the following: 
a. delay in, or total lack of, the development of spoken language (not accompanied by an attempt to compensate 
through alternative modes of communication such as gesture or mime) 
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b. in individuals with adequate speech, marked impairment in the ability to initiate or sustain a conversation with 
others 
c. stereotyped and repetitive use of language or idiosyncratic language 
d. lack of varied, spontaneous make-believe play or social imitative play appropriate to developmental level 
(3) restricted repetitive and stereotyped patterns of behavior, interests and activities, as manifested by at least two of the 
following: 
a. encompassing preoccupation with one or more stereotyped and restricted patterns of interest that is abnormal 
either in intensity or focus 
b. apparently inflexible adherence to specific, non-functional routines or rituals 
c. stereotyped and repetitive motor mannerisms (e.g. hand or finger flapping or twisting, or complex whole-body 
movements) 
d. persistent preoccupation with parts of objects 
B. Delays or abnormal functioning in at least one of the following areas, with onset prior to age 3 years: 
(1) social interaction 
(2) language as used in social communication 
(3) symbolic or imaginative play 
C. The disturbance is not better accounted for by Rett’s Disorder or Childhood Disintegrative Disorder. 
Given the extreme variability in autistic symptoms, which has been widely described by clinicians and 
researchers during the past 15 years, the authors of the DSM-5 substantially revised the concept of autism and 
PDD. The DSM-5 combined four previously separate disorders into a single condition under the heading of 
ASD with different levels of symptom severity. The previous DSM-IV autistic disorder, Asperger’s disorder, 
childhood disintegrative disorder, and PDD-NOS (atypical autism) are not recognized anymore as single 
nosological entities, while the Rett’s disorder became an independent disorder, with a specific genetic 
etiopathogenesis. The diagnosis of ASD requires two core symptoms: a) deficits in social communication and 
social interaction and b) restricted repetitive behaviors, interests, and activities (Achkova and Manolova, 
2014).  
The chronological criterion for the onset of symptoms has been widely modified from 36 months to ‘early 
childhood’, with the possibility of other ages of onset in the situations in which deficits may not become fully 
manifest until social communication demands exceed limited capacities. 
Some researchers have criticized the DSM-IV-TR and DSM-5 approach, considering responsible for both the 
widening of diagnostic criteria and the progressive increase in prevalence rates of autism spectrum conditions 
(Wing et al., 2011). 
According to DSM-5 the ASD diagnostic criteria include: 
A. Persistent deficits in social communication and social interaction across multiple contexts, as manifested by the 
following, currently or by history: 
1. Deficits in social-emotional reciprocity, ranging, for example, from abnormal social approach and failure of 
normal back-and-forth conversation; to reduced sharing of interests, emotions, or affect; to failure to initiate or 
respond to social interactions. 
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2. Deficits in nonverbal communicative behaviors used for social interaction, ranging, for example, from poorly 
integrated verbal and nonverbal communication; to abnormalities in eye contact and body language or deficits 
in understanding and use of gestures; to a total lack of facial expressions and nonverbal communication. 
3. Deficits in developing, maintaining, and understand relationships, ranging, for example, from difficulties 
adjusting behavior to suit various social contexts; to difficulties in sharing imaginative play or in making friends; 
to absence of interest in peers. 
B. Restricted, repetitive patterns of behavior, interests, or activities, as manifested by at least two of the following, 
currently or by history: 
1. Stereotyped or repetitive motor movements, use of objects, or speech (e.g., simple motor stereotypes, lining up 
toys or flipping objects, echolalia, idiosyncratic phrases). 
2. Insistence on sameness, inflexible adherence to routines, or ritualized patterns of verbal or nonverbal behavior 
(e.g., extreme distress at small changes, difficulties with transitions, rigid thinking patterns, greeting rituals). 
3. Highly restricted, fixated interests that are abnormal in intensity or focus  
4. Hyper- or hyporeactivity to sensory input or unusual interest in sensory aspects of the environment (e.g. apparent 
indifference to pain/temperature, adverse response to specific sounds or textures, excessive smelling or touching 
of objects, visual fascination with lights). 
C. Symptoms must be present in the early developmental period (but may not become fully manifest until social 
demands exceed limited capacities, or may be masked by learned strategies in later life). 
The DSM-5 defines three levels of severity based on the adaptive functioning: 
• Level 1: Requiring support  
• Level 2: Requiring substantial support  
• Level 3: Requiring very substantial support 
The disorder has been placed in a meta-syndromic or meta-structural grouping named ‘Neurodevelopmental 
Disorders’ which includes: 
• Autism Spectrum Disorder 
• Intellectual Disability (Intellectual Developmental Disorder)  
• Communication disorders 
• Attention-Deficit/Hyperactivity Disorder 
• Specific Learning Disorder 
• Motor Disorders 
The neurodevelopmental disorders comprehend conditions with onset in childhood, typically early, often prior 
to entry to school, and are characterized by developmental deficits which produce impairments of the personal, 
social, academic, or occupational functioning. The range of developmental deficits varies from very specific 
limitations in learning and executive functions to the global impairment of social skills or intelligence. The 
neurodevelopmental disorders frequently co-occur together; for example, people with autism often have ID.  
However, the debate on the final drafting of the autism core symptoms is still in progress. Some authors suggest 
centring the diagnosis on repetitive behavior and stereotypes, while others on sensorial sensitivity (Billstedt et 
al., 2007, Happe and Ronald, 2008, Leekam et al., 2007). 
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1.3.2 EPIDEMIOLOGY 
In the last decade the prevalence of autism has increased considerably. In the 1960s the highest reported rate 
was 0.5/1.000, whereas it currently stands at 1–2/1.000 (Newschaffer et al., 2007). The recorded prevalence 
of ASDs has increased dramatically in the last decade and they are now considered the most common disorders 
in childhood, with a rate of 6/1.000 (Newschaffer et al., 2007, Fombonne, 2009). A 2009 American report 
(Boseley, 2009) based on the 2007 Adult Psychiatric Morbidity Survey by the National Health Service in the 
UK, estimated that the prevalence of ASD in adults was approximately 1/100 (Brugha et al., 2011). A recent 
study (Kim et al., 2011) conducted by Kim and colleagues at the University of Yale found that about 2.64% 
of South Korean children are affected by autism.  
The age of onset traditionally occurs early in the first years of life (Ozonoff et al., 2008). The male-to-female 
gender ratio is approximately 3-4/1 (Newschaffer et al., 2007).  
 
1.3.3 ETIOPATHOGENESIS 
Definitive etiopathogenetic mechanisms of ASD have not yet been identified. Currently the international 
scientific community is inclined to consider a complexity of different causal elements including both 
environmental and biological factors, especially genetic ones. Their combination may induce structural and 
functional defects of the Central Nervous System (CNS) in the first years of life and may produce the 
characteristic phenotype of autism. The current theories suggest that ASD resulted from the disruption of 
normal brain development with subsequent effects on cerebral functioning related to the specific symptoms of 
ASD (Watts, 2008).  
 
Genetic factors 
Genetic mutations appear to be a major cause of autism. More than one gene may be implicated and several 
candidate genes have been located. Submicroscopic chromosomal abnormalities have been identified in almost 
1/5 of cases (Shen et al., 2010, Schaaf and Zoghbi, 2011), whereas ASD-linked mutations of many candidate 
genes have been identified. The heritability of autism showed that 82-92% of monozygotic and 1-10% of 
dizygotic twins develop ASD (Persico and Bourgeron, 2006). Furthermore, autistic symptoms are usually 
observed in many genetic syndromes, such as fragile X, tuberous sclerosis, phenylketonuria, as well as 
conditions affecting the first stages of CNS development during pregnancy, for example congenital rubella 
(Freitag, 2007, Betancur et al., 2009). 
Many of the genes associated with autism code for proteins involved in regulating synaptic connectivity and 
brain functioning (Persico and Bourgeron, 2006, Folstein and Rosen-Sheidley, 2001).  
Recent methodological advances of human genetics increased knowledge on the biological processes of 
ontogenesis and allowed the discovery of new DNA variants in ASD including the Copy Number Variations 
(CNVs) (Marshall and Scherer, 2012). CNVs are defined by a polymorphism from spontaneous deletions to 
duplications involving one or more DNA nucleotide. In the last years many studies found robust association 
between CNVs and ASD, mediated by specific structural and functional alterations of the CNS (Watts, 2008).  
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In 2004, to provide a better description of the ASD risk-associated genes, the Autism Genome Project (AGP) 
was launched. AGP is the world's largest research project on DNA mapping and included analysis of DNA 
samples from approximately 1.200 families. The AGP suggested the contribution of chromosome 11 
alterations in the pathogenesis of autism, along with the gene coding for the Neurexin 1 (NRXN1), a protein 
involved in synapse formation and synaptic transmission. Similarly, the dysfunction of the Neuroligin 
(NLGN), a cell adhesion protein on the postsynaptic membrane that mediates the formation and maintenance 
of synapses, was implicated in ASD. Mutations of the NRXN1 and NLGN genes have been also associated 
with schizophrenia, and ID too (Autism Genome Project et al., 2007, Sudhof, 2008).  
Additionally, one of the most studied genes was SHANK3 (SH3 and multiple ankyrin repeat domains 3) 
located on chromosome 22 and coding for the protein with the same name, also known as ProSAP2 (Proline-
rich synapse-associated protein 2), which is involved in synapses formation and in dendritic spines maturation 
as well as in the connection of various neurotransmitters receptors, ionic channels and other membrane proteins 
to the actin cytoskeleton (Durand et al., 2012). 
 
Epigenetic mechanisms  
Although increased evidence indicates genetic factors as a major cause of autism, the role of epigenetic 
mechanisms has been extensively studied. In fact, epigenetic mechanisms that alter gene expression and 
phenotype without changing the DNA sequences, seem to play a key role in mediating the interaction between 
genetics and environment in the etiopathogenesis of ASD. For instance, the genetic alterations of gene 
subsiding epigenetic control of DNA expression across life have been implicated not only in the pathogenesis 
of ASD but also of major mental health conditions such as schizophrenia (Neniskyte and Gross, 2017).  
DNA methylation is the most widely studied, and also environmental toxins exposures are known to influence 
epigenetic modifications prenatally and throughout life (LaSalle, 2011, Zhubi et al., 2014, Loke et al., 2015). 
Interestingly, Rett syndrome is an X-linked disorder characterized by ID, motor deficits and autistic-like 
behaviors. This syndrome seems to be caused by an epigenetic alteration in the gene encoding methyl-CpG 
binding protein 2 (MECP2), which binds to methylated regions and activates the deacetylation of histones, 
inducing DNA inactivation. Decreased MECP2 levels have also been found in the cerebral cortex of people 
with ASD (Woods et al., 2012). 
 
Biological and environmental factors 
Environmental factors have been considered to contribute to autism or exacerbate its symptoms. Infections, 
such as congenital rubella syndrome or cytomegalovirus, may occur during pregnancy and increase the risk of 
autism (Libbey et al., 2005). The possible contribution of allergic or mother's immune response during the 
pregnancy was supported by findings of maternal antibodies reactive to foetal brain proteins, which also seems 
to indicate their ability to pass through the blood-brain barrier and affect the development of brain.  
Toxic substances, which act through their teratogen potential and cause birth defect, include pesticides, 
phthalates, alcohol and some drugs, such as terbutaline, thalidomide, misoprostol, and valproic (Gardener et 
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al., 2009). Toxic metals such as antimony, arsenic, cadmium, chromium, lead, mercury, manganese, nickel, 
styrene, trichloroethylene, methylene chloride, vinyl chloride and particulate of diesel are associated with 
ASD. Therefore, the prenatal exposure to high air pollution containing many toxins impacts negatively on the 
neurological function and seems to double the risk of developing ASD (Roberts et al., 2013).  
Scientists have spent years debating whether the use of common antidepressants during pregnancy could 
increase the risk of ASD. Boukhris and colleagues (Boukhris et al., 2016) have recently published several 
reports suggesting that maternal exposure to selective serotonin reuptake inhibitors during pregnancy would 
be associated with an increased risk of autism, but this causal relationship does not seem supported by clear 
evidence (Andrade, 2017b, Andrade, 2017a, Croen et al., 2011, Suri et al., 2014, O'Dowd, 2014). 
On the contrary, metabolic problems that affect mothers during pregnancy, especially type 2 diabetes, are 
significantly associated with an increased risk of ASD, as well as maternal obesity during pregnancy, although 
further study is needed (Krakowiak et al., 2012, Li et al., 2016).  
It has been hypothesized that high levels of amniotic testosterone could play a role in ASD. Prenatal 
testosterone levels seem to play an important role in brain development by influencing communication skills 
and empathy and emphasizing masculine characteristics (Auyeung et al., 2009, Auyeung et al., 2010) giving a 
biological basis to the theory of the extreme male brain (Baron-Cohen, 2002). 
Autism is associated with some perinatal and obstetric conditions including low birth weight, abnormal 
gestation length and hypoxic-ischaemic insult at birth (Kolevzon et al., 2007).  
Furthermore, a broad variety of postnatal contributors to autism have been proposed, including: autoimmune 
diseases (Ashwood and Van de Water, 2004), leaky gut syndrome (Johnson, 2006), vitamin D deficiency 
(Cannell, 2008), and heavy metal toxicity (Davidson et al., 2004). For the majority of these risk factors, there 
is no definitive evidence of a causal or co-causal role in the development of ASD. As suggested above, it is 
plausible that at least an alteration of epigenetic mechanisms is needed to exert the specific final pathway to 
autism of this variety of factors.  
Some researches indicate that oxidative stress may be related to autism in individuals who are genetically 
predisposed (Kern and Jones, 2006). One theory is that stress increase the secretion of Corticotrophin-
Releasing Hormone (CRH) which stimulate mast cells to release cytokines, increasing the blood-brain barrier 
permeability and damaging the functional and structural integrity of Purkinje cells in the cerebellum (Chauhan 
and Chauhan, 2006). 
Recently, food substances containing gluten and casein have been implicated in ASD, but their pathogenic 
mechanism in brain damage has not yet been clarified (Mari-Bauset et al., 2014).  
Among these factors, childhood vaccinations, especially the Measles-Mumps-Rubella (MMR) vaccine, have 
attracted considerable attention. First Andrew Wakefield, a British physician known for his fraudulent 1998 
paper, suggested that MMR antibodies were significantly higher in the gut of autistic children, but this 
association was never backed up by extensive evidence based on a large sample of observations (Afzal et al., 
2006, Chen et al., 2004, Taylor et al., 2014, Wilson et al., 2003). 
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In 2013, Prof. Frank DeStefano and colleagues from the U.S.A. CDC (Centres for Disease Control and 
Prevention) conducted a study on over 1.000 children with and without autism. This study did not find any 
link between ASD and the antigens contained in the vaccine, which determine the activation of the immune 
system. The early exposure to heavy metals was also suspected of increasing the risk of ASD correlated to 
vaccinations. In particular the hypothesis involved the use of the mercury-based compound thiomersal as 
childhood vaccines preservative. There was an enormous debate, but once again, large-scale research showed 
that children vaccinated with products with and without mercury have the same risk of ASD occurrence. The 
stronger evidence is that the autism rate has remained unchanged since the 2002 when the thiomersal was 
completely removed from paediatrics vaccines (Roberts and Harford, 2002, Stratton, 2012). 
 
Neuroanatomical abnormalities and neurotransmitters system 
Functional Magnetic Resonance Imaging (fMRI) allows researchers to observe directly brain activities while 
subjects perform various perceptual, and cognitive tasks. Brain-imaging techniques like fMRI have shown 
altered functional patterns in several brain areas related to specific functions, such as social, cognitive, 
linguistic, and visuospatial processing in children and adults with ASD (Maximo et al., 2014). Currently, a 
very plausible hypothesis suggests that disrupted connectivity should be seen as part of the primary 
pathogenesis of ASD. Evidence showed both of local over-connectivity and of long-distance under-
connectivity that appear more severe in later-developing cortical regions (Minshew and Keller, 2010, Muller 
et al., 2011). The disconnection of these neural circuits could lead to deficits in complex information processing 
and integration (Courchesne et al., 2001, Courchesne et al., 2007, Geschwind and Levitt, 2007, Mizuno et al., 
2006, Noonan et al., 2009, Turner et al., 2006). The disruption of the typical development of neural circuitries 
probably involve histogenesis processes alterations since the first phases of CNS development during foetal 
life and then childhood: various processes may be involved and include neurogenesis, neuronal migration, 
dendritic development, synaptogenesis, synaptic pruning, dendritic plasticity and myelination. Some 
researchers reported an overall brain enlargement, while others suggested abnormalities in several areas, 
including the frontal lobe, limbic system, temporal lobe, and corpus callosum (Stanfield et al., 2008, Lefebvre 
et al., 2015). It is probable that each of these neurodevelopmental processes may be differently implicated in 
the pathogenesis in each individual with ASD, with the result of considerable heterogeneity of ASD 
phenotypes.  
Many neuroanatomical studies focused on the cerebral structures and neural circuits crucial for the ASD 
symptoms: 
1) difficulty in social interactions has been related to dysfunctions in the orbitofrontal cortex, anterior cingulate 
cortex, fusiform gyrus, superior temporal sulcus, amygdala, mirror neurons, inferior frontal gyrus and posterior 
parietal cortex; 
2) deficits in language development and communication skills have been related to the dysfunction of the 
inferior frontal gyrus - Broca's area, superior temporal sulcus, supplementary motor area, basal ganglia, 
thalamus, and cerebellum pontine nuclei; 
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3) repetitive behaviors, ritualized and restricted range of interests have been related to dysfunction of the 
orbitofrontal cortex, anterior cingulate cortex, basal ganglia, and thalamus. 
Volumetric studies are contradictory as some studies observed increased total brain volume (Minshew et al., 
2005), while other found at the opposite a decrease as well as smaller posterior subregions of the corpus 
callosum (Courchesne et al., 1993, Stanfield et al., 2008, Hardan et al., 2009). Other researchers found 
microstructural abnormalities mainly concerning a reduction of Purkinje cells of the cerebellum (Bauman and 
Kemper, 2005). In early knowledge, cerebellum was considered to be involved exclusively in motor function, 
while today it has been associated with broader functions including cognition and emotional regulation.  
The amygdala is involved in many significant processes of social cognition. Increased, reduced or normal 
amygdala volume have been described (Eigsti and Shapiro, 2003, Howard et al., 2000, Schumann et al., 2004, 
Stanfield et al., 2008).  
Despite the importance of communication and language deficits in autistic individuals, there are few studies 
that examined the neuroanatomical areas that perform these functions. The areas of language include: Broca’s 
area in the inferior frontal gyrus implicated in expressive language, Wernicke’s area in the temporal-parietal 
region implicated in receptive language and the superior temporal sulcus which play a role in both the 
processing of language and social attention. Lesions to the language centre resulted primarily in alterations of 
the normal pattern of asymmetry (De Fosse et al., 2004, Redcay, 2008, Rojas et al., 2005).  
Investigations into other brain regions that may be involved in autism are limited. Abnormalities of the 
thalamus (Hardan et al., 2006), hippocampus (Dager et al., 2007, Nicolson et al., 2006, Schumann et al., 2004), 
and basal ganglia (Hardan et al., 2003, Hollander et al., 2005) were found. In particular, studies highlighted 
that repetitive and ritualistic behaviors were associated with larger increases in caudate volume (Hollander et 
al., 2005). 
Recent evidences provide a better understand of neurotransmitter mechanisms regulating social behavior. 
Oxytocin and vasopressin neuropeptides play an important role in social cognition, affecting individual 
differences in social recognition, and parenting or affiliative behaviors. The processes of social cognition are 
also supported by reward circuitry, underpinned by the activation of the brain dopaminergic system. Reward 
processes play a role in the development of social skills, parenting and pairing, and also influence social 
interactions, which require trust or altruism. The effect of emotional regulation upon social behavior is also 
mediated by norepinephrine and serotonin systems (Skuse and Gallagher, 2011).  
 
Electrocortical alterations 
Some neurophysiological investigations on individuals with ASD reported abnormal frequency range (30-80 
Hz) in neuronal synchronization related to alterations in sensory and cognitive functioning, especially in 
working memory and perceptual binding (Saunders et al., 2012).  
Networks of GABAergic interneurons are implicated in synchronizing cortical activity, and seem to play a 
fundamental role in cognitive functions, such as attention and sensory processing (Endele et al., 2010, 
Rubenstein and Merzenich, 2003). 
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Imbalance between excitation, inhibition and increased excitatory-inhibitory (E-I) ratio is a commonly 
suggested mechanism in ASD, which is responsible for learning and memory as well as cognitive, sensory and 
motor deficits, and seizures occurring in these disorders. E-I imbalance in ASD is due primarily to abnormal 
glutamatergic and GABAergic neurotransmission in key brain regions such as the neocortex, hippocampus, 
amygdala, and cerebellum (Uzunova et al., 2016).  
 
Mirror neurons 
It has also been proposed that deficiency of the mirror neuron system may underlie cognitive disorders in 
individuals with autism. Mirror neurons were first discovered by Giacomo Rizzolatti and his colleagues at the 
Department of Neuroscience of the University of Parma (Rizzolatti et al., 1996). Using electrodes implanted 
in the pre-motor cortex of the macaque monkey, the researchers observed that some groups of neurons were 
activated not only when animals were intent on certain actions, but also when watching someone else perform 
the same actions. Subsequent studies, carried out with non-invasive techniques, demonstrated the existence of 
similar system in humans. Various areas in the brain contain mirror neurons, such as those of language, and 
provide a physiological explanation of human ability to relate one each other. When we observe any other 
performing an action, our brain activates the same neurons that come into play when we perform that action, 
or alternatively the same neurons that came into play when we undertook similar actions in the past. In fact, it 
seems that the mirror system comes into action only when the subject observes a behavior that he himself has 
previously performed. Even the recognition of emotions seems related to a group of neural circuits in which 
the same mirror feature was observed. Experimental studies on primary emotions show that when one observes 
others' facial expressions of disgust or pain the same neural substrate connected to the first perception is 
activated. Furthermore, clinical trials confirm that the loss of ability to feel emotions caused by neurological 
damages may lead also to lose the ability to recognize and interpret another person's emotions. 
The discovery of mirror neurons may provide a biological explanation for at least some forms or features of 
autism. In fact, experiments seem to indicate decreased functioning of these neurons in autistic children. 
Although this is just a hypothesis, it may help to understand why autistic people do not participate in the life 
of others, cannot empathize with the world around them, and do not understand the meaning of the gestures or 
actions of others (Gallese and Goldman, 1998). 
 
Theory of mind 
Uta Frith and Simon Baron-Cohen identified a deficit in the Theory of Mind (ToM) as the base of the 
difficulties of people with ASD to interact with others and with the outside world. Baron-Cohen described the 
ToM as the ability to infer a complete range of mental states including beliefs, desires, intentions, imagination, 
emotions, etc. from observable behavior. Handling with theory of mind means to be able to attribute intentional 
(desires) or epistemic (beliefs) mental states to oneself and to others, and to predict the behavior of oneself or 
others on the basis of individual ‘internal’ mental states which determine those behaviors (Baron-Cohen, 
1991). 
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The concept of theory of mind is closely related to the more general concept of metacognition. The ToM would 
be a specific aspect of a broader range of metacognitive skills acquired during ontogenetic development. 
Metacognition refers to a set of skills which makes it possible to recognize and attribute mental states to others 
starting with facial expressions, somatic states, behaviors and actions. Metacognition also makes it possible to 
estimate mental states and to use the resulting information to make decisions, to solve problems, and to master 
subjective sufferings (Semerari et al., 2012).  
Deficits in metacognitive capacity were associated with damage to the prefrontal cortex, superior temporal 
sulcus, front part of the temporal lobes and amygdala. 
Some phenomenologists and psychopathologists have recently expressed many doubts that the deficits in ToM 
have a role in ASD, and more generally in the processes of social cognition. Studies have found that many 
people with ASD and/or psychotic disorders consciously observe and imitate the behaviors of others. 
According to these researchers the processing of the perception of others would be conscious, finalized, and 
would not require any theory or simulation. For people with ASD the practice of explicit mind-reading seems 
to be a compensatory strategy which ultimately fails, and may even exacerbate their deficit of intuitive and 
interactive social understanding. A lack of embodiment interaction represents a valid alternative (Froese et al., 
2013a, Froese et al., 2013b, Gallagher and Varga, 2015). 
 
1.3.4 PROBLEMS ASSOCIATED WITH AUTISM SPECTRUM DISORDERS 
ASD is associated with a complex physical and especially psychic vulnerability based on biological, 
psychological and environmental factors. 
Several studies have found abnormal sensitivity to sensory stimulation in 90% of children (Leekam et al., 
2007) and in more than 95% of adults with ASD (Billstedt et al., 2007). Therefore, some authors suggested 
that sensory processing problems are more frequent than social interaction difficulties (Baum et al., 2015). 
This aspect is so significant that DSM-5 included sensory issue among the diagnostic criteria for ASD.  
ASD persons may also have a variety of neurological and medical illnesses: epilepsy, gastro-intestinal 
disturbances, immunity imbalance are the most frequent. Issues related to neurological and medical 
comorbidities are largely overlapping to those of intellectually disabled persons and have been extensively 
discussed in 1.2 section. 
 
Problem behaviors 
Problem behaviors (PBs or Challenging Behaviors) are common in people with ASD, with a prevalence of 
44% (Mattila et al., 2010) which can overcome the 85% in LF-ASD (McCarthy et al., 2010), rather, the co-
occurrence of the two conditions increases the risk of PBs comparing to the individual conditions.  
Hyper-activity, aggression, self-injurious behavior, irritability, and tendency to moodiness (Emerson et al., 
2001b) are often observed in people with ASD. Challenging behavior may also simply be a means of 
communication and occur most likely in individuals with communication impairment (McClean and Grey, 
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2007, Sigafoos, 2000). Research found a relationship between PBs, such as aggression, tantrums, destruction 
of property, and severity of communication deficit and socialization problems (Matson et al., 2009b).  
The majority of PBs have a complex multifactorial aetiology in ASD including biological, psychological, 
social and developmental factors. Challenging behaviors can occur as symptoms of other psychiatric disorders 
or physical diseases, but any particular behavior cannot be associated with one specific disorder. 
In people with ASD the most frequent causes of PBs are:  
• confusion and fear produced by unusual situations or events 
• interference with routine or repetitive activities 
• inability to understand instructions or explanations 
• lack of knowledge on how to behave in a way that is appropriate to the context 
• inability to communicate needs and emotions 
• sensorial hyperesthesia 
• specific phobias of situations or objects 
• stress related to the performance of tasks that are too difficult 
Determining whether PBs are the result of organic conditions, co-occurrent psychiatric disorders, 
environmental influences, or a combination of these, is difficult. Thus, the assessment procedure should 
consider all risk factors, in order to provide appropriate treatment options and support (Matson and Sturmey, 
2011). 
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1.4 DEPRESSIVE AND BIPOLAR DISORDERS 
1.4.1 DEFINITION AND CRITERIA 
The modern concept of Bipolar Disorder (BD) is due to Kraepelin (Kraepelin, 1896), who grouped endogenous 
psychoses in two distinct categories: manic-depressive insanity and dementia precox. Before that time other 
authors had conceptualized manic-depressive illness as folie circulaire (Falret), insanity of double-form 
(Baillarger) and cyclothymia (Kahlbaum and Hecker) (Snook et al., 2015). Kraepelin distinguishes manic-
depressive insanity form dementia praecox for the episodic and recurrent pattern, less or no impairment in 
cognition and relatively favourable long-term course and outcome.  
In 1957 the term bipolar was coined by Leonhard to indicate those patients with both manic and depressive 
episodes comparing to monopolar patients only reporting depressive episodes. Subsequently, some authors 
confirmed this distinction by describing case reports and through familial data (Angst, 1966, Winokour et al., 
1969). Other authors proposed unipolar and bipolar patients belonging to the continuum of manic-depressive 
illness (Goodwin and Jamison, 2007). DSM-III ((APA), 1980) separated Major Depressive Disorder (MDD) 
and BD putting them together in the chapter of Mood Disorders (MDs). In the same period some authors 
proposed the distinction of BD type I and II according to the history of manic episodes and only hypomanic 
episodes, respectively (Dunner et al., 1976). DSM-IV and DSM-IV-TR did not make substantial variations in 
the descriptions and nosography of MDs, except for the inclusion of BDII along with cyclothymic disorder 
((APA), 1994). BDI and II were also included in the tenth edition of ICD under the common label of bipolar 
affective disorder ((WHO), 1999). In the last four decades a great body of literature regarding MDs have been 
produced and the concepts of depressive and bipolar disorders are being continuously evolving. In the DSM-
5 ((APA), 2013) the panel for MDs made some significant changes. The biggest change is that the MDs 
category disappeared and was decompose in the two separated categories of Depressive Disorders (DDs) and 
BDs. In ICD-11 DDs and BDs have been separated too, but remaining under the persisting matasyndromic 
label of the MDs.  
The basic shape of the DSM-5 definition of major depressive episodes (MDE), fundamental for the diagnoses 
of MDD, BDI and BDII, is substantially unchanged: the presence of five of nine diagnostic symptoms 
including depressed mood and/or loss of interest and pleasure is required for at least 2 weeks. The severity of 
symptoms causes a change of the functioning. As in the previous editions, a variety of course and episodic 
specifiers are provided to facilitate a complete description of the disorder and, for research purposes, to better 
entail different phenotypes. Specifiers are the same for MDD, BDI, BDII and BD-NOS: they regard remission 
(partial and full), severity (mild, moderate, severe), peripartum onset, seasonal pattern, and clinical associated 
features: anxious distress, mixed features, melancholic features, atypical features, mood-congruent and -
incongruent psychotic features, catatonia. The course specifier “with rapid cycling” is related to only BDs. 
MDE is defined by the presence for at least two weeks of five or more symptoms including depressed mood, 
diminished interest or pleasure, significant reduction or increase of body weight or appetite, sleep disturbances 
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(both insomnia or hypersomnia), psychomotor agitation or retardation, fatigue or loss of energy nearly every, 
inappropriate or excessive feelings of worthlessness, guilt and other holothymic themes, diminished ability to 
think or concentrate or indecisiveness, suicidality including thoughts of death, recurrent suicidal ideation, 
suicide attempt or a specific plan for committing suicide. Depressed mood and loss of energy are essential 
symptoms, alternative one each other.   
DDs include along with MDD the newly conceptualized disruptive mood dysregulation disorder (DMDD), 
relative to children and adolescents, persistent depressive disorder (PDD) which represent the “evolution” of 
previous dysthymic disorder, and premenstrual dysphoric disorder. Other specified depressive disorders allow 
the diagnosis for those individuals do not meeting full criteria for other disorders, namely paucisymptomatic 
depression, short-duration depressive episode and recurrent brief depression.  
Except for its repositioning under DDs, at first sight MDD remained unchanged in DSM-5 comparing 
DSM.IV-TR. Three minor changes have been made in the criteria: 
1) The allowance of mood-incongruent psychotic symptoms arose some perplexities as it seems 
inconsequential with the depressive construct and better belonging with the bipolar one (Uher et al., 2014).   
2) Hopelessness was placed among the subjective descriptors as equivalent figure of depressed mood. This 
addition was in agreement with some research finding MDD patients potentially reporting hopelessness 
without sadness and vice versa. The change may broaden the diagnostic boundaries of depression and 
potentially increase the risk of overdiagnosis (Uher et al., 2014). 
3) DSM-5 removed the bereavement exclusion criteria relying on clinical judgment the diagnosis of MDE in 
the context of a significant loss. In spite of the clinical plausibility of this choice, this change provoked 
significant critiques (Wakefield and First, 2012). On one hand, some studies demonstrated that clinical and 
associated features, prognosis and response to treatments are similar to bereavement-unrelated MDE, 
questioning the utility of the differentiation (Kessing et al., 2010). On the other hand, the distinction between 
bereavement-related MDE, normal reaction to significant loss and complicated grief may appear too subjective 
and potentially leading alternatively to under- or overdiagnosis depending on the professional.  
The relationship of MDD with the other DDs may be somehow challenging. DSM-5 provided that MDD and 
PDD may co-exist as recurring MDE may superimpose to long-lasting subsyndromal depressive symptoms. 
Indeed, PDD includes both the DSM-IV-TR concepts of dysthymic disorder and chronic depression. In this 
vein, the relationship with MDD may be considered ambiguous as it is not completely clear whether or not the 
meeting of full criteria for the MDE for more than 2 years qualify MDD, PDD or both (Uher et al., 2014). 
Moreover, it is questionable the legitimacy of equalizing the constructs of former chronic MDE and dysthymia, 
which has solid and independent historical, epidemiological and clinical features. Even the new 
conceptualization of premenstrual dysphoric disorder, which is not considered an exclusion criterion for MDD 
and vice versa, may result ambiguous and the broadening of the criteria might lead to difficulties in establish 
reliable boundaries with other MDs as well as overdiagnosis.  
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The definitions of both manic and hypomanic episodes have been radically revised, with significant impact on 
both BD diagnoses. In a recent paper Jules Angst analyzed pros and cons of the new diagnostic criteria for BD 
(Angst, 2013), highlighting and discussing the main three changes:  
1) The change of the gate questions in criterion A is excessively restrictive and may lead to the exclusion of 
some individuals who were previously diagnosed as BD patients, or their classification as having subthreshold 
BD. Indeed, DSM-IV and DSM-IV-TR required the presence of elated/euphoric or irritable mood; in DSM-5 
the mood change has to be necessarily accompanied by “persistently increased activity or energy levels”. This 
modification is not actually based on reliable data, but it is in contrast with some evidences demonstrating 
exactly the opposite. A multicentric international study including 5635 major depressive patients clearly 
showed that any of those three gate questions (euphoric or irritable mood or increased energy levels) is valid 
on its own to identify BD patients (Angst et al., 2012). In this perspective, the author, as well as others before 
(Calabrese et al., 2017, Robins and Guze, 1970, Severus and Bauer, 2013), suggested the “under sizing” of 
mood in the diagnosis of MDs in favour of the reappraisal of psychomotricity as key altered function in MDs. 
In agreement with this point of view, a recent study found that the application of the dyadic criterion reduces 
the prevalence of manic and hypomanic episodes by about half (Machado-Vieira et al., 2017). By the contrary, 
other data shew only a minor impact on the prevalence of BDs according to DSM-5 criteria (Fassassi et al., 
2014). 
2) In the DSM-5 the list of exclusion criteria was reduced. One of the most important exclusion criteria 
removed was the hypomanic switch under antidepressants. If the full hypomanic syndrome persists after the 
interruption of antidepressants, the BDII diagnosis can be formulated. This modification conforms to some 
research data suggesting BDII to be actually as prevalent as BDI (Angst et al., 2012). Moreover, substance and 
medication-induced BDs have been reframed stressing that mood symptoms should disappear when the 
causative condition is removed: if anything, a diagnosis of BD is more appropriate. In clinical practice this 
strict causative relationship is often difficult to be ascertained.   
3) The introduction of the “Other specified bipolar and related disorder” represents the effort of DSM-5 task 
force to operationalize those subthreshold conditions previously falling under the vague label of Not Otherwise 
Specified (NOS). It seems also the attempts to maintain a connection between DDs and BDs: this new category 
includes those conditions in which MDE is associated with subthreshold excitative syndromes, for instance 
full symptomatic hypomanic presentations of short duration (2 or 3 days), paucisymptomatic presentations or 
hypomanic episodes superposed to dysthymia. Short duration cyclothymia is also included.  
As in the former versions of the DSM, mania and hypomania are both characterized by euphoric, elated or 
irritable mood and at least 3 out symptoms (4 if the mood is only irritable) from a list of 7 including inflated 
self-esteem or grandiosity, decreased need for sleep, talkativeness or pressured speech, racing thoughts or 
flight of ideas, distractibility, increased goal-directed activity or psychomotor agitation and excessive 
involvement in activities with high potential for painful consequences and risky behavior. The differentiation 
between BDI and BDII is essentially provided by the chronological and severity of the impairment criteria. 
The first pertains to the duration of full syndromatic presentation requiring at least one week for BDI and at 
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least 4 days for BDII. The latter refers to the severity of symptoms which has the shape of a clear and 
observable variation with respect to the usual functioning for hypomania, whereas for diagnosing mania a more 
substantial impairment is required in social or occupational functioning or the severity must be is such as to 
require the hospitalization to prevent harm to self or others. The presence of psychotic symptoms points out to 
the diagnosis of mania.  
In spite of some advances, the underdiagnosis of bipolar patients has to be expected, due to the heterogeneous 
ranks of MDD with significant implications for treatment strategies. In spite of this effort, some concerns 
already present for DSM-IV-TR and regarding the overall soft bipolar spectrum remain open. Indeed, the 
description of Cyclothymic Disorder (CD) has not been changed in DSM-5. CD is defined by the occurrence 
of “periods with hypomanic symptoms that do not meet criteria for a hypomanic episode and periods with 
depressive symptoms that do not meet criteria for a depressive episode”; thus, no specific type or cut-off 
number of symptoms is required. DSM-5 allows the diagnosis of CD, even with a history of hypomania, mania, 
or depression, but only if the CD came first and lasted for a sufficient period to support this diagnosis. 
Similarly, ICD-10 included cyclothymia among MDs, providing a rather broad definition of the disorder as “a 
persistent instability of mood involving numerous periods of depression and mild elation, none of which is 
sufficiently severe or prolonged to justify a diagnosis of bipolar affective disorder or recurrent depressive 
disorder”. ICD-10 overtly recognized that the disorder is frequently found in the relatives of patients with 
bipolar affective disorder and that some patients with cyclothymia eventually develop BD. Those definitions 
are quite appropriate to the reality, but in clinical practice the diagnosis of CD is too often missed, as the 
majority of cyclothymic patients seek psychiatric treatment for a major affective episode. This could be due to 
the key issue of the continuity with temperament and personality dispositions, which remains omitted. In fact, 
both in the ICD-10 and DSM-5 many of the core symptoms, psychological consequences and behavioral 
abnormalities of cyclothymia are left unmentioned. Excessive emphasis is given to variations in mood, while 
most of the essential motivational, volitional, emotional and cognitive aspects of the clinical picture are not 
even mentioned in the diagnostic criteria or among the associated features of CD. Mood reactivity and affective 
instability, extreme emotionality and impulsivity, which should be considered the true core features of 
cyclothymia, together with their psychological, behavioral and interpersonal consequences, are described from 
a different perspective in the DSM-5 criteria for dramatic or anxious clusters of personality disorders as well 
as in the ICD-10 definition of emotionally unstable and histrionic personality disorders. In the 
neurodevelopmental perspective similar symptoms _ or a part of them_ have been reframed under the label of 
emotional dysregulation, common not only in childhood and adolescence MDs, but also in ADHD, ASD and 
other neurodevelopmental disorders as well as in some organic psychiatric correlates (epilepsy, brain traumatic 
injury, etc.) (Mazefsky et al., 2013, Shaw et al., 2014).  
Moreover, DSM-5 introduces a new positioning of mixed episodes: mixed episodes do not exist anymore as 
independent entities, and mixed features become a specifier. This change represents the attempt to overcome 
longstanding concerns and actual difficulties in capturing complex mixed affective states with the combinatory 
model provided by DSM-IV-TR. These difficulties include the need to better capture the highly prevalent 
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subsyndromal presentations, very common in clinical practice (Vieta and Valenti, 2013). The mixed features 
specifier can be applied to depressive, manic and hypomanic episodes in MDD, BDI, BD II and BD-NOS. 
Mixed episodes are characterized by full meeting of the criteria for depressive, manic or hypomanic episode, 
respectively, plus at least three counterpolar symptoms present for most time during the episode. For the 
(hypo)manic episode potentially overlapping symptoms with MDE, for example psychomotor agitation, have 
been excluded. The list of depressive symptoms includes prominent dysphoria or depressed mood, diminished 
interest or pleasure, psychomotor retardation, fatigue or loss of energy, feelings of worthlessness or guilt and 
suicidality. For the MDE with mixed features all the (hypo)manic criteria are provided except for distractibility. 
This model creates a new concern regarding the impossibility to solve the unipolar-bipolar dichotomy, usually 
based on the presence or absence of manic features, often leading to significant rates of misdiagnosis (Bschor 
et al., 2012, Matza et al., 2005, Nusslock and Frank, 2011, Thase, 2006, Zimmermann et al., 2009). An MDE 
with mixed features belongs to DDs and the bipolar connection still remains unrecognized: however, in the 
manual, authors suggested caution in the choice of treatment strategies given the well-documented high rates 
of conversion to BD. Caution is also suggested given some clinical features specifically associated to mixicity, 
for example heightened risk of suicidality (Akiskal et al., 2005).  
In ICD-11 the clinical utility was the guiding principle of all the changes made comparing to ICD-10 as well 
as the applicability across transcultural differences. A prototype-based approach was preferred or integrated 
where necessary. In this vein, the major modification comparing to the previous revisions, not limited to the 
MDs section but extended to the overall revision, was to create a descriptive guideline accounting for a large 
variety of descriptions and including boundaries with normality and other disorders, developmental 
presentations, typical course, comorbidities, and culture‑ and gender‑related attributes (Chakrabarti, 2018, First 
et al., 2015, Maj, 2011). Comparing to DSM-5, ICD11 offered a more flexible approach to the diagnosis, 
minimizing excessively complex criteria and somewhat arbitrary thresholds. The counterpart is that the 
distinction between DDs and BDs is not fully emphasized (Paykel et al., 2012).  
The other major effort was the attempt to harmonize as much as possible the eleventh revision with DSM-5, 
especially in the overall structure. Thus, ICD-11 provided two separated blocks for DDs and BDs: however, 
the superordinate category of MDs was maintained in order to stress the traditional link between the two. A 
simplification was made as the description of all mood episodes was provided at the beginning of the MDs 
section. Individual diagnoses of different MDs were subsequently established according the differential 
patterns of mood episodes over time.  
Few conceptual changes have been made in the DDs section:  
1) Diagnostic symptoms were grouped in “clusters”. For example, reduced energy and fatigue were included 
in the “neurovegetative cluster” and not mentioned as essential features. In this vein, the “affective cluster” 
resulted predominant for the diagnosis.  
2) ICD-11, according to DSM, added functional impairment as essential feature. The severity subtypes (mild, 
moderate, severe) based on type, number and severity of the symptoms were retained across the versions in 
spite of the lack of evidences of their utility and reliability (Ayuso‑Mateos and Lopez‑García, 2012).  
 33 
 
3) ICD-11 provides clinical and course specifiers, here called “qualifiers”, used for single as well as for 
recurrent depressive episodes. Some qualifiers were maintained from ICD-10, for example melancholia and 
remission qualifiers, whereas others were borrowed by DSM-5 such as the seasonal pattern, the peri-natal onset 
and “with prominent anxiety symptoms”. The latter, similar to the DSM-5 “anxious distress” specifier, is 
supported by a body of research indicating the presence of severe anxiety during depression as an important 
phenotypization index as well as prognostic and treatment factor (Uher et al., 2014). This qualifier has not to 
be confused with “mixed depressive and anxiety disorder” accounting for those clinical pictures commonly 
found in primary-care settings, and characterized by subthreshold depressive and subthreshold anxiety 
symptoms (Chakrabarti et al., 2012, Moller et al., 2016, Paykel et al., 2012). This category, put under DDs in 
ICD-11, has not been included in DSM-5.   
4) Dysthymic disorder diagnosis has been enriched with more in depth descriptions than both ICD‑10 and 
DSM-5, emphasizing the subthreshold chronic course (Phillips, 2012). The superposition of MDE is allowed 
as in DSM-5, given full criteria for dysthymic disorder preceding the onset of MDE. In ICD-11 the boundaries 
with depressive personality disorder are better defined as well as the latter represents an exclusion criterion for 
the diagnosis of dysthymic disorder.  
The description of BDs and, for instance, manic and hypomanic episodes in ICD-11 was in agreement with 
DSM-5’s. ICD-11 also added to persistent euphoria, irritability, expansiveness, and lability, the changes in 
activity or energy as essential criterion for the diagnosis. The inclusion of an additional feature regarding 
effects of psychopharmacological medications, allowing the diagnosis of BD in case of persistent (hypo)mania 
beyond the known effects of these treatments, follows the DSM-5 indication. The ICD-11 qualifiers of BDs 
are similar to DSM-5 specifiers and pertain remission, severity, psychotic symptoms, melancholia, comorbid 
anxiety, perinatal onset, seasonal pattern, and rapid cycling.  
In contrast with DSM-5, ICD-11 retained the previously accepted definition of mixed episode (Maj, 2012), 
probably receiving the critiques to DSM mixed specifier (Malhi and Porter, 2016). Moreover, the MDE with 
mixed features is poorly differentiated from mania and hypomania. By the contrary, and according with a part 
of the classical literature (Kraepelin, 1913, Salvatore et al., 2002), ICD-10 emphasized as core features of 
mixed states the rapid alternation of depressive and counterpolar symptoms, rather than the simultaneity of full 
criteria (Maj, 2012). This definition, more adherent to classical and modern conceptualizations of mixed states 
as well as to clinical experience, is less operationalizable. In ICD-11 additional and detailed descriptions of 
excitative symptoms and qualifiers are provided in the attempt to reduce this gap. 
ICD-11 is aligned to DSM-5 in including for the first time in the ICD system the BDII diagnosis, considering 
the vast amount of research supporting its independency into the bipolar spectrum regarding familial, 
presentation, course and outcome (Strakowski, 2012). Contrary to DSM-5, with the exception of cyclothymia, 
no further soft bipolar spectrum condition has been included given the paucity of replicated data (Strakowski 
et al., 2011, Zimmerman, 2012). The description of cyclothymia is in agreement with DSM-5 but further efforts 
have been made to distinguish cyclothymic mood instability from mood fluctuations ranging in the normality. 
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On the other hand, similar attention has been dedicated to differentiate psychotic mood disorders from clinical 
pictures pertaining the schizophrenic spectrum (Strakowski, 2012). 
 
 
1.4.2 EPIDEMIOLOGY 
Depressive Disorders 
A large body of literature indicates DDs, namely MDD, as a major source of functional impairment and 
disability in Western Countries (Spijker et al., 2004, Kessler and Bromet, 2013, Moussavi et al., 2007, Bromet 
et al., 2011, Greenberg et al., 2015). MDD has been associated to poor socio-economic status (Kessler, 2012), 
lower educational level (Kessler et al., 2003), mental and physical health burden (Grant and Harford, 1995, 
Greenberg et al., 2015, Hasin et al., 2005, Kessler et al., 2003, Kessler et al., 1994, Regier et al., 1990, 
Vancampfort et al., 2015), and mortality (Kessler, 2012). Prevalence data on DDs and their epidemiologic 
correlates are mostly relative to pre-DSM-5 period. Large nation-wide surveys found lifetime prevalence rates 
of MDD ranging from 3.0% (Weissman et al., 1991) and 16.2% (Kessler et al., 2003). Despite the extent of 
the prevalence gap, all the studies agreed that MDD would have an early onset with a low risk in early teens, 
a linear increase in the second decade with the achievement of the peak of onset around 30 years. The rates of 
onset resulted slightly lower during the third and the fourth decade whereas a significant reduction was found 
after 60 years (Kessler et al., 2003). All the community surveys also found that persons with a lifetime 
diagnosis of MDD were more vulnerable to the lifetime development of further psychiatric disorders (Regier 
et al., 1990, Kessler et al., 1996). For example, in the National Comorbidity Survey Replication (NCS-R) 
almost the 75% of MDD patients had another lifetime psychiatric diagnosis, mostly anxiety disorders (59.2%), 
substance use disorders (24%), and impulse control disorders (30%). The rates of simultaneous co-occurrence 
of MDD with other diagnoses in the previous 12 months resulted similar. Higher severity was associated to 
higher rates of psychiatric comorbidities (Kessler et al., 2003).  
Recently the results of National Epidemiologic Survey on Alcohol and Related Conditions III (NESARC-III), 
a large national US study including more than 35000 participants, have been published (Hasin et al., 2018). In 
the survey the DSM-5 have been employed. The12-month and lifetime prevalence rates of MDD were 10.4% 
and 20.6%, respectively. Women showed in both the measures about doubled rates (13.4% and 26.1% among 
women vs. 7.2% and 14.7% among men): the study confirmed the gender difference previously reported 
(Goodwin and Jamison, 2007, Hasin et al., 2005, Mojtabai et al., 2016). MDD resulted associated to lower age 
and economic status, the mean age at onset of MDD was estimated between the second and the third decade 
and the median duration of the longest MDE was around 6 months (Hasin et al., 2018). Suicidality was also 
explored considering its detection when depression had been estimated to be at its severity peak: suicidality 
(including thoughts of death, desire of dying and contemplating suicide) resulted to be a depressive feature in 
almost the half of MDD patients lifetime comparing to around the 30% only considering the MDEs in the 
previous 12 months (Hasin et al., 2018).   
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In agreement with previous studies both 12-month and lifetime MDD were significantly associated to all the 
psychiatric comorbidities in the NESARC-III. Particularly prominent association emerged with drug use 
disorder (lifetime OR 2.5), higher than for alcohol or nicotine use disorders, and borderline personality 
disorders, stood out from other personality disorders (lifetime OR 4.4). The risk of the co-occurrence of an 
anxiety disorder was near to 4 times higher comparing to non-MDD participants, with the highest OR of 4.9 
for GAD (Hasin et al., 2018).   
The most interesting results of the NESARC-III regarded the two clinical specifiers. The anxious/distressed 
specifier characterized 74.6% and 70% of lifetime and 12-month MDD participants respectively, whereas the 
mixed-features specifier criteria was met in the 15.5% and 20.6% of lifetime and 12-month MDD participants, 
respectively. Both the specifiers resulted significantly associated with clinical and course indices of higher 
severity of the disorder. Specifically, MDD participants with positive lifetime mixed specifier more frequently 
belong to the MDD severe group. Mixed specifier was associated to earlier age at onset with mean age lower 
than 3 years comparing to non-mixed participants, but also to major treatment utilization with the highest gap 
reported in the need for emergency treatments and hospitalizations. Mixed MDD patients also reported 
significant higher impairment in all the functioning areas explored (mental health, social and emotional-role 
functioning). Suicidality was significantly associated to mixed features with very significant rates in general 
and particularly a doubled prevalence rate of suicide attempts (12.0% in non-mixed vs. 22.6% in mixed 
patients). The results are similar for the anxious/depressed specifier even if slightly lower in magnitude 
comparing to the mixed specifier. Noteworthy, there was a high co-occurrence between the two specifiers (the 
92.8% of participants meeting the mixed specifiers also met the anxious/depressed) (Hasin et al., 2018).   
Adverse experiences and traumatic events during childhood may be risk factors for depression in adulthood. 
Socioeconomic disadvantage, maltreatment, and social isolation during childhood have been associated to 
depression in adults as well as a greater number of adverse experiences would increase this risk (Danese et al., 
2009). 
Regarding familial and genetic load for MDD, conclusions from studies have to be drawn more cautiously 
than for BD, as “MDD bag” is a highly heterogeneous container, probably including very different conditions.  
The most part of the literature examined this issue via the assessment of the offspring of depressed parents. 
Results suggested that a family history for the MDD would represent the strongest and most reliable risk factor 
for the development of the disorder with 3- to 5-fold increase among first-degree relatives (Williamson et al., 
2004). The most interesting and reliable data pertain longitudinal studies of MDD in children and adolescents. 
The early onset of MDD may join more homogeneous phenotypes. MDD children and adolescents have been 
reliably sub-grouped according to three different illness trajectories (Schubert et al., 2017): onset during 
childhood with severe symptoms and persistence into adulthood (childhood persistent), onset during childhood 
with moderate to severe symptoms but decline during adolescence and young adulthood (childhood limited) 
and subtle and mild onset during adolescence with gradual increase of the severity of depressive symptoms 
over time (late adolescent onset) (Kwong et al., 2019).  The first and the latter trajectories were associated to 
poorer outcome, whereas the late adolescent onset was also related to polygenic risk of depression indicating 
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a significant genetic load in this subpopulation (Kwong et al., 2019). By the contrary, childhood limited 
depressions seem more correlated to circumstantial environmental stressors or events (Yaroslavsky et al., 
2013).  
Some longstanding studies observed a common transnosographic familial liability among depression and other 
psychiatric disorders, from time to time anxiety disorders specifically GAD and panic disorders (Weissman et 
al., 1986, Kendler et al., 1994), bulimia and alcohol dependence (Weissman et al., 1986): these data are not 
fully replicated.  
Some more recent studies focusing on structural and functional brain anomalies in youth at familial risk for 
MDD found specific alterations in regions involving emotion and reward as possible vulnerability markers for 
MDD preceding the onset of illness (Gotlib et al., 2014). This liability is partially shared with other disorders, 
namely BD (Nasrallah et al., 1989, Whalley et al., 2013a, Whalley et al., 2013b). These promising findings 
support the idea of a familial-mediated functional underpinning in MDD.  
 
Bipolar Disorders 
In the last decades a great amount of epidemiologic research has been conducted worldwide underlining the 
magnitude, correlates and consequences of BD. In the World Health Organization World Mental Health 
(WMH) surveys BD resulted the second cause of disability (Alonso et al., 2011). 
The lifetime prevalence of BD type I (BDI) according to community-based studies ranges from 0.0% in Nigeria 
(Gureje et al., 2006) to 3.3% in USA (Grant et al., 2005). The twelve-month prevalence is slightly lower, 
achieving a rate of 2.0%. As expected, with more inclusive disorder definitions, rates become even higher 
when BD type II (BDII) and the overall Bipolar Spectrum Disorders (BPS) are included: for example, in the 
WMH survey the cross-national prevalence of the overall BPS was 2.4%, with prevalence rates of 0.6% for 
BDI, 0.4% for BDII and 1.4% for subthreshold BD (Merikangas et al., 2011). The majority of the studies 
reported BDI rates higher than BDII (Merikangas et al., 2011, Wittchen et al., 1998). This datum may be 
explained by the difficulties to diagnose hypomania in most patients, who tend to seek treatment only during 
depressive phases. The requirement by current diagnostic systems of MDE criteria to be met, or, the fact that 
probably, most patients with hypomania may have also experienced at least one manic phase may contribute 
to the underestimation of BDII prevalence (Merikangas and Paksarian, 2015). Among youngsters the 
prevalence of BD is estimated around 1.8% (Van Meter et al., 2011).   
The incidence of BD in the general population has been also evaluated (Chou et al., 2011, de Graaf et al., 2013, 
Grant et al., 2009). In a recent large epidemiological study, the one-year incidence resulted 0.53% and 0.21% 
for BDI and BDII, respectively (Grant et al., 2009). A Dutch study reported a three-year BD incidence rate of 
0.41% among adults aged 18 to 64 (de Graaf et al., 2013). Similar incidence rates were found among the elderly 
(0.54% BDI; 0.34% BDII) (Chou et al., 2011). In spite of these numbers and the high burden of the disorder, 
only about the 50% of the adults and the 20% of the adolescents receive appropriate treatments.   
The mean age at onset of BD is around 18 years both in males and females (Zimmermann et al., 2009) with 
the first onset usually reported during adolescence or early adulthood for most patients (Lewinsohn et al., 
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2002). Indeed, in prospective cohorts the prevalence rate reaches 2% at age of 21 years (Lewinsohn et al., 
2002, Cannon et al., 2002).  
Historically, research reported similar rates of BD in males and females (Grant et al., 2009, Merikangas et al., 
2007), confirmed by more recent data in adulthood (Kessler et al., 2012) and in youth (Kozloff et al., 2010). 
By the contrary, the WMH surveys found BDI and subthreshold BD to be more common lifetime in males, 
whereas females had more frequently a lifetime diagnosis of BDII (Merikangas et al., 2011). It is possible that 
worldwide socio-cultural gender-mediated differences may influence the presentation of the illness.   
Regarding other demographic correlates, epidemiologic studies found as risk factors for BD low 
socioeconomic status and poor educational level (Grant et al., 2009, Grant et al., 2005, Merikangas et al., 
2007). Moreover, BD rates are higher among separated or divorced comparing to never married individuals 
(Subramaniam et al., 2013). No significant ethnicity differences in BD rates have been definitely detected, also 
because of the difficulties in including sufficiently homogeneous and large subsamples of distinct ethnic 
groups.  
Experiences of stressors and traumatic events during childhood are considered risk factors for BD (Mortensen 
et al., 2003): the likelihood to develop BD is increased especially in the victims of physical and sexual abuse 
during childhood (Wells et al., 2010) but an association have been reported also with physical and emotional 
neglect, parental violence and criminal behavior (Nierenberg et al., 2010), and economic adversities (Gilman 
et al., 2015). These risk factors are non-specific for BD and shared with other psychiatric disorders as well as 
substance abuse, ADHD, anxiety disorders, depression and suicidality, suggesting other general mechanisms 
mediating the causal effects of traumatic events.  A potential recall bias may also influence the reliability of 
these data (Merikangas and Paksarian, 2015).  
One of the strongest and most consistent risk factors for BD is a family history for BD, especially in first-
degree relatives. First-degree relatives of BD patients showed a 6.5 to 8-fold increase in the relative risk to 
develop BD (Aukes et al., 2012, Lichtenstein et al., 2009, Wilde et al., 2014). The high heritability of the 
disorder is confirmed by twin studies reporting an 8-fold increase in the risk of BD in monozygotic twins of 
bipolar patients than in dizygotic twins (Smoller and Gardner-Schuster, 2007). The genetic load seems stronger 
for BDI than for BDII and MDD (Merikangas et al., 2013, Vandeleur et al., 2014).  
Despites these observations, the results of molecular genetic studies are still inconclusive. The majority of 
genome wide association studies (GWAS) have substantially failed in identifying genes reliably associated to 
the disorder and effect sizes resulted often too small (Merikangas and Paksarian, 2015). The largest GWAS 
performed including thousands of patients and controls found two genome-wide significant loci: the first on 
chromosome 12, near to CACNA1C gene, and the second one on chromosome 11, near to ODZ4 gene 
((Psychiatric, 2011). CNVs have been reported to be also implicated but results are not conclusive (Malhotra 
and Sebat, 2012, Bergen et al., 2012). Small sample sizes and methodological differences in recruiting 
probands may have affected the results. Mostly, the poor differentiation among different phenotypes of BD 
and the lack of endophenotypes would have caused excessive heterogeneity.  
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Mixed episodes 
The overall mean prevalence rate for mixed episodes is about 30% (McElroy et al., 1992), varying from 6.7% 
and 66% according to narrower or broader definitions, respectively (Cassidy et al., 2008). Predominantly 
manic mixed states showed a prevalence of around 65%, with higher rates in females than in males (Cassidy 
et al., 2008), whereas predominantly depressive states have been studied at a lesser extent (prevalence rates 
ranging from 20% to 70% (Azorin et al., 2012, Benazzi, 2008, Goldberg et al., 2009) but no gender differences 
have been reported (Akiskal et al., 2005, Azorin et al., 2012, Benazzi, 2008, Perugi et al., 2001). Patients with 
mixed states, depressive and manic indistinctly, seem to report a younger age at onset and the mixed episode 
occurs in the early stages of the illness comparing to pure episodes eventually occurring along the illness course 
(Azorin et al., 2012, Benazzi, 2008, Cassidy and Carroll, 2001, Goldberg et al., 2009, Gonzalez-Pinto et al., 
2007, Perugi and Akiskal, 2005, Valenti et al., 2011). 
Comparing to pure manic patients, mixed manic patients exhibit a worse course of the illness with higher 
number and longer duration of the episodes (Martin-Carrasco et al., 2012), severer functional impairment 
(Rosa et al., 2009), higher rates of relapse, higher rates of psychiatric comorbidities as substance use, 
suicidality and shorter free intervals (Cassidy et al., 2008, Gonzalez-Pinto et al., 2007, Valenti et al., 2011, 
Baldessarini et al., 2010, Azorin et al., 2009). Mixed depressive patients have similar associated features with 
the addition of higher rates of rapid cycling and mood-incongruent psychotic features (Akiskal et al., 2005, 
Azorin et al., 2012, Goldberg et al., 2009, Perugi et al., 2001). 
 
1.4.3 ETIOLOGY 
The etiology and pathophysiology of MDs are still unknown and probably involve several biological 
mechanisms. The research in this field may have suffered for the heterogeneity of the MDs patients. It is 
probable that the etiopathogenetic cause is not unitary. 
(Fries and Kapczinski, 2015) Stress and its biological correlates have been implicated in the pathophysiology 
of depression and BD long time ago with evidences of the dysfunction of cortisol and hypothalamus-pituitary-
adrenal axis (HPA) (Grunze, 2011, Knorr et al., 2010). In some patients with MDD and BD the negative 
feedback loop subsiding the suppression of cortisol secretion by adrenal cortex appears impaired, as 
demonstrated by the response to dexamethasone infusion (Daban et al., 2005), CRH and DEX/CRH tests (Roy 
et al., 1986, Rybakowski and Twardowska, 1999, Schmider et al., 1995). Excessive glucocorticoids may have 
central effects as the induction of regression of dendritic processes in neurons and inhibition of neurogenesis 
(Sapolsky, 2000), the increase of glutamate concentrations in hippocampal synapses, contribution to 
mitochondrial dysfunction and oxidative stress (Du et al., 2012) with long-term effects on genes’ expression 
(Quiroz et al., 2008). Literature shows opposite and inconclusive data about whether HPA overactivity is a 
trait or state marker of MDs (Swann et al., 1992, Deshauer et al., 2003, Wedekind et al., 2007).  
The research about the neural substrates of depression mostly focused on of the functional and anatomical 
correlates of emotional information processing dysfunctions and over-reactivity or loss of resilience to stress. 
Dysfunctional activity in the salience network, including amygdala, dorsal anterior cingulate cortex, and 
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anterior insula as well as impaired thalamic network, have been demonstrated in MDD patients: these 
abnormalities would be correlated to impairment in processing negative stimuli (Hamilton et al., 2012, Pessoa 
and Adolphs, 2010). The regulation of emotion and reward processing seem also impaired in MDD patients: 
the former deficit would be underpinned by altered activation of medial, dorsal and ventral regions of the 
frontal lobe (Erk et al., 2010). The impairment of reward processing is related to reduced activity in striatal 
circuit (Gotlib et al., 2014). The anomalies of some brain structures have been associated to MDD and may 
involve subcortical grey matter, with the evidence of reduced volume of hippocampus (Gotlib et al., 2014); 
cortical gray matter thinning across frontal, temporal, parietal cortices (Peterson et al., 2009), prefrontal cortex 
(Amico et al., 2011), anterior insula and anterior cingulate (Foland-Ross and Gotlib, 2012); functional 
connectivity alterations in some white matter structures such as temporal (e.g., (Zhu et al., 2011) and occipital 
(Kieseppa et al., 2010) lobes and along midline structures (e.g, (Zhu et al., 2011, Kieseppa et al., 2010). 
Neuroimaging studies regarding BD pathophysiology and progression suggested that neuroanatomical and 
functional alterations occur in specific brain regions rather than in the whole brain (Fries and Kapczinski, 
2015). Among the numerous findings, the most replicated is the enlargement of lateral ventricle (Kempton et 
al., 2008), whose magnitude is also correlated with the number of illness’ episodes (Brambilla et al., 2001b, 
Strakowski et al., 2002). Smaller total brain volume (Frey et al., 2008), reduced volume of left putamen and 
left inferior prefrontal gray matter (Lopez-Larson et al., 2002), reduced hippocampal volume (Javadapour et 
al., 2010) and relative increase of amygdala volume (Bora et al., 2010) have also been associated to the progress 
of the disorder. By the contrary, changes in shape and volume of basal ganglia, especially striatum, was 
described as hallmark of BD since the onset of the illness (Fries and Kapczinski, 2015). According to these 
evidences, neuropathological studies have shown reduction of the glial cells pool and density, alterations of 
density and size of specific neuronal populations mostly regarding prefrontal and limbic cortical regions 
(Rajkowska, 2002). 
Cell death and loss of resilience have been suggested by biochemical studies implicating a variety of 
mechanisms. Signs of increased apoptosis have been found in oligodendrocytes of frontal cortices of dead 
bipolar patients (Uranova et al., 2001). Excitotoxicity plays a key role, mostly mediated by glutamate and 
calcium. Increased serum and prefrontal concentrations of glutamate have been found during mania and 
depression (Altamura et al., 1993, Hashimoto et al., 2007, Hoekstra et al., 2006), which are related to elevated 
intracellular calcium levels and disturbed calcium homeostasis in MDs (Warsh et al., 2004). Excessive 
cytosolic calcium may activate a cascade of intracellular mechanisms leading to cytoskeletal degradation, 
protein misfolding, oxygen reactive species (ROS) overproduction and, finally, apoptosis (Warsh et al., 2004).  
Oxidative stress, mitochondrial dysfunction, altered inflammatory response, and their relationship with 
alterations in calcium, dopamine and glutamate-mediate neurotransmission have been hypothesized to be 
implicated with BD (Andreazza and Young, 2014). For example, in post-mortem studies mitochondrial genes 
resulted downregulated in hippocampus (Lieberman et al., 2007, Konradi et al., 2004) and dorsolateral 
prefrontal cortex (Iwamoto et al., 2005, Sun et al., 2006), regions just implicated in the pathophysiology of BD 
by functional neuroimaging studies. The finding that antioxidant enzymes are altered (e.g(Andreazza et al., 
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2007, Benes et al., 2006, Machado-Vieira et al., 2007) is related to unbalance toward increase of oxidative 
stress. These alterations may regard several enzymes such as SOD, CAT, GPx and GST: genes codifying for 
these enzymes have been found downregulated in the hippocampus of bipolar patients (Benes et al., 2006). On 
the other hand, it seems that during acute illness phases, both depression and mania, the activity of SOD is 
much increased (Andreazza et al., 2007, Machado-Vieira et al., 2007, Gergerlioglu et al., 2007). Whether or 
not SOD hyperactivity is limited to acute episodes or is also present during euthymic intervals has to be 
clarified (Savas et al., 2006). Researchers also found indirect signs of increased oxidative stress, for example 
increased lipid peroxidation (e.g. (Andreazza et al., 2008) and increased levels of nitric oxide (e.g. 
(Gergerlioglu et al., 2007). 
There are increasing evidences of the involvement of inflammatory processes both in the periphery and brain. 
In BD patients are reported altered levels of peripheral cytokines depending on the phase (Brietzke et al., 2009, 
Kapczinski et al., 2009) and the stage of the illness (Kapczinski et al., 2008, Kauer-Sant'Anna et al., 2009): the 
studies reported increase of pro-inflammatory cytokines (IL-2, IL-6, TNF-alfa), anti-inflammatory cytokines 
(IL-1beta, NF-kB) and antagonist proteins of IL-1 receptor. Even post-mortem studies found altered mRNA 
levels of IL-1beta, NF-kB and IL-1R subunits in the frontal cortex of BD patients (Rao et al., 2010). Other 
acute inflammatory response proteins have been shown elevated in the plasma of BD patients such as 
haptoglobin, C-reactive protein and complement factors (Dickerson et al., 2007, Maes et al., 1997). Some 
findings support the hypothesis that in late stages of the illness the anti-inflammatory mechanisms are less 
responsive and effective as well as illness progression may be the resultant of the accumulation for years of 
oxidative damages (Andreazza et al., 2008, Kauer-Sant'Anna et al., 2009).  
Oxidative stress may also be triggered and maintained by direct inhibition of the mitochondrial electron 
transport, as it is the case of the Ca2+-channel. An involvement was suggested by GWAS studies (regarding 
CACNA1C), consistent findings of increased intracellular levels of CA2+ in bipolar patients (Kato, 2008) and 
functional imaging studies (O'Donovan et al., 2009, Vacher et al., 2008). 
A relationship between neuroinflammation and neurotransmission has been hypothesized: for example, a 
proinflammatory state may activate increase consumption of tryptophan, the precursor of serotonin, with 
increasing levels of tryptophan catabolites and dysregulation of the neurotransmitter system and mitochondrial 
metabolism (Berk et al., 2011).  Other neurotransmitters potentially involved in or by oxidative stress are 
dopamine and glutamate. Specifically, an increase in dopamine cerebral production leads to increase activity 
of monoamine oxidase (MAO) enzymes with overproduction of ROS, poorly compensated along the course 
of the illness (Berk et al., 2007, Chen et al., 2008, Andreazza et al., 2009). Similarly, an increased release of 
glutamate, via the hyperstimulation of NMDA receptors, augments the intracellular passage of Ca2+ with final 
overproduction of ROS, mostly nitric oxide (Coyle and Puttfarcken, 1993). 
Inflammatory proteins are not involved in the pathophysiology of BD and MDD only throughout the 
relationship with oxidative stress but also via a their direct signaling potential. Recent clinical studies 
demonstrated that BD patients show higher rates of autoimmune and infective diseases as well as a tendency 
toward atopy (Benros et al., 2013, Perugi et al., 2015). Research on MDD reported similar findings (Miller et 
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al., 2009). Many preclinical and clinical studies also showed that inflammation may induce depression and 
major depressive and bipolar patients display markers of inflammatory activation (Miller et al., 2009, Dantzer 
et al., 2008, Schiepers et al., 2005). Murine studies support the hypothesis for example indicating that the role 
of inflammation may be mediated by glycogen synthase kinase-3 (GSK-3), whose inhibition by lithium and 
other medications has been hypothesized to lead to mood stabilization (Klein and Melton, 1996, Stambolic et 
al., 1996).  
Human studies regarding the role of GSK-3 as well as other transduction proteins (phosphatidylinositol 4,5-
bisphosphate PIP2, protein kinase C PKC) are inconclusive but suggestive, especially because implicated with 
the effectiveness of lithium. Inositol depletion and abnormal PKC signaling could be involved in the 
pathophysiology of MDs (Jope et al., 2015).  
Also signaling pathways enhancing the expression or neurotrophins such as BDNF may be deficient in MDs, 
with subsequent impairment of multiple processes going from neurotransmission to neurogenesis. Such 
impairments have been found in both depression and BD. Epigenetic mechanisms are probably the best 
candidate, as demonstrated by the evidence increased methylation of BDNF gene promoter I in patients with 
BDII (D'Addario et al., 2012). Blood levels of BDNF are reduced in depressive patients (Autry and Monteggia, 
2012, Duman and Li, 2012) as well as in bipolar patients (Pittenger and Duman, 2008). Rodents models 
confirmed these findings: for example, the hippocampal infusion of BDNF in depressive rats may attenuate 
depressive-like symptoms (Duric et al., 2013). On the other hand, some researchers found that mood stabilizers 
and antidepressants may induce up-regulation of neurotrophins (Chiu et al., 2013, Duric et al., 2013, Eisch and 
Petrik, 2012). The disruption of BDNF signaling can lead to decreased dendritic spines and arborization, 
neuritic dystrophy and degeneration, and neuronal atrophy (Teixeira et al., 2010). These alterations in 
neurogenesis probably find their clinical correlates in the cognitive deficits of some individuals with MDD 
and BD and are concordant with the evidence from neuroimaging studies of faster age-related cortical neuronal 
loss (Brambilla et al., 2001a).  
 
1.4.4 CLINICAL FEATURES 
As noted by Goodwin and Jamison in their famous textbook (Goodwin and Jamison, 2007), the distinction 
between unipolar and bipolar forms of MDs significantly changed over time, since the original descriptions 
used both terms to indicate “phasic or cyclic course of recurrent episodes, characterized by autonomous 
endogenous features and clear functional impairment”. By the contrary, classificatory systems since DSM-III 
enlarged the boundaries of depression including under the label unipolar a heterogeneous population of 
patients still including endogenous recurrent disorders as well as all depressions, for example, reactive ones, 
“neurotic” forms, bereavement-related, depressive precursors of dementias etc. This problem has never been 
solved in the following versions of the DSM. In this perspective, results from studies about differences of 
depression in MDD and BD patients have obvious limitations. However, some suggestions can be drawn. 
Comparing to MDD patients, BDI patients showed earlier age at onset with a narrower range for the onset, 
major number of episodes, namely depressive, shorter length of both the depressive episode and the cycle. BDI 
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is equally prevalent among males and females, whereas MDD depression is more common among females. 
BD is also associated to a wider extent of psychiatric comorbidities, substance use, affective temperaments, 
mostly hyperthymic and cyclothymic, higher or better documented familial and genetic load. Even response 
to antidepressant treatments shows some differences as BDI patients report faster responses and higher rates 
of tolerance to antidepressants and (hypo)manic switches (Goodwin and Jamison, 2007). 
The heterogeneity of the “bag” also affected BDs, but at least the distinction in BDI and BDII brought some 
clarity. As written in the above paragraph, BD-I patients are characterized by history of one or more full-blown 
manic episodes, even if hypomanic episodes may occur during the course of the illness. The diagnosis of BDII 
requires a story of MDE and hypomanic episodes. However, the research on BDII has suffered for poor 
reliability of the diagnosis with current operational criteria, mostly because of difficulties in recollecting the 
history of past hypomania (Andreasen et al., 1981, Dunner and Tay, 1993). In fact, BDII patients mostly seek 
treatment when depressed, and during depression patients are even poorer at recalling previous hypomanic 
episodes. Moreover, hypomanic patients usually do not have insight of their condition: even after its conclusion 
they tend to misattribute to environmental factors and circumstances their peculiar emotional state and 
behaviors. This is the main reason why in clinical practice the use of multiple informants as well as the use of 
descriptive behaviors more than a mere list of symptoms may be much more appropriate in improving the 
diagnosis of BDII.  
 
Depression  
Depression is usually characterized by a decrease or slowing in most aspects of emotion and behavior: speed 
and amount of thought and speech, energies, ability to experience pleasure, sexuality and leisure may all be 
reduced at a variable degree. The severity of symptoms may vary from mild mental and physical slowing to 
most severe cases of psychomotor arrest associated with stupor, delusions, hallucinations and catatonic 
symptoms, sometimes resulting in life-threatening conditions. Depression, with peculiar exceptions, is the 
most frequent presentation in BD patients spending about the 40% of time depressed comparing to 9% of the 
time in (hypo)mania (Judd et al., 2002). At a cross-sectional examination there are no pathognomonic signs of 
bipolar depression to be distinguished from unipolar one (Snook et al., 2015). Meanwhile, some studies found 
atypical features of depression, such as psychomotor retardation, hypersomnia and hyperphagia, psychotic 
features and mood lability to be more common in bipolar depression (Mitchell et al., 2008). Main functions 
perturbed during depression as well as in mania are mood, activity and behavior, cognition and perception.  
1. Mood 
Depressive mood is usually bleak, pessimistic, and despairing. This affective color is often associated to 
feelings that things are meaningless and the person lost the capacity to experience pleasure. There may be a 
general flattening involving not only mood strictu sensu, but also motivation, physical experience and 
cognition. Irritability, anguish and anxiety, anger, emotional lability, sensitivity and paranoia may be present. 
Variations during the day with alternation and medley of all these figures are common with differential patterns 
among patients and across the course of the episodes or different episodes in the same patient. 
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The impairment of emotionality and the widespread dulling may elicit a generalized fear of insanity, especially 
when unreality feelings or experiences are associated. Beyond the basic affective tonality, even the mood 
reactivity to external stimuli is compromised, with the exception of some specific depressive forms, for 
instance called atypical. Indeed, comparing to melancholic depression, atypical depression is characterized by 
preserved mood reactivity. No significant differences in the severity of depression have been reported across 
the diagnosis of unipolar disorders, BDI and BDII (Goodwin and Jamison, 2007, Mitchell et al., 2001). 
2. Activity and Behavior 
Activity and behavior may be slowed in typical forms of depression. A general reduction of energies and a 
primary disturbance in volition are expressed by asthenia and fatigue, reduced or completely lacking activities, 
social withdrawal with more or less extensive impairment in daily functioning in few areas (familial, 
relationships, occupational). Full psychomotor retardation is quite rare but more common in BDI than BDII or 
unipolar patients (Parker et al., 2000, Benazzi, 2002). At the opposite, in some forms of depression 
psychomotricity may be characterized by a general activation ranging from a painful and unpleasant feeling of 
inner tension, up to restlessness and psychomotor agitation. According to classical descriptions but not to 
current classification, psychomotor agitation is a sign of the so-called agitated depression, included by 
Kraepelin among mixed states. Psychomotor agitation seems to be more common in BDII patients (Benazzi, 
2002).   
Facial expression, posture, movement and the general appearance of the patients can be very suggestive of 
depression. The reactivity and the coherence of mimics with environment is often lost and the expression of 
face and eyes may communicate sadness, anguish or fear. Movements are often slowed and reaction are 
sluggish. Gestures and body communication are reduced to the minimum. The general appearance may suggest 
reduction in self-care as well as an age older than the actual. Speech alterations are consistent with the general 
psychomotor slowing with a global reduction of its volume and increased latency of response (Mitchell et al., 
2008, Sadock et al., 2009).   
Neurovegetative alterations are often early signs: depressive patients report specific patterns of insomnia as 
well as qualitative alterations and non-restorative sleep. Vivid and disturbing nightmares are common. By the 
contrary, hypersomnia can be the hallmark of atypical depression. Unipolar patients more commonly 
experience insomnia, both initial as early morning awakenings (Mitchell et al., 2008). Appetite may be altered 
too, with general decrease often associated to gastrointestinal somatization, up to severe and debilitating 
anorexia. As for sleep, the polarity of the alteration is opposite in atypical depression: appetite can be excessive 
and may cause hyperphagia usually associated to preference or actual craving for specific foods, mostly 
carbohydrates. Corresponding weight variations are a reasonable consequence.  
Psychotic depression, considered the severest form, has similar symptoms of non-psychotic depression but 
usually at a worse degree with additional delusions and hallucinations. These forms may more easily be 
associated to catatonia, whose belonging to psychotic dimension has been extensively questioned (Fink, 2013). 
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3. Cognition and perception 
Mental activity including formal and content aspects as well as specific cognitive functions likely attention, 
procedural speed, memory etc., may be variously impaired: they are usually slowed. However, only in 
psychotic forms of depression symptoms in this area reach the severity level of consciousness alteration, 
delusions and hallucinations. By the contrary, inappropriate and continuous ruminations regarding holothymic 
figures such as hypochondriac, worthlessness, and guilt ideas, as well as a broad range of suicidal thoughts 
including vague ideas about death till precise plans for suicide, are common in the majority of depressive 
patients. Cognitive distortion about these negative thoughts may induce misinterpretation of past and current 
events (Sadock and Sadock, 2007). Similar to ruminations, incapacity to decide and a more general difficulty 
to think are present. Comparing to other neurological conditions, for example in the early stages of some 
dementias, depressive patients usually complain about their cognitive deficits often associating a hopelessness 
sense of impossibility of restitutio ad integrum. This feeling is distinctive of all depressive phases in any 
patient, even in those who have already experienced previous episodes as well as recovery: in spite of past 
experiences, they are often not sensitive to reassurance as the current moment would seem never-ending.  
Delusional mood-congruent contents are usually accentuations of prevalent ideas of non-psychotic depression 
and may regard guilt and worthlessness, mashed-up with somatic, religious or financial issues, ruin, sinfulness, 
illness, prosecution and never-ending sufferings themes. Auditory hallucinations (or pseudo-hallucinations) 
are usually denigrator and threatening in content. Delusions have been reported in 12% to 60% of bipolar 
depressive episodes (Black and Nasrallah, 1989, Carlson and Strober, 1979), less common than during mania 
(Goodwin and Jamison, 2007, Sadock et al., 2009). Hallucinations, more frequent in mania than in depression, 
are less commonly reported in both polarities. Clinical research suggested that psychotic symptoms are 
independently associated to unipolar and bipolar depression (Charney and Nelson, 1981, Coryell and Tsuang, 
1982, Frances et al., 1981, Glassman and Roose, 1981, Nelson et al., 1984, Spiker et al., 1985).    
 
Mania and hypomania  
In mania and hypomania acceleration and sharpness are the core features (Snook et al., 2015). Mood is 
heightened and overreactive, rapidly oscillating among euphoria, elation, irritability and dysphoria, and a 
subjective feeling of well-being is present. Psychomotricity is increased and fastened as expressed by quicker 
thought with a sense of clarity, larger volume of and faster speech, increased energy levels with motor 
activation, increase of activities, reduced need for sleep, hypersexuality and impulsivity. Reduction of 
inhibitions and impaired judgement are distinctive features. Positive changes in self-esteem including at the 
extreme pole grandiosity, paranoia and megalomaniac delusions may be present.  
The severity and the duration of these mood, cognitive and behavioral disturbances define the differences 
between mania and hypomania. During hypomania such alterations are of moderate entity comparing to the 
disastrous consequences of mania, often disrupting life arrangements of people suffering for it and their 
families. According to different temperamental and personality structures, for example anankastic and 
depressive, hypomania may be even lesser evident, without the usually observable variations. Rather, for some 
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persons hypomanic phases remain unrecognized or remembered as “the only periods in the life they were really 
fine, and self-confident, and successful”.  
1. Mood 
Mood is elevated with some qualitative differences between mania and hypomania. In hypomania self-
confidence, elation and cheerfulness prevail, but with easy irritability. Classical descriptions underlined the 
labile and volatile nature of hypomania (Goodwin and Jamison, 2007). Feelings of well-being, the so-called 
eutonia, are another fundamental feature. In acute mania these characteristics are exaggerated and patients may 
appear euphoric, joyful and expansive but mood may abruptly change in anger, rage and dysphoria. In some 
cases, dysphoric nuances may predominate.  Jocularity is usually associated to euphoria, often reaching the 
level of clamorous, disturbing and socially inappropriate behavior.  
2. Activity and behavior 
Overactivity should be considered the true core criterion of mania and hypomania. The level of increased 
energy and the reflexes on psychomotricity are diversified across the severity continuum. Overactivity refers 
to reduced fatigability, increased finalistic activities, physical hyperactivity, social disinhibition as well as 
rashness and impulsivity, aggressiveness and agitation. Behavior may become erratic, disorganized and violent 
in severe mania: these patients may appear bizarre, paranoid, impulsive, and grossly inappropriate. 
Insight and self-awareness are affected in both hypomania and mania going from a loosening of judgment 
leading to over-planning and wrong or hasty romantic or occupational choices, up to frankly inappropriate and 
dangerous behaviors and complete lack of the insight of the illness and of the consequences of their behaviors.  
As in depression, neurovegetative patterns are involved, especially sleep. The reduced need for sleep is a very 
early sign of (hypo)manic switch, and manic patients may sleep only for two or three hours per day without 
feeling tired the next morning. This aspect differentiates it from insomnia. Sexual appetite and sexually-
oriented behaviors are increased too and sometimes associated to promiscuity. 
3. Cognition and perception 
Thoughts are fast, accelerated in hypomania and mania across a severity continuum from racing thoughts up 
to flight of ideas and loss of associations. Other formal disturbances of thought and specific cognitive deficits 
can be found on this continuum as well as tangentiality, assonance associations, disorganized thought and 
distractibility of various degree. In hypomania associational fluency is furthered and can be associated to the 
subjective feeling of mental clarity and improved cognitive ability: however, mostly because of the co-
occurrence of distractibility and inconclusiveness, such a feeling is not always accompanied with a real 
improvement of performance. Usually, the loss of association and disorganization are associated to the severest 
forms of mania and psychosis. Distractibility becomes pervasive and thinking may result incoherent, in these 
cases alertness and orientation can be affected. These features are prominent in dramatic but rare cases of 
delirious mania, characterized by abrupt onset and a sort of crepuscular state associated with subtotal insomnia, 
highly pervasive and bizarre hallucinations, stupor, confusion, and sudden shifts from melancholia to mania.   
Psychotic symptoms are reported in about two third of BDI patients (Goodwin and Jamison, 2007). The themes 
of delusions as well as of illusions and hallucinations are usually on a megalomaniac background and may 
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involve religious, political, financial or romantic thoughts. Perceptual disturbances are usually aligned with 
thought contents.  
By definition, psychotic symptoms are not present in hypomania. However, a soft form of grandiosity with 
increase in self-esteem, increased self-confidence and fluency in sociality, is a common feature. Some kind of 
sensitivity, soft and volatile paranoid impressions can also be present.   
 
Mixed episodes 
Mixed states as the simultaneous occurrence of opposite polarity affective symptoms have been described at 
the end of 19th century (Kraepelin, 1896, Weygandt, 1899) and categorized in six subtypes according different 
combination of alterations in the three fundamental dimensions involving affectivity: mood, motor activity, 
and ideation. The subtypes were depressive mania, excited depression, unproductive mania, manic stupor, 
depression with flight of ideas and inhibited mania. These descriptions currently preserve their validity from a 
clinical point of view. Mixed states are common in BD, whereas there are not reliable data regarding MDD, 
given the too recent modification of the definition. As different definitions have been adopted, prevalence rates 
vary significantly across studies.  
The presence of mixicity has relevant implications for prognosis and treatment. Mixed episodes are associated 
to worsening of the illness’ course and worse cross-sectional outcome. For example, the combination of 
depressive hopelessness and manic energy and impulsivity underlie a substantial increase in suicide risk 
(Swann et al., 2013).  Temperamental factors may predispose to mixed features: in fact, depressive and 
hyperthymic temperaments are associated with higher rates of mixed episodes as the natural disposition of the 
person seems to influence and color the presentation of the affective episode. Thus, mania superposed to 
depressive temperament may result in a mixed manic episode, whereas depression in hyperthymic individuals 
has high probability to be diagnosed as a mixed depressive episode (Perugi et al., 1997). That innate 
pathological emotional features may constitute a bridge with mixicity, is a new and intriguing hypothesis 
linking emotional dysregulation of neurodevelopmental disorders and BD. Few data are available to confirm 
this hypothesis, but for example two recent studies, one in children and the other in adults with MDE (Purper-
Ouakil et al., 2017, Vannucchi et al., 2019a), confirmed that ADHD is associated to mixed features of 
depression. Frequencies of mixed versus classic manic features were not systematically studied in adults with 
other neurodevelopmental disorders, namely ID and ASD.  
Mania or hypomania with mixed features may more commonly present with prominent dysphoria, irritability, 
increased speed of thought and speech but also simultaneous or rapidly alternating depressed mood, depressive 
feelings such as guilt, anhedonia and poor energy (Snook et al., 2015). Anguish and anxiety may be pervasive.  
Depression with mixed features is in continuity with “pure” depressive forms with agitation or irritability and 
distinguishing them is a matter of numbers and a tailored job: the most suggestive signs of mixed features 
during depression are increased of goal-directed activities and reduced need for sleep (Ketter, 2010).     
 
 47 
 
1.5. PSYCHIATRIC COMORBIDITY IN INTELLECTUAL DISABILITY AND LOW-
FUNCTIONING AUTISM SPECTRUM DISORDERS 
1.5.1 GENERAL AND DIAGNOSTIC ISSUES  
The prevalence of mental disorders in PwID is up to four times higher than in the general population (Cooper 
et al., 2007d). However, the concept of dual diagnosis is relatively recent, originated in the ‘(P., 2007). Prior 
to that period, despite the sparse presence of descriptions and case series about psychiatric presentations in 
PwID, the dominant opinion in the scientific community was that psychiatric disorders could not occur in 
PwID, especially in those with worse severity of the ID (Earl, 1961). Various explanations were given, 
including a lack of consensus on which problems in ID should be considered as mental health problems 
(Holland and Koot, 1998). This long-lasting preconception has had a negative impact and restraining effects 
to the research on the specific phenomenological and psychopathological features in ID, and to the 
development of effective assessment procedures as well as reliable data about management and treatments.  
A variety of reasons are implicated in the debate on this field and, from a practical perspective, are the cause 
of a very complicated psychiatric diagnostic process in ID. These reasons can be grossly distinguished in those 
pertaining the ID condition per se and the peculiar psychiatric phenomenology in ID; on the other hand, there 
are those specifically addressing the psychiatric diagnosis and the methodology of the assessment. 
Intellectual distortion, psychosocial masking, diagnostic overshadowing, appropriateness, developmental 
baseline exaggeration, and neurovegetative vulnerability, all may lead to atypical presentations of PDs in ID 
and complicate the diagnosis.  
Intellectual or cognitive distortion refers to the complex set of difficulties in introspection capacity, in defining 
one’s own life experiences, and in communicating states of uneasiness or suffering (Cooper et al., 2003, Sovner 
and DesNoyers Hurley, 1986). Although cognitive distortion may regard at some degree even milder forms of 
ID, it is as more interfering as the severer is the ID, mainly when ID is associated with severe language 
limitations or its absence, communication problems and sensory dysfunctions. These limitations affect the 
recognition of thought disorders as well as internalizing symptoms such as anxiety, depressed mood and related 
complex feelings, for example worthlessness and guilt (Einfeld, 1992, Marston et al., 1997), suicidal ideation 
or diminished ability to think (Smiley and Cooper, 2003).   
Furthermore, given their poor verbal capacities, PwID may be passive, inclined to acquiescence and may show 
deviations from the norm in attributing meanings to communicative contents because of frequent peculiarities 
in the experiential range (Sovner and DesNoyers Hurley, 1986). These attitudes belong to psychosocial 
masking. For example, people with borderline intellectual functioning or mild ID have been reported to be 
quite capable of describing about their own behaviors and feelings (Bramston and Fogarty, 2000, Deb et al., 
2001a, Moss et al., 1996). However, even in these cases suggestibility, acquiescence, attention deficit, trouble 
with temporal sequencing, or distractibility, may determine considerable difficulty in providing a full account 
of their own feelings and experiences. 
The most discussed interfering aspect of the psychiatric diagnosis in ID pertains to both a conceptual and a 
practical level. As discussed in chapter 1.2, previous versions of DSM placed MR/ID on Axis II along with 
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the personality disorders, while Axis I included ‘major’ psychiatric disorders (depression, psychosis, etc.). The 
placement of PDs and MR/ID on separate axes represented the expression of the denial of a possible co-
occurrence among them. As research developed and knowledge challenged this axiom, this division seemed 
to be anyway functional to reduce diagnostic overshadowing (Reiss et al., 1982). Diagnostic overshadowing 
is the difficulty to attribute the observed or referred dysfunctions to the basic condition of ID or to a comorbid 
psychiatric disorder (Deb et al., 2001b, Jopp and Keys, 2001, Reiss et al., 1982, Reiss and Szyszko, 1983). 
The supposed effect was to avoid the tendency of clinicians engaged in evaluations of PwID to focus almost 
exclusively on intellectual and adaptive functioning, ignoring other important information on overall mental 
health. However, in most cases this separation has had the opposite effect, reducing the relevance of 
pathoplastic role of MR/ID on psychopathology and clinical presentations. Diagnostic overshadowing can lead 
to a lack of systematic psychiatric assessment and therefore suboptimal treatment and care (Szymanski et al., 
1998, Yoo et al., 2012). Adaptation deficits, poor skills and communicative impairment further hamper the 
diagnosis. The complex framework of PBs and the concerns regarding their relationship with PDs are 
connected to this issue (Reiss et al., 1982, Reiss and Szyszko, 1983, Ross and Oliver, 2003). In chapter 1.2 the 
multifactorial causality of PBs has been outlined. In fact, PBs are not necessarily signs of psychopathology 
and the clinician should consider that people with more severe ID have a restricted repertoire of communicative 
behavior: PBs may be caused by physical illness and pain, as well as any kind of environmental, emotional or 
psychological distress. This is particularly difficult when behaviors qualitatively pertaining to PBs, for 
example self-injury, aggressiveness and stereotypies, are part of the usual behavioral repertoire of the person 
or there are background behavioral disturbances (Hurley, 2008).  
Clinicians should be specifically trained to overcome this diagnostic challenge in PwID (Werner and Stawski, 
2012). Some concepts may guide the diagnosis: all the behaviors and alterations have to be contextualised in 
the set of previous life experiences, cultural, and environmental influences, but mostly according to the actual 
developmental level of the person. For example, in adults with severe ID the adaptive and emotional 
development may be estimated around 12-18 months of age comparing to neurotypically developed persons. 
These factors impact on the presentation of eventually co-occurring symptoms, which often is atypical, chaotic, 
intermittent, fluctuating, masked, mixed, or poorly defined (Bouras et al., 1999, Sovner, 1986). In addition, 
the symptomatology of PDs in ID is often characterised by neurovegetative vulnerability; pains, organ 
dysfunction, and circadian rhythm disorders are frequently the main expression of emotional dysregulations 
(Costello and Bouras, 2006). In this perspective, the precise knowledge of the baseline functioning of the PwID 
is fundamental to notice significant and suggestive variations. According to the concept of baseline 
exaggeration, PBs or other behaviors and functioning parameters might indicate the onset of a co-occurrent 
PD when a sustained variation in frequency, severity and duration of usual behaviors is reported as well as the 
abrupt onset of PBs previously not reported, once other causal factors have been excluded (Moss et al., 2000, 
Sovner and DesNoyers Hurley, 1986, Sturmey and Ley, 1990). The course of the behavior in respect to other 
possible symptoms of a PD would represent the main reference to decide whether the considered behavior can 
be considered a symptom equivalent (Charlot, 2005).  
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The state of the art provides inconclusive suggestions. Some studies demonstrated a relationship between PBs 
and PD (Emerson et al., 1999, Felce et al., 2009, Hemmings et al., 2006, Kishore et al., 2005, Moss et al., 
2000, Rojahn et al., 2004), particularly strong in individuals with lower level of functioning (Felce et al., 2009), 
and some behavioral equivalents have been identified for specific symptoms (Hurley, 2006). By the contrary, 
other studies found no evidence that PBs were behavioral equivalents of PD (Tsiouris et al., 2003) and some 
authors sentenced PBs and maladaptive behaviors to be interpreted as nonspecific indicators of emotional 
distress rather than atypical symptoms (Rojahn and Meier, 2009). 
Atypical clinical presentations of PDs, including maladaptive behaviors, lent support to the need for research 
in this field and for the development of adapted criteria for PDs in ID, although some authors concerned that 
most studies suggesting atypicality of psychiatric manifestations in PD had failed to offer external validators 
for this hypothesis (Ross and Oliver, 2003). Unfortunately, a vicious circle affects achievements: the lack of 
reliable criteria, adapted to all the degrees of ID, implies the insufficiency of assessing instruments. 
Subsequently, the methodology of the studies are very heterogenous and results are by definition inconclusive 
and often poorly generalizable. In fact, the pragmatic application of current standardized criteria (both DSM 
and ICD) could, at some extent, show reliability in less severe degrees of ID (Clarke and McKenzie, 1994, 
Marston et al., 1997, McBrien, 2003, Meins, 1995, Pawlarcyzk and Beckwith, 1987, Werner and Stawski, 
2012). The same criteria are instead poorly useful in most persons with more severe ID (Cooper and Bailey, 
2001, Sovner and DesNoyers Hurley, 1986). This represent a significant bias in the interpretation of clinical 
and epidemiological studies: most studies about PDs in ID have been conducted in persons with mild to 
moderate ID (Ross and Oliver, 2003), but even when including severe and profound ID, studies found higher 
rates of PDs in mild subjects (Paclawskyj et al., 1997). It remains unclear whether the result is due to true 
differences according different ID levels or it is only the reflex of the scarce sensitivity to PDs in severe and 
profound ID.  
The diagnostic criteria of the current nosographic systems, including the DSM-5, ICD-10 and ICD-11, show 
some characteristics that may interfere with the reliability of the psychiatric diagnosis in PwID. Many of the 
diagnostic criteria require verbal descriptions, especially of emotional state that are difficult to understand and 
express for PwID. Furthermore, the standard diagnostic criteria are not developed for use with informants (e.g. 
caregiver, and family), and require detailed information on the psychopathology that are not fully applicable 
to PwID. On the other hand, the framework of PBs is lacking in any of the nosographic systems (Cooper et al., 
2003), and rather, in neurotypical persons behaviors commonly found in ID persons, namely aggressiveness, 
self-injury and stereotypies, have different explanations and implications and cannot be equalize. Some 
reviews across the last three decades concluded that the use of unmodified standard diagnostic criteria may be 
inappropriate in ID (Cooper and Collacott, 1996, Davis et al., 1997a, Janowsky and Davis, 2005).  
Some authors coined the concept of behavioral equivalence to describe alternative and atypical manifestations 
of PDs in ID (Lowry and Sovner, 1992, Sovner and Hurley, 1982). The evaluation is always based on direct 
observation of behaviors and the person’s way of interacting with the outside world through the knowledge of 
precise meanings in the context of various environmental factors. This method requires the interview of one 
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or more care-givers with a detailed knowledge of the person. The purpose is not to rely on self-report. Later, 
other authors argued that this observational method was promising but needing systematic studies including 
large number of patients since it had been applied only in case reports and case series (Ross and Oliver, 2003). 
In order to improve diagnostic sensitivity of clinicians, the Royal College of Psychiatrists (UK) and the 
National Association for Dual Diagnosis (USA) have respectively produced adaptations of the ICD-10 and 
DSM-IV-TR called Diagnostic Criteria for Learning Disability (DC-LD) (Psychiatrists, 2001), and Diagnostic 
Manual - Intellectual Disability (DM-ID) (Fletcher et al., 2007). Additional consideration and researches have 
been conducted to produce a more reliable conversion in the updated to DSM-5 version of DM-ID2 (Fletcher 
et al., 2016). Both the DC-LD and DM-ID-2 provide a variety of examples with detailed descriptions of most 
categories of PDs. It represents a first important step on behalf the improvement of psychiatric diagnostic 
process in ID and toward the reduction of the utilization of residual categories. At this regard, there are few 
unfortunate issues: at first, these manuals are poorly known and used among psychiatrists and their impact on 
clinical practice is being of lesser extent than expected. Secondly, adaptations are actually very accurate and 
based on clinical literature. However, the literature is not solid and replicated in some psychiatric fields (e.g. 
bipolar disorders, addictive and related disorders etc.) with the result that for some categories not exhaustive 
adaptations were provided.  
Another issue regards the reliability of the source of information. As already told, specific cognitive, adaptive 
and communication features of most PwID make them not completely reliable subjects to be directly assessed.  
Some features of PD, such as sense of hopelessness or worthlessness, suicidal ideation, delusional perception, 
distortion of self-rule body, are very complex and require a high level of expressive language, abstract thinking, 
conceptualization, memory, and self-awareness. An attempt to involve patients in their own evaluation should 
be done, mostly in mild ID, but caution in the interpretation of the information is required (Bertelli, 2015). For 
example, when ASD co-occurs with ID, the lack of social skills may produce withdrawal behaviors after the 
exposure to social environment resembling paranoid reactions, as well as typical autistic self-talk when 
associated to mood or anxiety symptoms might be confused with hallucinatory behaviors.  
Thus, the usefulness of available “significant other” to provide or integrate information on the onset and course 
of psychiatric symptoms is undisputable. Nevertheless, also what others report can be characterised by many 
troublesome issues. When the informant is a family member it is not infrequent that atypical presentations of 
PDs are difficulty understood or remembered (Costello and Bouras, 2006, Mikkelsen and McKenna, 1999). 
Moreover, it is widespread belief that all problems of PwID are inevitable and unchangeable (Costello and 
Bouras, 2006, Reiss and Szyszko, 1983), and proxies are often poorly prone to believe or accept that the PwID 
may have an additional mental health issue and deny the presence of psychiatric symptoms. Minimizing 
attitudes are often sustained by fear for psychotropic medications. Both familial care-givers and staff members 
may have at this regard opposite attitude, emphasizing the connection between PBs and a supposed PD in order 
to obtain medications. This peculiar aspect is correlated with the burn-out of the care-giver. In other occasions, 
both family members or other care-givers tend to “revise” information according to their interpretation of 
symptoms and behaviors leading both to under- or over-estimation of the type and the severity of the 
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psychiatric problem (Bertelli, 2015). The literature indicates some proxy factors influencing this kind of 
evaluation, such as the cultural level and other personal characteristics as well as the nature of the relationship 
and the affective and practical involvement (Pickard and Knight, 2005, Petry et al., 2009). Thus, integrating 
information from different sources, such as familiars, carers, or other proxies is recommended.  
A certain number of assessing instruments have been developed to detect psychopathology in ID, some general 
screenings, others area- or disorder-specific tools, based on modified standardized criteria (Feighner et al., 
1972, Sovner, 1986, Sovner and Hurley, 1983) or novel diagnostic systems (Matson et al., 1991, Moss and 
Goldberg, 1991, Reiss, 1987). However, the majority of the instruments that have been produced to date are 
only applicable to subjects with more mild cases of ID, have a suggestive value, are not very sensitive, or are 
time consuming (Bertelli et al., 2012). An integrated or combined approach with mixed categorical and 
dimensional properties could be helpful.  
 
1.5.2 EPIDEMIOLOGY 
PwID can experience the full range of mental disorders, and there is evidence that PDs occur more commonly 
than observed in the general population. PDs are frequently underdiagnosed or misdiagnosed, and can 
markedly reduce cognitive and adaptive functioning.  
Prevalence rates of PDs in PwID extensively vary across studies, ranging from 10 to 75% (Bouras and 
Drummond, 1992, Bradley et al., 2011, Cooper et al., 2009, Deb et al., 2001a, Jacobson, 1982, Lund, 1985). 
As already outlined in the paragraph above, this heterogeneity is mainly due to methodological problems 
relative to sampling and ascertainment of the psychopathological condition. ASD and, even at a lesser extent, 
anxiety and mood disorders resulted the more frequently diagnosed disorders (Cooper et al., 2007b).  
In this vein, the heterogeneity of the results requires an interpretation effort within the context of each study 
(Smiley, 2005). For example, the setting of the study may make the difference according to selection bias of 
samples in which PDs and behavioral problems may be actually over- or underrepresented. The former is the 
case of those studies performed in psychiatric services. On the other hand, the studies conducted within 
administratively defined populations such as rehabilitative services, residences, independent living locations, 
etc., might be considered more representative of the overall ID population (Cooper, 2019).    
Nonetheless, there is a certain agreement that the mean prevalence is around four-fold higher than in the general 
population. Moreover, the 25-44% of PwID has at least one PD, the 21% have two and the 8% three or more 
(Cooper et al., 2007b). 
1.5.2.1 Prevalence of psychiatric disorders in intellectual disability  
The point prevalence of PDs in ID found in a milestone study performed by Cooper and her colleagues was 
about 40%. The rate was reduced to 28.3% excluding PBs and 22.4% also excluding ASD (Cooper et al., 
2007d). The authors highlighted how psychiatric comorbidity may vary considerably depending on the 
diagnostic criteria applied, ranging from 52.2% when the diagnosis is based only on clinical assessment, to 
45.1% when the diagnosis is based on the DC-LD, up to 11.4% in surveys applying the criteria of the DSM-
IV-TR, or even up to 10.9% by application of the Diagnostic Criteria for Research of the ICD-10 (DCR-ICD-
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10; WHO, 1993). These rates were similar to those found in another important population-based study made 
in Scotland (Census, 2011) and reliant on self- or proxy reports, found that 23.9% of ID adults reported 
comorbid PDs comparing to the 5.2% of the adults without ID in the same population (Observatory, 2016). 
The incidence of PDs in adults with ID, excluding persons with only PBs, has been reported to be 12.6% over 
a two-year period; 8.3% for affective disorders, 1.7% for anxiety disorders and 1.4% for psychotic disorders 
(Cooper et al., 2007d, Cooper et al., 2007c, Morgan et al., 2008). 
The prevalence of unipolar depression in PwID is estimated about 3.8%, bipolar disorder 1.3%, and manic 
episode 0.6% (Cooper et al., 2007c, Morgan et al., 2008). The epidemiologic data regarding mood disorders 
will be discussed in the following chapter. The prevalence rate of anxiety disorders was found to be 
approximately 3.2% using DC-LD criteria. Point prevalence of individual anxiety diagnoses resulted 1.7% for 
GAD, 0.4% and 0.2% for agoraphobia and panic disorder, respectively (Reid et al., 2011). Psychotic disorders 
in intellectually disabled adults were estimated ranging from 2.6% to 4.4% according to different diagnostic 
criteria (Cooper et al., 2007b, Cooper et al., 2007d).  
Prevalence rates of PTSD vary substantially, from 2.5 to 60 % (Mevissen and de Jongh, 2011). Obsessive-
Compulsive Disorder (OCD) has been less extensively studied in ID persons. OCD features have been 
described as occurring within the behavioral phenotypes of specific genetic syndromes such in Down’s 
syndrome (Pary, 2004), Prader-Willi syndrome (Dykens, 2004) and in permutated Fragile-X patients 
(Schneider et al., 2016). In a clinical sample of moderate-to-severe intellectually disabled adults, the 9.4% 
shew over-the-threshold OCD symptoms (Holden and Gitlesen, 2004).  
Problematic eating behaviors including formal eating disorders (EA) have been found in about one third of 
PwID, reaching the 80% rate in individuals with more severe impairment and PBs (Gal et al., 2011, Matson 
and Kuhn, 2001). Regarding the prevalence of anorexia nervosa, bulimia and binge eating disorder (BED) 
prevalence rates are more uncertain and related studies often do not clearly explain how diagnostic criteria 
were applied to this population (Hove, 2004). In a well-conducted study including mild to profound ID patients 
(Hove, 2004), the rates of total eating disorders were 22.7%, 29.9% and 29.4% in mild, moderate and 
severe/profound ID patients, respectively. Most of the comorbidity were accounted by BED, almost four-fold 
higher than the rate showed by psychiatric obese outpatient with average IQ (Ricca et al., 2000). 
Rates of co-occurring personality disorders in ID shew the higher across-studies variability, ranging from 1% 
to 91% in community-based samples and from 22% to 92% in hospital settings (Alexander and Cooray, 2003). 
A reasonable intermediate result should be the 19.1% for personality disorder-NOS and 8.7% for borderline 
personality disorder in a study conducted by Wieland and colleagues (Wieland et al., 2013).  
 
1.5.2.2 Prevalence of psychiatric disorders in low-functioning autism spectrum disorders 
Psychiatric comorbidity in adults with ASD is highly frequent and may represent the main reason for medical 
and psychiatric help request. The wide overlap between some symptomatologic features of autism and some 
PDs may complicate the correct framework in this population (Bakken et al., 2010, Clarke et al., 1999, 
Ghaziuddin and Zafar, 2008).  
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The prevalence rates of PDs in adults with ASD range from 16% to 35% (Psychiatrists, 2014). 
The prevalence of depression is estimated between 15% and 42% (Ghaziuddin et al., 2002, Matson and 
Cervantes, 2014)and most studies indicated unipolar depression to be the most frequent comorbid disorder in 
ASD, both high- and low-functioning (De Bruin EI, 2007, Ghaziuddin et al., 2002). Some authors suggested 
that the prevalence of BD is instead underestimated (Raja and Azzoni, 2008), reporting rates ranging from 3% 
and 9%, depending on the features of the samples (Rosenberg et al., 2011, Stahlberg et al., 2004). 
Psychotic symptoms are not infrequent and this comorbidity represents a crucial diagnostic issue. However, 
few studies investigated it. Two population studies showed a prevalence rate of psychotic disorders ranging 
from 4.4% (Cooper et al., 2007b) to 18% (Tsiouris et al., 2011). Similar findings were reported also in clinical 
studies, with percentages between 7% and 16% (Hutton et al., 2008, Mouridsen and Sorensen, 1995). More 
specifically, in low-functioning ASD prevalence rates are around 15% (Leyfer et al., 2006, Psychiatrists, 
2014). 
Anxiety in adults with ASD is reported to be 7%-22% (Ghaziuddin et al., 2002, Matson and Cervantes, 2014). 
Social anxiety and GAD were the most frequent (22%), while panic disorder and agoraphobia represented the 
13% and 15%, respectively (Lugnegard et al., 2011). 
In people with ASD, the rate of exposure to trauma in childhood is estimated between 25% and 45% (Costello 
and Angold, 2000, McCloskey and Walker, 2000), while the risk of developing a PTSD after trauma ranged 
from 5% to 45% (McCloskey and Walker, 2000). The lifetime prevalence rate of PTSD in this population is 
estimated between 6% and 8% (Stallard, 2006). 
OCD prevalence rates ranged from 7% to 24% (Leyfer et al., 2006, Psychiatrists, 2014). This comorbidity is 
particularly hard to be correctly framed as over-, under- and misdiagnosis is frequent, mainly due to large 
overlap of symptoms. In PwID the lack of defence psychism may further hamper the diagnosis.   
Similarly, a considerable overlap may be also found among ASD and some personality disorders, mostly 
cluster A and C: indeed, many trait features of ASD patients overlap with criteria for schizoid, schizotypal, 
avoidant, obsessive-compulsive, and narcissistic personality disorders’ DSM criteria. In a recent report on 54 
young adults with ASD diagnosis, about half of the participants also met criteria for a PD according to DSM-
IV-TR criteria: approximately two-thirds of the men and one-third of the women met criteria for only 4 PDs: 
schizoid, schizotypal (cluster A), avoidant, and obsessive-compulsive (cluster C) (Lugnegard et al., 2012). 
Reliable data in this field are inconclusive.  
 
1.5.2.3 Co-occurrence of ASD in ID: additional vulnerability factor for psychiatric comorbidity  
Whether or not persons with low-functioning ASD are at increased risk of developing further psychopathology 
than PwID without autistic features still remains an unanswered question. Indeed, few studies considered this 
issue with systematic comparisons. Some literature suggests an increase of the psychiatric vulnerability when 
ID and ASD co-occur, estimated 5-fold higher than in only-ID persons (Bradley et al., 2004). 
To address this issue, our research group recently performed a systematic mapping of the literature including 
papers published since 2004 to 2016 (Vannucchi et al., 2017a). We identified 15 papers meeting the inclusion 
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criteria of the research and comparing PDs rates in adults with ID or low-functioning ASD. We found somehow 
contradictory results. Given the already discussed methodological problems and heterogeneity across the 
studies, we found rates ranging from 16% to 30.4% for MDs, 12% and 47.8% for anxiety disorders, 17 and 
21.7% for schizophrenia spectrum disorders and around 47% for OCD [(Bakken et al., 2010, Bradley et al., 
2004, Lunsky et al., 2009, McCarthy et al., 2010, Thalen, 2011, Tsakanikos et al., 2006). According to different 
assessing instruments and psychopathological parameters, ten papers of the selected fifteen (Bakken et al., 
2010, Hill and Furniss, 2006, Hove and Havik, 2010, La Malfa et al., 2007, LoVullo and Matson, 2009, 
McCarthy et al., 2010, Smith and Matson, 2010b, Thalen, 2011, Totsika et al., 2010, Tsakanikos et al., 2006) 
reported higher rates or severity or both of psychiatric symptoms in ID/ASD probands comparing to only-ID, 
suggesting that ASD may actually represents an additional vulnerability factor for the development of further 
psychopathology in ID individuals.  Moreover, it is possible to extrapolate that also increasing severity of 
autistic symptoms could be related to further psychopathology as well as more PBs and adjustment issues. In 
this vein, was not surprising that in two of these papers also considering the use of psychotropics the authors 
reported higher load of medications in ID/ASD patients (LoVullo and Matson, 2009, Tsakanikos et al., 2006). 
Two studies did not confirm this result, but it is possible that they referred to different samples and typology 
of patients as they were among those studies not observing differences in psychopathologic presentations 
(Lunsky et al., 2009, Melville et al., 2008).  
 
1.5.3 CLINICAL FEATURES 
1.5.3.2 Clinical features of psychiatric disorders in intellectual disability  
Anxiety disorders 
All types of anxiety disorders can occur in PwID. Clinical features of anxiety include fearful anticipation, 
irritability, concentration and memory problems, repetitive worrying thoughts, increased drinking up to 
psychogenic polydipsia, hyperventilation, increased urinary frequency, anger, sweating, avoidance behavior, 
agitation, and excessive motor activity (Cooray and Bakala, 2005). Sometimes anxiety disorders, mostly panic 
attacks, may be cause of fugue and escape with, paradoxically, the enactment of apparently impulsive and 
risky behaviors. Even aggression and self-injurious behaviors are often seen in clinical practice. This 
observation is in line with some studies reporting that PwID exhibit challenging behaviors such as aggression 
or self-injury as learned dysfunctional coping strategies, especially in those with greater difficulty in 
communication (Cooray and Bakala, 2005, Stavrakaki, 2002). Panic attacks characterized by derealization and 
depersonalization are not uncommon in clinical practice with PwID, but such symptoms are often 
misdiagnosed as psychotic manifestations due to the difficulties of patients in describing the associated 
unreality feelings. In these cases, typical neurovegetative symptoms may be reduced or may remain in the 
background or, alternatively, they might be interpreted as an alarm state.   
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Psychotic disorders 
The prevalence of psychotic symptoms in ID seems three-time more frequent than in the general population 
(Ayub et al., 2015). The diagnosis of psychosis is based on complex assessing procedures and the referred 
subjective experience and beliefs regarding thought contents and perceptions are usually crucial. This 
represents a challenge point in PwID and requires a careful and prolonged effort for the clinician to correctly 
interpret new onset symptoms and behaviors. Moreover, intellectually disabled people with limited verbal 
skills may exhibit strange behaviors and communicate unusual thoughts basically. On the contrary, many of 
the same behaviors that might indicate psychosis can be interpreted as ID features when the story of the patient 
is not correctly collect. If a PwID says that his name has been mentioned in the radio, or in television, it is not 
sufficient to diagnose a reference delusion; the developmental age of the person should be considered in the 
interpretation. PwID may also think that someone is trying to control their own actions, but it can be basically 
true when they require support by others, and it is possible that their apparent distress is mostly related to the 
poor self-awareness of the ID condition more than to actual broadcasting and influencing delusions. On the 
other hand, delusion contents may be simple in this population: for example, grandiose delusions can consist 
in the certainty that they can drive a car. Such a simplicity could divert the interpretation toward minimizing 
the symptoms.  
Furthermore, some adults with ID may speak to themselves, an object, or an imaginary person. These behaviors 
could be indirect signs of hallucinations, but could also be symptoms of ID caused by underlying brain 
abnormalities (Deb et al., 2001a). It is important to distinguish true ‘psychotic’ from ‘psychotic-like’ 
symptoms; in the latter case ‘fantasy thinking’ can be part of the be behavioral repertoire of the PwID. 
 
Personality disorders 
Features of borderline personality disorder, such as self-injurious behavior, impulsive behaviors and affective 
lability, often occur in PwID (Mavromatis, 2000). Attention-seeking and dramatic reactions as well as 
adhesiveness and dependence behaviors or lack of empathy and regret are also common and condition the 
interpersonal attitudes. However, communication deficits and maladaptive behaviors can make a personality 
disorder very difficult to be diagnosed in this population, especially in those with more severe impairment 
(Alexander and Cooray, 2003, Wilson, 2001). Some authors concern the validity of the construct in ID persons, 
because by definition the full organization of the personality requires a developmental level corresponding to 
that of young neurotypical adults.   
 
Eating Disorders 
Numerous and heterogeneous types of eating and feeding problems affect PwID (Gal et al., 2011). Common 
dysfunctions are pica (Hove, 2004), rumination/regurgitation, psychogenic vomiting (Gravestock, 2000), 
faddy attitudes toward food, and selective food refusal (Gravestock, 2000, Psychiatrists, 2001). The core 
cognitive and perceptual distortion accompanying anorexia and bulimia are difficult to be investigated in 
moderate-to profound ID. Indeed, according to DC-LD definitions disturbed body image and also hormonal 
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dysfunctions are not considered among the diagnostic criteria in this population. By the contrary, the 
compensatory behavior of self-vomiting assumes a crucial relevance in both. Similarly, compulsive eating is 
commonly shared by bulimia and BED, assuming in BED severer levels. Other peculiarities of eating are 
common in BED, such as fast and eager eating, “bolting”, stealing or hiding food (Hove, 2004). Obviously, 
the physical hallmark is usually represented by various degrees of obesity.      
 
Post-Traumatic Stress Disorder 
PwID have been found more likely to experience traumatic events comparing to the general population, such 
as sexual and physical abuse (Focht-New et al., 2008). Fewer abilities in managing adverse life events, 
maladaptive coping strategies, and low social support make PwID more vulnerable to develop PTSD and 
related disorders (Tomasulo and Razza,  2007). Language deficit and impairment in identification or 
description of their experiences and emotional state make it difficult to identify PTSD in individuals with ID. 
Studies found that traumatic experience in this population often manifests itself with disorganized or agitated 
behavior, while re-experiencing the trauma takes the form of behavioral acting out of traumatic experiences, 
self-injurious behavior, nightmares without recognizable trauma-specific content that can appear as symptoms 
of psychosis (Fletcher et al., 2007, Mevissen and de Jongh, 2011).  
 
1.5.3.2 Clinical features of psychiatric disorders in low-functioning autism spectrum disorders 
Psychiatric comorbidities are common in ASD and frequently lead to further associated impairment. Diagnosis 
of co-occurrent PDs is often challenging due to several difficulties including the core symptoms of ASD 
themselves, communication deficits, atypical presentation of psychiatric symptoms, and scarcity of 
standardised diagnostic tools (Vannucchi et al., 2014a). Furthermore, the clinical manifestations of ASD often 
overlap with the symptoms of other disorders; thus, it can be difficult distinguishing between them (Matson 
and Sturmey, 2011, Underwood et al., 2015). Finally, the superposition of some PDs on the basal 
neurodevelopmental disorder may arise clinical pictures easily confused as other clinical conditions in standard 
psychiatric settings because of the pathoplastic effect of ASD on the secondary condition.  
 
Anxiety disorders 
Clinically significant anxiety is common in individuals with ASD and is related to increased psychosocial, and 
familial impairment (Nadeau et al., 2011). Several features of autistic persons may make them particularly 
prone to anxiety-driven reactions. For example, insistence on sameness and adhesion to routine are considered 
core features in most patients. Environmental perturbations or more substantial changes (for example, change 
of living arrangement, transition to different educational settings, loss of significant others) may cause dramatic 
reactions as well as they can act as triggers for a full-blown anxiety disorder.  
People with ASD and comorbid anxiety may show increased ritualistic behaviors and PBs, even self-injury 
and aggressiveness toward object or others, as well as tantrums and fugues (Davis et al., 2012). The difficulties 
in expressing worry and fear challenge the diagnosis and such behavioral manifestations may suffer of both 
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diagnostic overshadowing or misdiagnosis. For example, agitation may be misattributed to manic states or 
other residual and generic diagnoses. 
Social anxiety disorder is more likely among high-functioning ASD individuals than in low-functioning. In 
this population social anxiety and ASD may have areas of differential diagnosis. Contrary to the popular 
opinion, in spite of their impaired social skills, most persons with ASD strongly desire social interactions but 
struggle with them. Negative experiences with others and actual ostracism by peers may be the ground of 
avoidant behaviors and social withdrawal. In spite of the fear of appearing inappropriate in social contexts, 
neurotypical social phobic patients are usually adequate; ASD is instead associated to social awkwardness up 
to bizarre and inappropriate behaviors (Bejerot et al., 2014). 
 
Obsessive-Compulsive Disorder 
Obsessive thoughts and stereotypical behaviors are commonly observed in ASD and overlap with OCD in the 
symptomatic profile (Ivarsson and Melin, 2008). Thus, it can be difficult to distinguish symptoms that are 
related to a comorbid OCD, particularly in people with lower functioning levels. Some studies have indicated 
that repetitive thoughts and autistic behaviors differ from those of OCD (Cadman et al., 2015, Ruzzano et al., 
2015). In OCD, typical obsessive themes include worries about germs, harm to self or others, pathological 
doubt, and obsessive preoccupations with moral, religious or sexual themes. Therefore, typical compulsions 
include ritualized washing, checking, ordering, apologizing, or mental rituals such as counting or praying. 
People with ASD may perform repetitive or ritualistic behaviors such as ordering, arranging, counting, or 
touching/tapping resembling compulsive behaviors (McDougle et al., 1995). These behaviors are more likely 
complex stereotypies than compulsions. Indeed, defence psychism is not present in these cases: autistic 
subjects with stereotypic rituals are not aware or preoccupied about the reason behind their ritualized 
behaviors. Rather, ritualized behaviors and repetitive thoughts may satisfy other needs, such as modifying 
sensory input, knowing what is going to happen next in their daily routine, controlling and gaining 
reinforcement from the environment, or preserving routine and sameness in their daily lives. In this 
perspective, someone can argue the substantial absence of obsessions and ego-dystonia. However, even in low-
functioning ASD, OCD may be present, usually with absence of insight. Despite DSM-5 separate OCD by 
anxiety disorders, the anxiety underpinning and accompanying rituals is a meaningful hallmark of co-occurring 
OCD in low-functioning ASD. The rituals tend to become more pervasive with time, are not related to 
environmental stimuli, as for example changes of routines which can instead elicit stereotypies. OCD rituals 
are always absent or minimal in unknown context, but are completely absorbing in familiar settings. When the 
person is prevented to act or complete the ritual may remain on look out to the moment of resume it or may 
blow up in severe rage. The attenuation of symptoms under behavioral and antidepressant treatments is an ex 
adiuvantibus criterion for the co-occurrence of OCD in ASD.  
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Psychotic disorders 
There is a broad overlap between ASD and schizophrenia spectrum disorders (King and Lord, 2011) not only 
including the phenomenology of the disorders but also commonly shared cognitive, neurobiological and 
genetic underpinnings. Transition into adulthood and exposure to stressful events are related to the onset of 
brief psychotic episodes in adults with ASD. Furthermore, psychotic symptoms may be in most cases the 
hallmark of an underlying mood disorder or a schizoaffective disorder (Underwood et al., 2015).  
As discuss for the diagnosis of psychosis in PwID, it seems important to distinguish psychotic-like from 
psychotic symptoms. Emotional reciprocity deficits may condition misattribution of significance to 
interpersonal interactions resembling referential ideas. Sensory issues in non-verbal subjects may be 
misconceived as perceptual disturbances. Stereotyped or unusual behaviors may seem bizarre and odd. When 
depression or mania occur, these symptoms may result intensified and they be misinterpreted as psychotic 
symptoms and the misdiagnosis of schizophrenia can be made rather than mood disorders (Skeppar et al., 
2013). On the other hand, the co-occurrence of hallucinations and delusions as well as negative symptoms of 
schizophrenia may actually be recognized in ASD persons along with the typical deteriorative course of 
schizophrenia or the episodic nature of MDs. The pervasiveness of symptoms, the association with alarm signs, 
the fluctuations in intensity and the influence of hallucinations and delusions on behavior may be signs of true 
psychosis in ASD.  
It can be hypothesized that when negative symptoms prevail a diagnosis of schizophrenia is likely in ASD 
persons (Kästner et al., 2015), whereas the prevalence of productive clinical picture is suggestive of a MDs, 
mainly mania (Larson et al., 2017).  
 
Eating disorders 
Eating disorders are often reported among adults with ASD, particularly pica, food refusal, and food selection 
for colour, type or texture. Selective food refusal is also associated with food spitting, obsessions, and rituals 
in ASD (Gravestock, 2000). Autism and eating disorders, especially anorexia nervosa, have common features 
concerning cognitive style and behaviors (Rastam, 2008), such as the tendency to focus on details and the 
insistence on sameness (Gillberg et al., 2007).  
 
Post-Traumatic Stress Disorder  
Although negative life events, physical and sexual abuse are quite common in people with ASD studies are 
lacking. Traumatic events and clinical presentation of PTSD are difficulty detected in people with ASD 
especially for their difficulties in defining their inner psychic state (Mehtar and Mukaddes, 2011). The 
diagnosis of PTSD requires an accurate assessment to understand cognitive interpretation, PBs, emotional 
disorders, and recognise signs of increased physiological arousal and sensory processing of the traumatic 
events, which might otherwise be misdiagnosed as exacerbation of ASD symptoms. 
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1.6 DEPRESSIVE AND BIPOLAR DISORDERS IN INTELLECTUAL DISABILITY AND LOW-
FUNCTIONING AUTISM SPECTRUM DISORDERS 
1.6.1 GENERAL ISSUES AND DIAGNOSIS 
Affective disorders in PwID and low-functioning ASD (LF-ASD) are an understudied area and the available 
epidemiologic and clinical data raise uncertainties. In the previous chapter the complex issues regarding the 
psychiatric diagnostic process and the substantial inadequacy ang generalizability of current standardized 
diagnostic criteria were discussed. The history and the issue of diagnosing MDs in intellectually disabled 
persons followed the same pathway. The first descriptions of melancholia and mania in mentally retarded date 
back to the 19th century and some authors identified ID as a risk factor for the development of depression 
(Sikabofori and Iyer, 2012). Despite these observations, almost another century was needed to overcome the 
prominent concerns regarding the occurrence of clinical affective disorders in ID, especially in persons with 
severe impairment (Earl, 1961). Some authors described development and features of depression and mania in 
mental retardation as well as the response to lithium (Hasan and Mooney, 1979, Naylor et al., 1974, Reid, 
1972). Therefore, in the ‘80s Sovner and Hurley (Sovner and Hurley, 1983) stated that individuals with ID 
may experience the full range of affective disorders and systematically conceptualized depression and BD in 
ID, also suggesting the utility of special “symptom criteria”. Later, this concept was resumed and Sovner 
(Sovner and Pary, 1993) produced an adaptation of DSM criteria for BD in ID, providing articulated examples 
and descriptions. 
Most of the available literature in this field regards depression rather than mania and BD. Depression occurs 
in ID and LF-ASD more frequently than in the general population (Cooper et al., 2018, Hurley, 2006, Janowsky 
and Davis, 2005). Although the demonstrated validity and reliability of the diagnosis of MDs according to 
standardized criteria in BIF and mild ID, the diagnosis of depression _as well as mania_ may result more 
challenging in persons with greater cognitive and communication impairment. This aspect relies the diagnosis 
mostly on informant reports, in contrast with usual practice requiring a deep investigation of internal states as 
essential dimension of mood syndromes (Charlot et al., 2007b, Courchesne et al., 2001, Hurley, 2007). 
Individuals with ID may not be able to describe their own emotions accurately or reliably, and this clue does 
not regard only severely impaired persons but also verbal individuals with mild ID (Bertelli et al., 2015, 
Costello and Bouras, 2006, Ross and Oliver, 2003). This is a general issue for the diagnosis of any PD in ID 
and LF-ASD, but it becomes an essential point for especially diagnosing depression. The cognitive impairment 
may also reduce the ability to understand and report complex concepts and feelings such as guilt, 
worthlessness, diminished ability to think, but also thoughts of death and suicidal ideation. These symptoms 
all represent individual criteria for the diagnosis of the MDE: it is expectable that the rigid application of full 
standardized criteria referring to these concepts and using the same cut-off for the minimum number of 
symptoms designed for neurotypical individuals, may be result inadequate (Cooper and Collacott, 1996, Davis 
et al., 1997a, Janowsky and Davis, 2005, Smiley and Cooper, 2003). Instead, a more pragmatic application of 
standardized criteria may, to some extent, overcome this issue (Marston et al., 1997, Meins, 1995). 
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The reliability of the informant is the other great issue to deal with in diagnosing depression. In ID the 
presentation of internalizing non-disruptive symptoms may be overlooked by care-givers and observers who 
usually over-report externalizing symptoms such as irritability, over-reactivity, agitation and behavioral 
correlates, mostly aggressiveness toward self or others (Charlot et al., 1993, Marston et al., 1997, Moss et al., 
1998). Those PBs are the first reason to seek treatment for ID and LF-ASD persons (Hurley, 2007). The 
overlook of other signs and symptoms suggesting a depressive underpinning is a major cause of inaccuracy in 
the assessment of MDs: the subsequent implication is the choice of behavioral and pharmacological treatments 
focused on the extinction of the PB rather than to treat the underlying disorder. This is also the reason why a 
psychiatric diagnosis only based on behavioral equivalents as unique reference of psychopathology is not 
recommended (Fletcher et al., 2016). PBs are intended to be possible “state dependent” features of depression 
but they are not diagnostically specific to depression (Charlot, 2005, Sturmey et al., 2010, Tsiouris et al., 2003). 
Some authors had an extreme position at this regard, down-grading the relevance and validity of behavioral 
equivalents (Ross and Oliver, 2003). However, some research demonstrated that DSM diagnostic criteria and 
depressive equivalents were both related to the diagnosis of depression in intellectually disabled persons, with 
also a significant relationship among the diagnosis of depression, depressive equivalents and PBs likewise 
aggression and self-injury (Langlois and Martin, 2008).  
The minimal modification of existing guidelines and criteria accounting for the pathoplastic effect of the 
neurodevelopmental level on the presentation of depression is the most accepted approach in the scientific 
community (Cicchetti and Toth, 2009).  
The use of multidisciplinary assessment, multiple informants, and longer time to observe the patient and collect 
information reduce the diagnostic biases. To avoid or reduce the interpretations of the informants, it should be 
preferred the use of tools providing detailed descriptions of the appearance and behavior of the patient rather 
than mere checklists (Fletcher et al., 2016, Hayes et al., 2011, Ross and Oliver, 2003). The clinician and the 
assessing instruments should account for the baseline exaggeration of symptoms and behaviors, carefully 
considering the baseline developmental level and behavioral repertoire of the individual. This helps to both 
avoid automatic attribution of behaviors mostly PBs to psychopathology, as well as the overshadowing of 
psychopathological ground, leading to over- (Davis et al., 1997a, Holden and Gitlesen, 2004) and 
underdiagnosis (McBrien, 2003), respectively. Targeted questions regarding clinical features but also age at 
onset of symptoms and PBs, variations over time, clinical course, treatment-emergent conditions, 
environmental variables, life-events and family history for MDs are important clinical validators for the 
diagnosis of depression and MDs in general (Hegerl et al., 2008). The exclusion of other sources of distress is 
likewise important: PBs may be underlie by a variety of environmental stressors but it is crucial to exclude co-
occurring medical illnesses including urinary retention and infections, gastric reflux, constipation, pain, 
seizures and others (Charlot et al., 2011, Espie et al., 2003, Kennedy et al., 2007, Kwok and Cheung, 2007). 
Side effects of medications, namely antipsychotics, may fully mimicry the clinical picture of depression 
(Sovner and Hurley, 1983): reduced reactivity and motivations, psychomotor retardation or agitation and 
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restlessness may commonly be caused by these compounds and, in this population, it is particularly difficult 
to identify them as extrapyramidal symptoms such as flattening, parkinsonism and akathisia.  
The proposal for substituting or integrating standardized criteria with behavioral equivalents raises from a 
documented tendency to underdiagnosis, mostly related to difficulties in obtaining reliable self-reports from 
verbally impaired patients. On the other hand, the application of behavioral equivalents has been argued to be 
misleading toward over-inclusiveness (McBrien, 2003).   
The adaptation of DSM-IV-TR criteria produced by the National Association for the Dually Diagnosed 
(NADD) in collaboration with the APA, Diagnostic Manual – Intellectual Disability (DM-ID), later revised to 
after DSM-5 was published (DM-ID-2), according to some part of the literature, provided only minor changes 
to the standard criteria for depression (Charlot et al., 2007b). The most important suggestions of the DM-ID 
and DM-ID-2 were that: 
1. In PwID irritability may present frequently as or more than sadness (Charlot, 1997, Davis et al., 1997b), 
thus irritable mood has to be considered an equivalent of depressive mood and not a counterpolar symptom. 
Similarly, psychomotor agitation seems to be a feature of depression more commonly found in ID than in the 
general population.  
2. The cut-off for the minimum number of symptoms for MDE was at least four symptoms and not five. 
3. Specific emphasis were given to the change of functioning, also including not only the new onset but also 
the worsening of ‘agitated behaviors’ such as assaults, self-injury, disruptive or destructive behaviors, as well 
as stereotypes and ritualistic behaviors. Some descriptions and examples were provided in order to depict how 
symptoms may be inflected in ID.  For example, reduced appetite may present as refusing meals, or exhibiting 
agitated behaviors at meal times such as throwing food and screaming when meals arrive. 
The Royal College of Psychiatrists in the DC-LD suggested modifications to ICD-10 criteria for depression, 
specifically addressing the diagnostic difficulties in persons with moderate to profound ID. DC-LD also 
attempted to provide a legitimate framework of PBs according to a hierarchical approach: clear instructions 
regarding organic disorders and behavioral phenotypes. The adaptation of the symptomatic criteria was 
somehow more pragmatic than in DM-ID: it provided the replacement of some self-report items with 
observable items (Smiley and Cooper, 2003). Moreover, the DC-LD suggested for these subpopulations the 
elimination of cognitive-based symptoms ( feelings of guilt and unworthiness, pessimistic views about the 
future and ideas of self-harm) and in place of the inclusion symptoms, behavior-based, such as the increase of 
specific maladaptive behaviors or somatic symptoms concurrent with mood and psychomotor symptoms of 
depression _but also mania_.  
Similar considerations are applicable to mania too, although the literature is far less extended than for 
depression. Some authors suggested a particular relevance of the developmental appropriateness: in fact, there 
are some evidence suggesting that not only the atypicality of the single episode but also the course of BD may 
resemble the features reported in bipolar young children (Rutter, 2011). The detection of full counterpolar 
episodes as well as mood and symptomatic fluctuations across time is the core diagnostic feature of BD. These 
aspects of atypicality and often stormy nature of the course of the illness in ID patients represent a major 
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hamper to the diagnosis. This suggestion is confirmed by the observations that BD is commonly misdiagnosed 
in ID because of difficulties in eliciting histories of mood change and tendency toward an overemphasis on 
psychotic and pseudo-organic symptoms (McCracken and Diamond, 1998). By the contrary, other authors 
concerned mania to be over-diagnosed because hyperactivity and excitement are common in these individuals 
(Einfeld, 1992), often in the form of hyperkinesia mixed to impulsivity as it has been extensively historically 
associated to the so-called minimal brain damage, the forerunner of current ADHD. 
There are data actually indicating that the presentation of BD in PwID may be distinctly different from the 
general population (Ruedrich, 1993), not only because the cross-sectional manifestations may be atypical, but 
also because of it frequently presents a chronic, or rapid cycling course (King, 2000, Sovner, 1989, Wieseler 
et al., 1988). Both chronicity and rapid cycling are associated to worse outcome and reduced response to 
standard treatments as in average IQ persons (King, 2000).  
From a symptomatic perspective, mania in individuals with ID may present similar diagnostic issues as 
depression., mostly in individuals with moderate-to-profound ID. Data from case descriptions and 
retrospective chart reviews, suggested that irritability and dysphoria may be equally or more common than 
euphoria (Cain et al., 2003). Comparing to other psychopathological ID groups, BD-ID patients also may be 
more likely to exhibit higher number and severity of non-mood symptoms such as increased energy, decreased 
sleep, disturbances of speech, distractibility, impulsivity and increased engaging in pleasurable activity, but 
also increased self-esteem. These symptoms taken together, are all suggestive of mania and fit with 
standardized criteria, in fact no adaptations have been provided in the DM-ID-2 to the symptomatic criteria for 
both mania and hypomania, and it only provided descriptions and explanations of the symptoms. However, 
symptoms may also have peculiar presentations which make the diagnosis less clear in clinical practice: for 
example, when language is absent and severe motor disability co-occur, altered speech might be replaced by 
increased production and tonality of vocalizing and screaming. Pressured speech might be rather represented 
by augmented intensity of social interactions often assuming the aspect of disturbing behaviors. Indeed, a wide 
range challenging and maladaptive behaviors have been reported (Cain et al., 2003). The increase of self-
esteem can be hard to detect, because of the cognitive skills required to be correctly explored. Moreover, 
pseudological thinking is common in intellectually disabled persons and not necessarily indicative of 
excitement. Cyclical behavioral deterioration might be in some cases the prominent sign of the disorder 
(Fletcher et al., 2016). 
The most challenging diagnostic issue may be the differentiation between mania and hypomania, BDI and 
BDII. That there are no studies regarding the phenomenology of BDII in PwID does not help in solving this 
issue. The differences regard by definition the severity of the overall clinical picture, reflected in the measures 
required to treat the syndrome and prevent disruptive consequences. For hypomania the change from usual 
functioning has to be unequivocal and observable by others but not so severe to require hard measures as in 
the case of mania. Such a difference is much vaguer in clinical practice, not only between mania and hypomania 
but also between hypomania and normal functioning. In most cases self-reported symptoms are not available 
and the diagnosis is almost exclusively based on the observation of an informant. Subsequently, this fact 
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reduces the reliability of this criterion. Moreover, with some differences across Countries (Wu et al., 2013), 
the tendency toward hospitalizations of intellectually disabled persons in acute psychiatric units appears less 
likely than for average IQ persons: they are more frequently managed where they live, mostly if they live in 
residencies. The presence of psychotic symptoms is indicative of mania. Not considering the difficulties of 
diagnosis psychosis in ID and especially LF-ASD, the presence of psychosis may hamper the differential 
diagnosis with schizophrenia and other schizophrenia spectrum disorders. The prominence of neurovegetative 
symptoms, agitation, and psychotic symptoms during the excitement phase and the long-lasting mild course 
of depression, with prominence of anergia ad motivational deficits may easily lead the clinician to a diagnosis 
of schizophrenia a (Mazzone et al., 2012). 
In conclusion, it is important to understand that, although current diagnostic criteria and psychiatric diagnostic 
process conducted as usual my result inadequate to correctly frame MDs in ID and LF- ASD, behavioral 
equivalents alone are not sufficient to make a diagnosis. A compromise position would be that behavioral 
equivalents could be operationalized as additional descriptive alternatives to the symptomatic criteria for MDs 
provided by DSM and ICD: a mixed approach providing the use of additional clear, behavior-based 
descriptions of possible manifestations of each DSM-5 or ICD-11 criterion is likely to better ensure the highest 
reliability in assessing and diagnosing these disorders in this peculiar population (Clarke  and Gomez 1999, 
Fletcher et al., 2016). 
 
1.6.2 EPIDEMIOLOGY 
The issues regarding the diagnosis and classifications of affective disorders in ID necessarily affect 
epidemiological data. According to different assessing methods, sampling and diagnostic criteria, MDs have 
been considered underrepresented, equal, or overrepresented comparing to the rates found for the general 
population (Janowsky et al., 2003). Usually, clinical studies suffer for large referral bias: it is expectable that 
the rates of PDs, namely MDs, are higher in clinical facilities, ambulatories and rehabilitative centers because 
it is more probable to find mental health issues among individuals needing intensive care. This aspect creates 
a bias especially for persons with BIF and mild ID, usually not entering psychiatric or psychological assistance 
pathways when not problematic. Equally, data derived from populations living in residencies may lead to 
overestimation of the rates: young persons with severe and profound ID are usually managed at home in 
absence of maladaptive behaviors. On the other hand, large population-based studies, in which the diagnosis 
is relied on the mere application of standardized criteria rather than a complete and complex assessment by 
trained professionals, may suffer for reduced diagnostic sensitivity and may lead to overestimation of the 
impact of MDs in this population, mostly in persons with moderate-to-profound ID.    
 
Depressive Disorders 
Depression is common among ID persons (Cooper et al., 2018), although some authors found different results. 
For example, in a dated study on a sample of PwID, with mainly severe and profound ID, the point prevalence 
of depression resulted 0% in contrast to higher incidences of those with schizophrenia and anxiety disorders 
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(Linaker and Nitter, 1990). In the same sample the authors suggested that this datum was coherent with the 
very low use of antidepressants in both institutionalized and non-institutionalized intellectually disabled 
persons comparing to the general population (3% vs. 9%, respectively) (Rinck, 1998). In contrast, although 
the general paucity of reliable data, there is a certain agreement that PwID may show an increased vulnerability 
to depression than the general population (Cooper et al., 2018): for example, mild ID teenagers have shown a 
four-fold increase of the risk for developing depression and other affective disorders in the following years 
(Richards et al., 2001) and the severity of depressive symptoms is higher among adolescents with ID 
comparing to their typical peers (Heiman, 2001). 
In the milestone population-based study conducted by Cooper and her colleagues (Cooper et al., 2007d, Cooper 
et al., 2007c) they found depression to be prevalent in the 4.9% of the overall sample of more than a thousand 
of PwID. This prevalence relied on the DC-LD criteria for depression. Differential point prevalence according 
to the ID level was 3.8% in mild ID, 4.4% in moderate ID, 4.6% in severe ID and 2.2.% in profound ID. In 
this large study, depression was associated to female gender and preceding life events, whereas occupational 
status and sensory impairment did not emerge as risk factors. These data were obtained using adapted criteria. 
The same sample evaluated with DSM-IV-TR criteria reported a prevalence of affective disorders of 1.1%, 
almost five-fold smaller (Cooper et al., 2007a). In the 2-year follow-up of the Cooper’s study, the 2-years 
incidence was 6.1% according to the clinical diagnosis, 1.5% using DSM criteria. In a replication of this study, 
Cooper substantially confirmed these results (Cooper et al., 2018), comparing these rates to those of the general 
population, reporting 2.9% rate for DDs (Lehtinen et al., 2005).   
In psychiatric settings, the rates are markedly higher with lower amplitude of the differences between the 
application of standardized and adapted criteria: for example, in a sample recruited in a psychiatric admission 
unit the prevalence of MDE was 44% and 59% with DSM criteria and a specific assessing instrument for 
intellectually disabled persons (MASS), respectively (Charlot et al., 2007b).   
It seems that depression in PwID may be more enduring than in typically developed persons, maybe because 
it is likely undertreated (Cooper et al., 2018). 
 
Bipolar disorders 
As claimed in DM-ID-2, although the literature provided descriptions of BD in PwID, reliable systematic, 
controlled studies assessing the prevalence of BDs, not only BDI, according to DSM-5 criteria are lacking. 
Some earlier studies reported BD ranging from 0.9% to 4.8% in the intellectually disabled population (Reid, 
1972, Ruedrich, 1993). The variability of rates depended on criteria as well documented by a more recent study 
investigating different diagnostic approaches (Cain et al., 2003): of the 68 ID patients clinically diagnosed with 
BD, only around the half (36) met the DSM criteria. In a community-based study also accounting for BDII, 
the prevalence of mania and hypomania together reached the 2.2.% (Deb et al., 2001a). In the studies by Cooper 
and colleagues (Cooper et al., 2018), mania showed considerably higher incidence rates comparing to general 
population, reaching 1.1%. Incidence rates for bipolar depression are comparable. Interestingly, the 
standardized incidence ratio (SIR) for the first episode of mania was 41.5 and grew to 52.7 excluding persons 
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with Down’s Syndrome (who had 0% incidence for BD). The SIR for a bipolar affective episode was 2.35 and 
2.54 according to clinical and DC-LD diagnoses, respectively, comparing to 1.19 and 1.07 for depression. 
These results are very important as they can be interpreted as the consequence of poorly diagnosed BD in spite 
of its clinical relevance in this population.  
According to this perspective it is expectable that prevalence rates in clinical populations may result much 
higher. For example, the rates of BD in ASD children and adolescents, including both high and low-
functioning, has been found to range between 2.3 and 10.4% (Rosenberg et al., 2011). In pediatric populations 
of LF-ASD the prevalence of BD was found around 6% (Rosenberg et al., 2011), expectably growing among 
adults, given that the onset peak is estimated during the transition from adolescence into adulthood. 
There is a substantial paucity of studies about the occurrence of BD in first-degree relatives of persons with 
ID, whereas the familial relationship between BD and ASD seems more replicated by studies (Bolton et al., 
1998, Piven and Palmer, 1999). Among ASD persons, a positive family history for affective disorders can be 
found in the 17% and 13% of the family members of Autistic and Asperger subjects, respectively (Gillberg 
and Gillberg, 1989). Several studies reported higher prevalence of depression and BD among ASD patients’ 
relatives compared to family members of children with other types of disabilities (Bolton et al., 1998, Lajiness-
O'Neill and Menard, 2008, Piven et al., 1991). This relationship seems to be stronger for high functioning 
autism (DeLong and Aldershof, 1987, DeLong, 2004), whatever identifiable in LF-ASD too. The majority of 
the studies on psychiatric morbidity of ASD patients’ parents showed that MDs onset usually precedes the 
birth of the offspring. This observation suggests the prominence of biological and genetic underpinnings in 
MDs among relatives of ASD patients, particularly HFA; on the contrary, a reactive component linked to the 
stress of care-giving a disabled child might have less pathogenetic weight (Bolton et al., 1998, Cohen and 
Tsiouris, 2006). A large Swedish study, including 988 couples of mother and child, examined the potential 
association between maternal history of mental disorders and phenotypes of ASD (Vasa et al., 2012). It was 
found a significantly higher prevalence of both depression (47.1% vs 39.1%) and BD (10.1% vs 6.2%) in 
mothers of high functioning ASD probands than in the mothers of LF-ASD children. Noteworthy, both the 
rates for high ang low functioning are significantly higher than those of the general population. On the other 
hand, other studies found the co-occurrence of ID in ASD to be associated to a risk of having a parent with 
BD almost equal to the general population (OR 1.1), whereas it increases up to 1.7 in ASD without ID. On the 
other hand, the risk of ASD is higher (O.R. 2.5) among the siblings of bipolar patients (Sullivan et al., 2012). 
There are no data accounting for the differential prevalence of different BDs and most studies regarded BDI 
or did not provide a subcategorization. Thus, no data are available about the overall bipolar spectrum including 
cyclothymic disorder. Moreover, in our knowledge only few studies explored the epidemiological 
characteristics of mixed states in PwID, although some experts suggested that they are much more common 
and characterizing MDs presentation in ID, as well as rapid cycling (Reid et al., 1981, Ruedrich, 1993). The 
incidence of mixed affective episode according to different diagnostic criteria resulted 0.2% in the study by 
Cooper and colleagues (Cooper et al., 2018), while in a chart review study in young PwID, the prevalence of 
mixed affective symptoms was 4.5% (Felstrom et al., 2005). Further information may be derived in specialistic 
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clinical setting. Only one study examined the differential prevalence of pure manic and mixed manic episodes 
in ID. It was a retrospective chart review of 80 adolescent inpatients admitted in hospital for acute manic or 
mixed episode. The study provided the IQ evaluation for all the patients and found that the 21.3% of them ha 
ID (Brunelle et al., 2009). The comparison of ID and non-ID subgroups evidenced that ID adolescents 
accounted for the 10% of the overall mixed manic episodes and the 29% of those with pure manic features 
(Brunelle et al., 2009).  It has also been reported that a significant proportion of patients with mixed affective 
episodes can present with catatonic symptoms (Braunig et al., 1998, Kruger et al., 2003). Interestingly, acute 
bipolar inpatients have been reported to suffer for inequalities in treatments. Contrary to the expectations and 
to data claiming PwID to be usually overtreated, when correctly identified they may receive lower dosage of 
appropriate medications comparing to their average IQ peers. This attitude implies much longer duration of 
hospitalizations, incomplete symptom resolution and long-lasting functional impairment (Wu et al., 2013).  
Epidemiological data about rapid cycling BD in PwID are still inconclusive but suggestive. In 1999 a 
systematic literature review was conducted on this topic (Vanstraelen and Tyrer, 1999). The authors found 14 
papers including a total of 40 intellectually disabled persons with BD evaluated. Contrary to the literature 
about rapid cycling in typically developed persons, in PwID rapid cycles are not associated to female gender 
but are equally represented in male and females. Rapid cycling has also been associated to earlier onset of PDs 
in general and specifically BD and it seemed that over one-third of rapid cyclers started with rapid cycling. 
Regarding the heritability of BD, the authors reported that the majority of patients with comorbid ID and rapid 
cycling BD had family history for affective disorders and this relationship resulted surprisingly more 
significant for those persons with higher cognitive impairment. No organic pathologies were specifically 
associated to rapid cycling.  
 
1.6.3 CLINICAL FEATURES 
Depressive Disorders 
There is a considerable debate about the clinical characteristics of depression in PwID and LF-ASD. To 
summarize, individuals with mild ID may show classic features fitting with standardized diagnostic criteria, 
whereas those with moderate-to-severe ID may present depression in different forms and with atypical features 
(McBrien, 2003). According to the idea that persons with ID show peculiar neurovegetative vulnerability and 
psychomotor involvement during depression, symptoms as psychomotor retardation, apathy, withdrawal, 
appetite and sleep disturbances, but also loss of daily skills and reduction in the cognitive performance, are 
common features across the ID levels (Davis et al., 1997a). In severer cases ID are also very common 
behavioral disturbances associated to depression, namely aggressiveness, self-injury, crying, screaming and 
temper tantrums (Cooper and Collacott, 1996, Marston et al., 1997).    
The onset and risk factors for DDs in PwID are similar to those in the general population. The onset is usually 
between late adolescence and early adulthood (Tonge and Einfeld, 2003), whereas late onset, for example 
around the fifth decade, requires careful consideration and long-term follow-up to draw conclusions because 
a psychiatric presentation could probably be the first manifestation of neurodegenerative processes. Some 
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subpopulations are particularly vulnerable: it is well-known the increased risk for Alzheimer-type dementia in 
persons with Down’s syndrome since the fourth decade of life. Environmental stressor immediately preceding 
the onset, at least for the first unipolar depressive episodes, and pre-existing problem behaviors are risk factors 
for the development of unipolar depression in adults with ID (Cooper et al., 2018). There is no agreement 
regarding the influence of heritability, gender and socio-occupational status. 
The diagnosis of MDD would require a recurrent pattern with multiple episodes. Comparing to bipolar 
depression, unipolar one has been found to show less abrupt development (Hegerl et al., 2008). There are no 
systematic data regarding seasonality of recurrences but in clinical practice is common to find recrudescence 
of depressive and anxiety symptoms with seasonal pattern. In most cases, the intensity of seasonal symptoms 
does not achieve the severity of full MDE but can be softly impairing anyway.  
There are no systematic and population-based studies addressing persistent depressive disorder, formerly 
dysthymia. The few reports regarding it (Jancar and Gunaratne, 1994, Puigh-Antich and Chambers, 1983), 
described clinical pictures similar to those in average IQ persons. Symptoms are at most mild but long-lasting 
and interfering with the functioning, especially with social adaptation. The mood can be depressed or irritable, 
energies are usually poor as well as concentration and volition, thus the person engage with daily activities 
with difficulties. In PwID these difficulties may assume more easily the behavioral features of malingering, 
but attention-seeking behaviors are frequently found. In mild ID individuals, chronic feelings of guilt and low 
self-esteem co-occurring with generalized anxiety are associated to lamenting. Persistent depressive disorder 
in moderate-to-profound ID represents a diagnostic challenge. With the exception of cognitive symptoms 
usually poorly evaluable in this population, there is a large overlapping area with negative symptoms of chronic 
schizophrenia spectrum disorders but also with iatrogenic affective flattening and impairment of hedonic-
motivational pattern due to long-term use of antipsychotics.  
As for mood disorders in individuals with typical neurodevelopment, the phenomenology of depression can 
be sectioned exploring the three fundamental dimensions involving affectivity: mood, activity and behavior, 
cognition and perception.  
1. Mood 
The quality of depressive mood is similar in mild ID as in average IQ individuals. Independently from the IQ 
level, the hallmark of depression is that depressed affect varies little day to day and is poorly responsive to 
circumstances (Sikabofori and Iyer, 2012). As in the general population, diurnal variations of intensity or 
prominence of different symptoms are possible in ID too. However, sad pervasive affect may be prominent 
only in a proportion of patients: in fact, irritability, dysphoric mood (Lowry, 1998, Tsiouris et al., 2003) and 
mood lability (Charlot et al., 1993) may be as common as sadness or rapidly alternating one each other. This 
is coherent with the developmental perspective which parallels depression in intellectually disabled individuals 
to that in typically developed young children (Cicchetti and Toth, 2009). Irritability and reactivity usually 
increase the sensitivity to frustration. The person with good verbal skills may report feelings of sadness or 
rage, may appear tearful and demanding. However, vague and highly variable complaints are more common, 
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mostly about somatic symptoms (Charlot, 1997, Charlot et al., 1993, Lowry, 1998, Rojahn et al., 1993, Tsiouris 
et al., 2003).  
Loss of interest, reduced emotional response and anhedonia are core features of depression. They are constructs 
very difficult to be described by persons with low cognitive and verbal skills, but often there are behaviors that 
can be interpreted as their correlates. For example, a person with mild ID could not be able to tell that is not 
able to “feel feelings” or that he/she lost the will or the pleasure to do things: thus, when asked to do or to 
choose something, he or she could only shows renunciatory attitudes and says “I don’ care” (Fletcher et al., 
2016). At a first sight these could be interpreted as laziness or, when repeating over time, as a tendency to 
become easily tired of activities. In severer depression, withdrawn and social avoidance may become 
prominent aspects in the clinical picture (Cooper and Collacott, 1996). In persons with severe/profound ID, 
the combination of irritability and altered hedonic-motivational pattern often represents the underpin of PBs 
during depression. In fact, PwID and depression may display oppositional-defiant behaviors, tantrums or 
aggressiveness toward objects or others in order to escape care-givers’ requests, stimulations or the 
participation to activities in which they have no longer interest (Lowry and Sovner, 1992). 
Finally, anxiety and its behavioral correlates are also frequent in depressive PwID (Charlot et al., 2007a, Hurley 
et al., 2003, Marston et al., 1997). Excessive preoccupations, fears and thoughts regarding health and safety, 
physiological signs of anxiety may occasionally be reported by the patient, but an effort has sometimes to be 
done to frame eventual odd and peculiar interpretations. An intellectually disabled person with panic attacks 
or anxiety crises could simply repeat “I don’t want to go to the doctor”, “no more, no more”. PwID may also 
have difficulties in identifying that chest pain is related to tachycardia and palpitations, for example, and may 
generally talk about stomachache. Neurovegetative symptoms are equally present in mild as in moderate-to-
profound ID, may be related to environmental stimuli or spontaneous and, when anxiety is a feature of 
depression, recurrent diurnal variations may be identified. Neurovegetative signs, for example sweating, 
trembling, gasping for air or frantic breath, coughing, vomiting, diarrhea and reduced urinary and fecal 
continence, can be associated to crying, screaming, running around or away, restlessness or grabbing to 
someone. In some cases, anxious ID patients may become strongly demanding and may act self-injury in order 
to obtain the attention of the reference adult. There are also other symptoms equivalents possibly related to 
anxiety during depression. In PwID and LF-ASD, stereotypies, involuntary movement, repetitiveness, and also 
OCD spectrums symptoms including environment hyper-control, rituals, but also skin picking and 
tricothillomania, can increase during depression and are usually accompanied by anxiety (Charlot et al., 2007a, 
Hurley et al., 2003, Marston et al., 1997). 
2. Activity and Behavior 
Lack of energy is strictly related with anhedonia and altered motivational pattern. Various degrees of fatigue, 
asthenia, lethargy, but also psychomotor retardation may implicate noncompliance and unresponsiveness 
(Matson et al., 1999). The global aspect of the person and the mimic are coherent with mood: the depressive 
patient usually shows under-reactivity of facial expression to environmental stimuli, smiling is difficult to be 
elicited, the facial expression can oscillate from flatness to sadness, tearfulness, or it can express rage and 
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aversion. The person can be oppositional toward interaction, isolated, and a loss of confidence with persons 
and environment can be the final result. When speech is present, it is reduced in volume and content, in some 
cases the person refuses to talk and answer. Mutism is not uncommon. In non-verbal patients reduced 
interactions even with familiar people, scarce research of interpersonal contact, avoidance of social 
circumstances can be considered behavioral equivalents of these aspects. A reduction in self-care is very 
common and the attempt of the care-giver to help the person providing self-hygiene or wearing clean clothes 
is one of the commonest triggers or antecedents for tempers and aggressions.   
Psychomotor agitation seems to be twice as common as retardation in PwID (Tsiouris, 2001). Psychomotor 
agitation is easy to be detect because of its disruptive nature. Rather, it is often the symptom which clinicians 
and informants focus on, and it may unfortunately mislead diagnosis and management. Restlessness, running 
away, sudden screaming, vocalizing or disorganized and purposeless motor activity are behavioral signs. 
Agitation is often associated to PBs, even if they are not specific as extensively discussed. By no means, most 
individuals show a combination of both psychomotor retardation and agitation, rapidly shifting from one to 
the other, often in response to a demanding environment (Charlot, 1997, Charlot et al., 1993, Meins, 1995) . 
In severe and profound ID as well as in LF-ASD it can be very difficult to distinguish a “simple” combination 
of these psychomotor symptoms from catatonia. In some cases, rapidly alternating counterpolar psychomotor 
symptoms would configure a mixed state, for example agitated depression. When changes are extreme, a 
diagnosis of catatonia should be considered. The classical symptoms of catatonia, for example posturing, 
grimaces, motor rigidity, waxy flexibility, stereotypies and echolalia may pertain to core features of ASD or 
may be not identifiable in persons with severe motor disability, for example in severe cerebral palsy and when 
severe spasticity is present. This is not a moot point, especially considering the complex interrelationship 
existing between catatonia, affective disorders and some PBs. Indeed, some authors and expert clinicians 
hypothesized severe self-injury with recurring pattern to belong to catatonia in depressive and bipolar ASD 
children (Fink et al., 2006). In most cases, standard psychopharmacological treatments fail or worsen 
symptoms, whereas electroconvulsive therapy has been demonstrated to be effective (Wachtel et al., 2018). 
Sleep and appetite disturbances have been found to be markers of depression in PwID and have to be 
considered even more important hallmarks in severe and profound ID (Tsiouris, 2001). Insomnia, nightmares, 
multiple awakenings associated with screaming, fear and attention-seeking behavior have been documented. 
Less is known about the presence of diurnal hypersomnia, which is commonly found in clinical practice. 
However, hypersomnia may be easily due to sedation as side effects of medications used to treat insomnia or 
disruptive behavioral disturbances. Similar considerations can be drawn for the alterations of appetite and 
weight during depression: hyporexia, refuse to eat, increase of pre-existing selectivity for foods are common 
symptoms (Mayville et al., 2005). By the contrary, hyperphagia, binge episodes, craving for foods with 
addictive attitudes, such as stealing food, are also common and are usually associated to increase of body 
weight, especially when there is a general reduction of activities. Th role of medications can be controversial.  
Sexual activity, when present, can be affected to, especially in the form of a reduction in all the sexually-
oriented behaviors comparing to the baseline functioning.  
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3. Cognition and perception 
PwID usually do not complaint about reduced ability to think and concentrate, but indirect signs can be 
indecisiveness and vacillation (Clarke et al., 1994). Depressive ID patients may appear dull, difficult to focus 
on tasks previously handled. The difficulties in engaging or finishing tasks may elicit irritability and 
unproportionate reactions. When indecisiveness and slowing are associated the person remains blocked, for 
example expanding the entity and duration of stereotypies or rituals. In severest cases the slowing of mental 
functions and the impairment of executive functioning are massive giving the impression of an abrupt 
regression involving the overall pragmatic functioning, not only cognitive skills, memory and logical-
abstractive thinking. 
Ideas of worthlessness, self-reproach, guilt, hopelessness and death are present in PwID beyond the intellectual 
deficit [(Benson and Laman, 1988, Charlot, 1997, Hurley, 2007, Pawlarcyzk and Beckwith, 1987). In verbal 
patients thought contents may be simple and very concrete. For example, a person with mild ID would often 
complain about the fact he/she cannot drive, work or going out with friends dancing. Thoughts of death are 
vague: in fact, the notion of death in typical children is usually developed at the end of childhood and further 
emotional development is required to fully conceptualize it. In most cases the ideas of death may regard the 
fear of losing persons or, when significant others are dead, the desire to reunite with them “in heaven”. 
Hypochondriac preoccupations, usually associated to anxiety symptoms, are also frequent. Some individuals 
may verbalize punishment for themselves, for example “You have been bad, tomorrow you won’t go in that 
place”. In non-verbal patients these contents are for most virtually impossible to be assessed and very limited 
cognitive skills are supposed to impede the structuration of consistent holothymic ideation. On the other hand, 
it is possible that lower IQ patients experience during depression negative feelings about selves and others. 
Possible behavioral correlates could be, again, withdrawal but also seeking reassurance or physical contact of 
significant persons, beating themselves and crying. In more severe forms, these feelings may become 
pervasive, reaching a delusional intensity. The difficulties to correctly understand non-verbal communication, 
may influence the manifestations: PwID during depression may avoid food for the fear of harm; they may 
avoid or assault previously appreciated persons showing unmotivated hostility as they were afraid from them.  
PwID may experience the full range of psychotic symptoms, namely hallucinations. As in the general 
population, psychosis is less common during depression than mania. The behavior can be influenced by 
hallucinations and usually they are fully participated.  
 
Bipolar Disorders 
No data are available regarding the clinical features of BDII, cyclothymic disorder and BD NOS in PwID and 
LF-ASD nor about the differences in risk factors, course, prognosis and response to treatments comparing to 
BDI and other MDs, namely MDD. All the research has been focused on BDI and mania. To date, the studies 
regarding the clinical features of mania and BDI are at most limited to case reports, case series and chart 
reviews.  
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BDI in PwID may frequently assume the clinical and course features of BD in children, indicating the 
pathoplastic role of developmental level on the illness. Similar to the general population, BDI is associated to 
high familial load for BD but also other MDs and high rates of further comorbid PDs (Vanstraelen and Tyrer, 
1999). Differences emerge instead regarding the course of the illness: in fact, comparing to the rates reported 
in neurotypical adults, highly unstable course characterized by rapid cycling (at least or more than four 
episodes per year) has been reported from 10% to 54% according to different sampling across the studies 
(Charlot et al., 1993, Glue, 1989, Goldberg and Harrow, 1999, King, 1999). In a review article about this topic, 
authors found that a greater severity of ID would be associated to shorter and more frequent episodes. In fact, 
they found that the mean number of episodes per year was around 25 per year in severe and profound ID 
comparing to 14.5 per year in BIF, mild and moderate ID (Vanstraelen and Tyrer, 1999). Comparing to rapid 
cycling in average IQ individuals, associated demographic and clinical features are not confirmed in PwID: 
thus, rapid cycling is associated to male rather than female gender (Cooper and Collacott, 1996, Vanstraelen 
and Tyrer, 1999). Moreover, rapid cycling in PwID is associated to young age at onset of the mood disorder 
and the rapid cycling, but also other psychopathology, often before the age of puberty (Vanstraelen and Tyrer, 
1999). No medical illness has been specifically associated to rapid cycling, nor thyroid dysfunctions, instead 
very common among mid-age average IQ women with rapid cycling BD, neither epilepsy, which is associated 
to the severity of ID but not to the course of the bipolar illness (Vanstraelen and Tyrer, 1999). Interestingly, 
rapid cycling in ID are also associated to higher family burden for affective disorders, and this association is 
directly proportional to increased severity of ID. This evidence, together with the half of rapid cycling BD 
patients reporting the onset before 17 years of age, was explained by Vanstraelen and colleagues (Vanstraelen 
and Tyrer, 1999) as the effect of genetic anticipation in those patients with a familial load for BD. It is also 
possible that in those patients with a  familial bipolar diathesis, constitutional emotional dysregulation may 
become prominent in the clinical picture and, on one hand it can facilitate or mediate the co-occurrence of BD 
in PwID and LF-ASD; on the other hand, emotional dysregulation may colour the manifestations of the 
affective disorder conferring to the episode and to the course an additional instability feature. If we consider 
these variables as independent, it is somehow possible that when the familial load and unspecified emotional 
dysregulation related to the neurodevelopmental basic condition co-exists, they have an additive effect 
producing these massively unstable affective pictures, alternatively called ultra-rapid cycling. Some questions, 
not yet answered, may arise considering the very high number of reported episodes and taking into account 
that, in our knowledge, no studies have considered the prevalence, features and relevance of mixed states in 
the ID population. In fact, it is possible that at least some of the cases diagnosed as ultra-rapid cycling BD 
might be actually better reframed as chronic mixed states, as some authors indicated in the past (e.g., (Reid 
and Naylor, 1976, Ruedrich, 1993). Probably, the emphasis given by DSM to the simultaneous co-occurrence 
of counterpolar affective symptoms, rather than the possibility of rapid shifts, alternation and co-existence in 
the same episode of both depressive and excitement symptoms, may have influenced the perspective and 
subsequently the poor interest toward this topic. It is suggestive that in samples of adolescents hospitalized for 
acute manic or mixed episode, the mean IQ is usually low, with about the 20% of patients having intellectual 
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disability. The 10% of the mixed manic episodes involve exactly patients with ID (Brunelle et al., 2009). 
Clinical pictures characterized by a combination of withdrawn, underactive behaviors alternating with agitated, 
restless behaviors, extreme reactivity and dysphoria in response to demands have been described (Charlot, 
1997). It is quite hard to define such mixed states according to current DSM-5 specifiers as depressive or manic 
episodes with mixed features.  
Comparing to the peers with ID and other PDs, bipolar ID patients reported higher rates of thought 
disturbances, even when compared to primary psychotic disorders, including misinterpretations and obsessive 
thinking, severer functional impairment and higher rates of PBs, mostly aggression, self-injury and disruptive 
behaviors (Fletcher et al., 2016). Interestingly, DSM symptoms of mania, taken individually, are not specific 
for the diagnosis of mania but are commonly associated to other psychopathology with the exception of the 
decreased need for sleep. The most reliable parameter is the variation of the symptoms along a significant time 
frame (Gonzalez and Matson, 2006). 
Noteworthy, some authors claimed the prominence of non-mood symptoms in ID, especially for mania (Cain 
et al., 2003). This can be a particularly relevant issue in the case of LF-ASD, in which background irritability 
and mood dysregulation may be core features of the neurodevelopmental disorder. Unfortunately, this aspect 
is critical to the under-meeting of current categorical criteria for BD. Anyway, manic symptoms may be 
decomposed according to the three main dimensions of functioning relying to affective disorders.  
1. Mood 
Mania in PwID and LF-ASD may be characterized by both euphoria and irritability, but dysphoria, over-
reactivity and extreme lability are usually prominent (Fletcher et al., 2016). DM-ID-2 does not provide 
adaptation for manic mood, but examples are given in the note for hypomanic mood. Elated mood may rapidly 
alternate with irritable mood, both spontaneously or reactively to environmental stimuli. The reaction is usually 
disproportionate to the type and intensity of the stimulus. Temper tantrums are also common during 
excitement. Patients may appear cranky, extremely happy or cheerful without any reason, silly, excessively 
giddy, loud and they can inappropriately laugh or sing, they can be intrusive and excessively pushy with others. 
Even the mimic and gestures are usually coherent and expressive of the current affective state: for example, 
patients may appear excessively or inappropriately smiling, sometimes fatuous and poorly in agreement with 
the environmental emotional atmosphere.  
2. Activity and behavior 
Psychomotricity is usually increased during mania. This acceleration may cover a range of manifestations 
including increased energy and movements, fidgeting or restlessness, up to agitation in severest cases. 
Sometimes stereotypies, when present, may result augmented. The speech may be accelerated and pressured. 
When the acceleration is accompanied to a formal disturbance of the thought, the speech can become less 
understandable and eventual pre-existing motor language disorders may be accentuated. In non-verbal patients 
it can manifests as increase in volume and tonality of vocalizing and loudness. It is possible to evidence the 
intensification of the engagement in daily activities or the person may become overdemanding toward others 
to make more activities. For example, a person may ask to leave home and go out walking more than usual, 
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and may become cranky or aggressive when it is not possible to be satisfied. The research for interpersonal 
interactions is often elevated: the person may show jocularity but intrusiveness, scarce respect of social rules 
and impulsivity may make the social behavior problematic and inappropriate. During mania the acceleration 
can be so high that the behavior may become actually disorganized, characterized by actual purposeless 
hyperactivity, running or wandering away: thus, the person can show an abrupt regression of previously 
handled adaptive skills.  
Increased sexual impulse and activity is an important sign of excitement, in some cases becoming prominent 
and qualifying oligo- or mono-symptomatic manic forms. Hypersexuality usually consists in a large increase 
of masturbation (Pary et al., 1999). This activity may be poorly controlled and the patient does not take care 
of the surrounding environment. Poor social skills and pre-existing disinhibition may be further affected during 
(hypo)manic phases and sexually-oriented behaviors may be not only increased but also socially challenging: 
unrequested or socially inappropriate research of physical contact is very frequent, and can range from insistent 
attempts to touch others, in some cases with poor distinction of gender preference previously expressed, up to 
get undress in public circumstances, exhibition of genitals and, in severest cases, a strict surveillance is required 
to avoid sexual assaults.     
Among the neurovegetative signs, reduced need for sleep is an early sign of excitement, which unfortunately 
may be masked or under-recognized in patients taking sedative medications. Even appetite can result affected, 
usually increased and associated to voracity, sometimes binge eating with pushy and continuous requests of 
food. It is not uncommon that patients steal food from others during the meal as well as along all the day, 
especially during night. In some cases, manic ID patients may become actually seeking for food or beverages 
and may show a sort of craving toward them.  
PBs are very commonly associated to excitement in PwID and they may be underlain by different motivations 
according to the degree of ID. In BIF and mild ID, oppositional defiant behaviors, threating and aggressiveness, 
are commonly elicited by the need to obtain secondary advantages such as full attention, objects or the 
satisfaction of other requests. In fact, during hypomania and mania, the sensitivity to frustration, reject and the 
capacity of respecting timing and delay the reward may result increased comparing to the baseline or fully 
compromised. Throwing away or breaking others people’s objects, dirt things, losing control of urines and 
feces on purpose, manipulating or eating them, are non-aggressive defiant behaviors commonly found in 
severer degree of ID. Self-injury may also be present, but recent data suggested that is less specific for mania 
comparing to aggressiveness toward others or objects (Baudewijns et al., 2018).  
3. Cognition and perception 
Cognition and perceptual disorders are difficult to be evaluated in PwID and their assessment is challenging 
for most patients. Flight of ideas or accelerated thoughts may be more easily evinced by acceleration of the 
speech and a tendency to pass from a conversational topic to another without any kind of reciprocity or respect 
of the rules of the conversation. However, it is common especially when ASD coexists, that the person with 
ID shows focused and restricted interests with a tendency to perseverance and difficulties in following the 
course of the conversation. Thus, a significant qualitative difference in the speed of thoughts and speech has 
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to be detected comparing to the usual. Distractibility is a common feature of (hypo)mania in PwID and LF-
ASD as well as in neurotypically developed patients. However, baseline cognitive deficits may include 
alterations in executive functioning such as the attention flexibility, shift and maintenance, planning and 
control of the task, cognitive impulsiveness. These deficits may imply short-living time for the execution in 
tasks and the need for support of care-givers to remain engaged in a task. Pleasant tasks or activities of special 
interest for the person may not be affected. To identify distractibility as a feature of (hypo)mania in PwID, the 
clinician should formulate target questions focused on those tasks in which the person can remain usually well 
engaged. Increased distractibility may also be evinced when external low stimuli (noises, others talking, etc.) 
capture the attention of the patient differently than usual, interfering with activities normally performed. The 
performance has to be significantly impacted by such a distractibility and it may seem that the PwID lost some 
skills, for example the capacity to remember and perform well-known sequences of actions. 
Disturbances of the thought content is not uncommon during mania. Increase of the self-esteem is difficult to 
evaluate as strange beliefs or scarce self-awareness of the own limitations may be present as features of the 
basic condition and in agreement with a low developmental level. By the contrary, grandiosity may regard 
simpler contents than average IQ patients. For example, a PwID may develop the belief he/she can drive the 
car boasting about having driving license, he/she has a romantic relationship with a neighbor, he/she is an 
educator etc. This content is not actually evaluable in persons with severe and profound ID and with severe 
communication impairment. It is possible that risky behaviors (for examples fugues or try to “fly”) are dragged 
by megalomaniac beliefs rather than impulsiveness or defiance, but it can be very hard to settle the actual 
motivation of such behaviors, especially because one reason does not exclude the others. Sudden avoidance of 
places, persons, activities or objects, food for example, may suggest delusional beliefs even if these symptoms 
follow in differential diagnosis with anxiety and panic attacks in persons with moderate-to-profound ID.  
PwID present the full range of perceptual disturbances, but the differential diagnosis with normal behaviors 
can be challenging especially in LF-ASD. In fact, autistic persons may often present self-talk. It mostly 
represents a reiterative self-dialogue in which they repeat, often with pronominal inversion, sentences, orders 
or suggestions heard in the previous day. Sometimes the autistic self-talk is stereotypic in nature. The presence 
of auditory hallucinations may be suggested when the person suddenly interrupt the ongoing activity and may 
appear frightened or withdrawn from the social context. Similarly, the person with poor or without verbal 
skills, may appear freezing, or looking at places in the room where there is nothing to see or may behave as 
something terrific was there or on the body. Beating, scratching or hiding parts of the body, wearing peculiar 
dresses may all be behavior related to visual or tactile misperceptions.    
These symptoms have to be carefully investigated because hallucinations, especially visual ones, 
disorganization and alarm state may be also arisen during delirium which requires a different management.  
 
As illustrated in the above descriptions of manic features in persons with ID and LF-ASD, behavioral 
equivalents may have the value of additional validators of the diagnosis. This concept is clearly exemplified 
in a significant study conducted by the group of Matson (Sturmey et al., 2010): the authors explored the 
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symptomatic factors associated to the diagnosis of mania in PwID. They found four main factors accounting 
for around the 40% of the variance. The first factor of mania, accounting for the 20% of the variance, was 
characterized by verbal maladaptive behaviors toward others and impulsiveness, for example curses and 
imprecations, verbal abuses and repetitiveness about some subjects or concerning over and over. These 
behaviors also cluster with easy frustration, loudness and accelerated speech and, at lesser extent, with irritable 
mood. The second factor, including distractibility, was characterized by attention-seeking, demanding and 
defiant behaviors (for example throwing objects, hitting, kicking or pinching people). The third factor included 
euphoric mood, restlessness and agitation and talking quickly. Interestingly, increased stereotypies such as 
rocking, flapping, spinning and amusing with repetitive behaviors belong to this factor. Finally, the fourth 
factor included equivalents of psychomotor activation and decreased need for sleep: related behaviors are 
temper tantrums, opposition to instruction or guidance, aggressiveness and screaming.  
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1.7 ASSESSING INSTRUMENTS 
Standardized assessing instruments represent a valuable resource for the psychopathological diagnostic 
process in PwID and LF-ASD. Indeed, they complement, fasten and optimized more than in the general 
population the collection of clinical information usually performed by means of the interview and direct 
observation of behaviors. Moreover, they favour different professionals to share clinical judgments and 
projects.  
The psychopathological evaluation of neurodevelopmental disorders has been substantially expanded only in 
the last three decades. Specialized researchers of this field worked on one hand on the development of ex novo 
tools, on the other hand on the translation and adaptation of tools previously developed for the general 
population. In both the cases, the assessing instruments show several applicability and efficacy limitations. 
Adapted questionnaires also show limited sensitivity, mainly due to the significant atypicality of 
psychopathological symptoms in PwID and LF-ASD. 
Currently, the most popular assessing tools are general screenings, aimed to give indications toward all the 
diagnostic categories compatible with occurring symptoms and behavioral equivalents, rather, 
psychopathological area-specific instruments also exist. Otherwise, there are few standardized diagnostic 
interviews: they are usually long, expensive and less useful for the multidisciplinary collaboration. By no 
means, the systematic application of standardized assessing tools to support and integrate the diagnostic 
process, the monitor of course and treatment outcomes is fundamental in the ID and LF-ASD population. 
Advantages are summarized in Table 1. 
 
Table 1. Advantages for the use of standardized tools in the diagnosis and management of psychopathological 
issues in persons with ID and LF-ASD 
To support in the diagnostic process, especially regarding behavioral equivalents in persons with sever-to-
profound ID  
To favour the direct involvement of the persons with ID/ASD and caregivers in the assessment pathway 
To facilitate the comparison and discussion among professionals and different context 
To increase interdisciplinary sensitivity and specificity toward behavioral equivalents  
To enhance the multidisciplinary cooperation 
To draw objective evaluation of the intervention’s results 
Continuous improvement of standardized instruments 
To improve the evidence-based research 
To expand the knowledge about the peculiar and specific presentations of psychopathological symptoms 
and syndromes.  
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1.7.1 STANDARDIZED DIAGNOSTIC INTERVIEWS 
The few standardized diagnostic interviews for the investigation of psychopathology in PwID and LF-ASD 
are mainly addressed to persons with good communicative and introspective abilities (Heal and Sigelman, 
1995).  
The most famous is the Psychiatric Assessment Schedule for Adults with Developmental Disabilities (PAS-
ADD), developed by Stephen Moss e co- for the evaluation of PDs in adults with ID workers (Moss, 2011, 
Moss et al., 1994, Moss et al., 1993); it is based on ICD-10 categories and criteria.  In fact, it is derived from 
the Schedules for Clinical Assessment in Neuropsychiatry (SCAN), semi-structured clinical interviews made 
by the World Health Organization in 1994, starting from the Present State Examination (PSE) (Wing et al., 
1974), and used by specifically trained clinicians to support the diagnosis of PDs in adults. Recently, 
correspondence profiles with DSM diagnoses have been proposed.  
PAS-ADD includes 145 questions originally referring to seven subscales corresponding to the main Axis I 
PDs, thus excluding personality disorders: schizophrenia and other psychotic disorders, bipolar disorder, 
depression, anxiety disorders and phobias, obsessive-compulsive disorder, autistic spectrum disorder and 
hyperkinetic disorders (including ADHD). The clinical interview is not able to detect all the disorders codified 
in the diagnostic manuals, but only those ones diagnosable by means of an interview. Direct questions about 
ASD and ADHD are not included, nonetheless it is possible to make their diagnoses due to specific sections 
in integrative instruments.     
PAS-ADD is a semi-structured interview designed to be used by physicians. It is available in two versions: the 
first for those cases which allow the direct interview of the PwID, the other dedicated to the interview of a 
proxy, a person who knows very well the patient. In both cases the diagnosis is formulated using the adaptation 
of SCAN informatized algorithms. The authors compared the scores obtained with the two versions of the 
instrument and found low convergence (41%). Thus, they suggested to always administer both the versions to 
improve the diagnostic sensitivity. The psychometric properties of PAS-ADD have been evaluated by Costello, 
Moss, Prosser e Hatton (Costello et al., 1997, Moss et al., 1997). The inter-rater reliability of the direct version 
has been measured by means of a session in which some clinicians autonomously completed several 
questionnaires basing on the view of registered interviews. The reliability was low for both the individual items 
and diagnostic groups (Cohen’s K = .65 e .66, respectively). A factorial analysis identified for each subscale a 
factor with a good reliability with the clinical diagnoses: the PAS-ADD diagnosis agreed with the pre-existing 
psychiatric diagnosis in the 76% of the probands. No information was given about internal consistency and 
test-retest reliability. The results of other researchers and the experience of several clinicians indicated that 
PAS-ADD would seem useful for the screening of mental health issues rather than to identify a specific PD. 
Comparing to the Mini e Checklist versions, the PAS-ADD would be preferred when the evaluation is 
addressed to an intellectually disabled person with good verbal skills, the aim of the evaluation is to draw a 
ICD-10 or DSM-IV-TR diagnosis for administrative purposes and/or there is the suspect for psychotic 
disorder, as this tool  is particularly sensitive in this domain. Around a decade ago, the PAS-ADD has been 
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adapted also to children and adolescents, the Child and Adolescent Psychiatric Assessment Schedule (ChA-
PAS) (Moss et al., 2013). 
The Psychopathology Checklists for Adults with Intellectual Disability (P-AID) (Hove and Havik, 2008) is a 
more recent interview. It is a set of tools to be used with informants, and is aimed to identify 10 PDs and 8 
PBs according to DC-LD (Psychiatrists, 2001). The P-AID sowed good internal consistency and inter-rater 
reliability, 8 orthogonal dimensions in the factorial analysis, whereas sensitivity and specificity are still to be 
evaluated (Hove and Havik, 2008). P-AID is convenient comparing to PAS-ADD because it includes a detailed 
evaluation of the main PBs; otherwise it is not directly usable with the person with ID or LF-ASD and this a 
disadvantage.   
Another semi-structured interview is the Schedule for the Assessment of Psychiatric Problems Associated with 
Autism (and Other Developmental Disorders) (SAPPA) (Bolton and Rutter, 1994). This interview too has been 
developed in United Kingdom and it includes items derived from the Research Diagnostic Criteria developed 
by Spitzer, Endicott e Robins (Spitzer et al., 1978). It has to be directly performed with the evaluated person 
or, in case of severe communication impairment, to a family member or other significant persons. Its main 
purpose is to help clinicians in identifying in ASD persons significant variations of behavioral features which 
may represent symptoms of one or more co-occurring PDs. Once detected, the symptoms are defined on the 
chronological and nosographic levels.  This instrument defines a behavioral change as relevant when it is 
clearly out of the range of usual behavioral variations of that specific person, it is associated to psychotic 
symptoms (delusions, hallucinations, catatonia, etc.) or it markedly impairs the functioning, as indicated by 
the appearance of alterations in at least one of the main life areas: interests, self-care, social involvement, drive, 
supervision, housing arrangement, and work (Bolton and Rutter, 1994). The clinical relevance of a behavioral 
change is further investigated according to whether or not it can be managed by oneself or a care-giver 
intervention is required. The duration of symptoms has to be defined accounting for the context in which they 
appeared and maintained, eventual extraordinary life events or circumstances, such as loss, bereavement, 
therapy changes, or health issues. Episodic PDs identified by SAPPA are mood, anxiety and psychotic 
disorders. The interview includes questions about the familial psychopathological history and related to PBs 
and other issues without episodic course. The tool has been used in some epidemiological studies (Bolton et 
al., 2011, Bradley and Bolton, 2006, Hutton et al., 2008, Raznahan et al., 2006), mainly with for research 
purposes and with ASD persons (without apparent co-occurring ID), often needing modifications to be fully 
applied. An attempt to adapt it to clinical use has been recently made (Battaglia et al., 2016), whereas a 
validation study and the evaluation of its psychometric properties have never been performed yet. 
The last standardized diagnostic interview to note is one specific for anxiety and mood disorders, the Mood 
and Anxiety Semi-Structured Interview (MASS) (Charlot et al., 2007a). It has been designed to be used with 
usual caregivers of persons with ID and LF-ASD and it is made of 35 items, corresponding to likewise DSM 
symptoms or behavioral equivalents. The time frame covered is the month preceding the evaluation.  The 
MASS showed good sensitivity and specificity, with high rates of concordance with clinical diagnoses and 
Hamilton Depression Rating Scale scores (HDRS) (Hamilton, 1967). 
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It has to be noted that none of the above-mentioned assessing tools have an Italian validated version. 
 
1.7.2 SCREENING TOOLS 
The first published psychopathological screening for PwID is the Psychopathology Instrument for Mentally 
Retarded Adults (PIMRA) (Matson et al., 2012, Matson et al., 1984, Senatore et al., 1985), which has been 
demonstrated to be efficacious in the research, planning and evaluation of intervention outcomes. The 
interview, available for self and hetero-administration, is composed by 8 subscales, each including 7 
dichotomous items (Yes/No). The item content is strictly related to the main symptoms of the major diagnostic 
categories (schizophrenia, depression, psychosexual disorders, adjustment disorders, anxiety, somatoform and 
personality disorders), as they were described in the DSM-III ((APA), 1980). A subscale evaluates the absence 
of psychopathological issues. The individual scoring is possible by means of a comparison with the reference 
sample in the form of percentage. The firs study by Matson and colleagues (Matson et al., 1984) confirmed 
high levels of internal consistency as well as acceptable test-retest reliability. However, other studies (Linaker, 
1991, Minner et al., 1994, Sturmey and Ley, 1990) indicated low inter-rater reliability. The psychometric 
properties of PIMRA were examined by its developers. The internal consistency was .85 e .83 respectively for 
the direct and the informant versions. The split-half reliability showed high scores (.88), even if lower for the 
proxy version (.65). The test-retest reliability of the patient version was acceptable for the total scale (.68), 
while was from low to acceptable for each of the 8 subscales (da .42 a .68). The test-retest reliability of the 
informant version was higher for the total scale (.91) comparing to the area-specific subscales (from .48 to 
1.00). The correlation between the scores of the subscales and the total scores was low for both the versions 
(from .01 a .30 for the subscales and .18 for the total scale). The validity of the instrument has been investigated 
basing on the concordance with the Affective Disorder (Depression) subscale of the informant version of the 
Beck Depression Inventory (BDI) (Beck and Steer, 1987) and the Zung Self-Rating Depression Scale (SDS) 
(Zung, 1965). The concordance was very high. The construct validity has been examined for the Schizophrenic 
Disorder subscale (Linaker and Helle, 1994, Swiezy et al., 1995), and the Psychosexual Disorder subscale 
(Matson and Russell, 1994), whereas a rigorous evaluation of the remaining 5 subscales is lacking. The 
factorial analysis of PIMRA (Balboni et al., 2000, Sturmey and Ley, 1990) produced poorly clear and reliable 
results. The authors identified four main factors and suggested that the 8 subscales are not referred to 
independent constructs. The inter-rater reliability is discordant across the studies (Linaker, 1991, Minner et al., 
1994, Sturmey and Ley, 1990). It seemed that PIMRA may produce false negatives among those persons with 
more severe ID because of the missing compilation of those items implying high language and abstractive 
thinking skills (La Malfa et al., 1997).  Reproducibility of the results among different evaluators have been 
attributed to different professionals or in absence of a specific training (Havercamp and Reiss, 1996).  
The second instrument, considered a sort of evolution of PIMRA, is the Diagnostic Assessment for the Severely 
Handicapped (DASH) (Matson et al., 1991), developed in 1991 and revised in 1995 (DASH-II) (Matson, 
1995). It is a questionnaire evaluating the presence of PDs in persons with severe and profound ID. It includes 
84 items organized in the following subscales base on the DSM-III-R diagnostic criteria ((APA), 1987): 
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Anxiety, Depression, Mania, Pervasive Developmental Disorder/Autism, Schizophrenia, Stereotypies/Tic, 
Self-injurious Behavior, Elimination Disorders, Eating Disorders, Sleep Disorders, Sexual Disorders, organic 
Syndromes, Problems with Impulse Control and Behavioral disturbances. DASH evaluates frequency, duration 
and severity of each symptom and is administered to an informant with a good knowledge of the PwID. The 
psychometric characteristics have been evaluated in some studies. Sevin, Matson, Williams e Kirkpatrick-
Sanchez (Sevin et al., 1995) found the validity and test-retest reliability to be .84 for frequency, .84 for duration 
and .91 for severity. The internal consistency was from poor to moderate for different subscales with 
Cronbach’s alfa ranging from 53 and .84 (Paclawskyj et al., 1997). The factorial analysis showed not univocal 
results. Matson, Coe, Gardner e Sovner (Matson et al., 1991) evidenced 6 factors: emotional lability, 
aggressiveness/conduct disorders, language disturbances, social withdrawal/stereotypies, eating and sleep 
disorders. Afterwards, Sturmey, Matson e Lott (Sturmey et al., 2004) identified a similar structure but only 5 
factors emerged: emotional lability, language disturbances, sleep disorder psychosis and anxiety. The 
concurring validity has been tested comparing DASH-II with the Aberrant Behavior Checklist (ABC) 
(Paclawskyj et al., 1997). The investigation showed that the subscales Mania, Organic Syndromes and Impulse 
Control and Behavioral Disturbances were highly related with the Irritability and Hyperactivity ABC 
subscales. The subscales Pervasive Developmental Disorder/Autism and Stereotypies/Tic were correlated with 
the ABC subscale for stereotypic behavior (Paclawskyj et al., 1997). Further evidence confirmed the validity 
of Mania and PDD/Autism subscales (Matson and Smiroldo, 1997, Matson et al., 1998) Similarly, the 
depression subscale of the DASH-II underwent a validation procedure by comparison with the DSM-IV 
diagnosis. By excluding too peculiar presentations, the DASH-II depression scale resulted to identify around 
the 93% of clinically depressed subjects (Matson et al., 1999). Moreover, the authors found that the depressive 
clinical picture in sever and profound ID would be predominantly characterized by symptoms non-verbal in 
nature pertaining to sleep and eating difficulties, psychomotor disturbances, and irritability frequently 
associated to abnormal behavior such as aggressiveness, stereotypies, noncompliance, unresponsiveness to the 
environment, and manic symptoms. 
One of the numerous studies from the group of Matson (Matson et al., 1997) also evidenced that in persons 
with severe and profound ID anxiety symptoms would be evaluable only via their behavioral correlates, with 
the subsequent risk of insufficient diagnostic sensitivity and need for the development of more refined tools. 
The data of the literature indicate that the DASH-II is the most used assessing instrument in clinical and 
epidemiological studies, including those addressing the psychiatric morbidity in persons with severe and 
profound ID at the opposite poles of the life, adolescence or young adulthood (Bradley et al., 2004) as well as 
among the elderly (Cherry et al., 1997). The general reliability has been confirmed over and over again. 
However, further research is needed to demonstrate the construct validity of all the subscales. DASH-II has 
been adapted in Italian by Guaraldi, Ruggerini, Neviani e Vicini in 2002. 
The Mini version of Psychiatric Assessment Schedule for Adults with Developmental Disabilities (Mini PAS-
ADD) (Prosser et al., 1998) and the Checklist (PAS-ADD Checklist) (Moss et al., 1998) are currently the main 
assessing instrument used in Europe in clinical studies involving PwID. Both the versions are based on the 
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PAS-ADD Interview. The Mini PAS-ADD was developed in 1998 by Prosser and colleagues with the aim to 
evaluate mental health issues in PwID with every severity level. It is a semi-structured interview administered 
to a caregiver. It can be used even by someone without clinical competencies after a brief training. Mini PAS-
ADD includes a questionnaire with 64 items corresponding to likewise symptoms. A severity score is attributed 
to each item and significant life events are listed in a dedicated checklist.  Clinical items are grouped in 7 
subscales related to the major Axis I PDs: Depression, Anxiety, Bipolar Disorder, Obsessive-Compulsive 
Disorder, Psychosis, Not Specified Disorder (including Dementia), Autism Spectrum Disorder. It is possible 
to calculate the single subscale score. The over-the-threshold scores indicate the possible co-occurrence of a 
disorder and suggest the need for a direct detailed clinical evaluation. The evaluation of the psychometric 
properties (Moss et al., 1998) evidenced a moderate internal consistency (Cronbach’s alfa ≥.8) for four 
subscales and lower for the others (Cronbach’s alfa ranging from .6 e .8). The inter-rater reliability, including 
psychiatrists and community operators, was low for the overall subscales (Spearman’s r ranging from .32 e 
.65). The construct validity was examined comparing the Mini PAS-ADD with subsequent psychiatric 
diagnoses. With regards to the presence or absence of a PD the concordance was of 91%, but the results of 
each subscale were not consistent. Afterwards, the Mini PAS-ADD has been indicated by other researchers as 
useful as a screening rather than a diagnostic instrument. Nonetheless, the Mini PAS-ADD has been used by 
several epidemiologic studies with great scientific value, pertaining both ID and ASD. The manual provides a 
clinical glossary which can be used to collect information about symptoms directly by the informant, a 
description of the formation pathway and coding exercises.  
Other significant tools that deserve a mention are the Developmental Behavior Checklist for Adults (DBC-A) 
(Einfeld and Tonge, 1995) aimed to measure a wide range of emotional and behavioral problems in adults with 
ID, the Assessment of Dual Diagnosis (ADD) (Matson and Bamburg, 1998) developed to detect the full range 
of PDs in adults with mild and moderate ID and the Reiss Screen for Maladaptive Behavior (RSMB) 
(Havercamp and Reiss, 1996), a general screening completed by care-givers. 
 
1.7.3 ASSESSING TOOLS DEVELOPED IN OUR COUNTRY 
The first Italian tool specifically addressed to PwID was the “Valutazione degli Aspetti Psicopatologici 
nell’Handicap” the eValuation of Psychopathological Aspects in Handicap (VAP-H) (Pilone et al., 2000), 
developed on the basis of the ICD-10 diagnostic criteria ((WHO), 1999). The items are presented in sparse 
order to reduce influencing phenomena by the completer. Several items belong to more than one category as 
they refer to symptoms possibly present to different syndromic pictures. A first validation of the tool has been 
conducted according to the empirical method by the comparison of VAP-H diagnoses and those traditionally 
formulated with ICD-10 in a large sample of PwID. A further control confirmed the precision and validity of 
the instrument. The purpose of VAP-H is to collect structured and objective information about behavioral and 
socio-emotional aspects, as well as to facilitate and orient the psychopathological diagnosis.  
Its use allows the identification of the main psychopathological traits, to note their frequency, and to obtain 
indications related to ICD-10. At most, VAP-H represents a semi-structured support to the clinical diagnostic 
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procedure and their results are not summarized in a score. It allows longitudinal comparisons useful to monitor 
the psychopathological course and the effectiveness of therapeutic interventions. Some limitations have been 
argued regarding the procedure used for the item’s construction. The items were derived by the conversion of 
symptoms described in ICD-10 which, although is one of the most famous and used international classification 
systems for mental health issues, it remains a valid model only in Europe. Another problem pertains the 
excessive length of the VAP-H, which may imply quality data variations or errors.   
In the last ten years the research group of Marco Bertelli in Florence worked on the development of a complex 
panel of assessing tools aimed to implement the diagnostic evaluation and subsequent follow-up of PDs in 
PwID and ASD, with a specific attention to those persons with marked communication and conceptualization 
difficulties, the Systematic Psychopathological Assessment for persons with Intellectual and Developmental 
Disabilities (SPAIDD). The SPAIDD system was designed in order to overcome some of the issues detected 
for other similar tools, such as inapplicability to all the levels of ID, lacking alignment to DSM (DSM-5 
specifically), the tendency to overlook some symptoms or main syndromes, the paucity of differential 
chronological criteria, long time required for the administration, and poor interdisciplinary availability. Some 
of these tools showed weaknesses in the commonest psychometric properties, such as test-retest reliability and 
inter-rater reliability (Bertelli, 2019).  
The SPAIDD panel include tools for each phase of the clinical intervention, such as the psychopathological 
screening, the specific categorical diagnosis, the dimensional diagnosis and the following symptomatic follow-
up. The items of every tool belong to a unique set of behavioral equivalents and psychopathological symptoms 
related to the major PDs. The tools are mostly base on observable behaviors and can be administered to persons 
who know very well the person with ID. This aspect allows to overcome the limitations related to severe 
cognitive and communication impairments. However, the manual provides for each equivalent full description 
encompassing examples from clinical practice related to a large span of abilities or reported phrases also 
regarding feelings and thought contents. In this perspective, the intellectually disabled person able to answer 
may participate to the own evaluation integrating information. Thus, all instruments can be indiscriminately 
used regardless the ID level and the presence of ASD, are aligned with DSM-5 ((APA), 2013)be, require brief 
or very brief time for the training, are usable from multiple professionals. The area-specific instruments also 
evaluate the chronological presentation of symptoms, supporting clinicians in drawing differential diagnosis 
and prognosis.  
The General version (SPAIDD-G) is the first SPAIDD instrument according to both its order of development 
and utilization. It is a screening tools and support professionals participating to clinical and rehabilitative 
activities in evaluating the presence and type of a psychopathological condition, rather to determine the level 
of symptomatic equivalence of one or more significant behavioral variations. SPAIDD-G evaluates the 
following syndromic groups, according to DSM-5: eating/feeding disorders, psychotic disorders, mood 
disorders – depression and mania separately, anxiety disorders, medications’ side effects, delirium, dementia, 
substance-related disorders, odd, dramatic and anxious personality disorders separately, impulse control 
disorders, autism spectrum disorder, identity dissociation disorders, somatic symptom disorders, sexual 
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disorders, obsessive-compulsive disorders. SPAIDD-G has been perfected along time up to the current version, 
SPAIDD-G 1.9 (Bertelli, 2019), updated to DSM-5. In this version further improvements toward a higher 
diagnostic specificity have been carried by the addition of criteria for relative syndromic weight, syndromic 
specificity, and clinical relevance of the scores. SPAIDD-G passed through various validation processes 
(Bertelli et al., 2012). The concordance was evaluated in subsamples with DASH-II and diagnoses formulated 
by expert clinicians according to DSM criteria and validation samples included PwID from mild to profound. 
The psychometric properties of the SPAIDD-G 1.9 (Bertelli, 2019) resulted overall good. The correlation 
analyses among syndromic groups were variable but consistent for the majority of psychopathological 
orientations (Spearman’s r ranging from .02 and .95), and the correlations between the total scores and each 
orientation showed similar results (Spearman’s r ranging from .30 and .97).  The internal coherence of overall 
scale resulted adequate (Kuder-Richardson’s coefficient - KR20 .84) whereas the internal coherences of each 
syndromic group are variable, ranging from .14 and .81. The Cohen’s k for inter-rater reliability was equal or 
superior of .76. The face and criterion validity were on the whole was good. The study of concurrent validity 
was limited by the paucity of comparable validated assessing instruments translated in Italian. Generally, the 
comparison with DASH-II showed SPAIDD-G to have similar or higher face validity, applicability and 
syndromic sensitivity. The time required for the administration was generally lower.   
 
1.7.4 ASSESSING INSTRUMENTS FOR THE EVALUATION OF MOOD DISORDERS 
Most area-specific instruments consist in adaptations of tools originally developed for the population with 
typical neurodevelopment. Such instruments have been extensively demonstrated useful when applied to 
persons with good cognitive and communication skills but their sensitivity and reliability are much lower in 
case of more severe impairment.  
Several instruments have been developed to detect MDs, probably because their marked importance in clinical 
practice with PwID. Among the main instruments are: Affective Rating Scale (Wieseler et al., 1988); Hamilton 
Depression Scale – Mental Handicap Version (HDSMH) (Sireling, 1986); Beck Depression Inventory (BDI) 
(Kazdin et al., 1983); Mental Retardation Depression Scale (Meins, 1993, Meins, 1996); Self-Report 
Depression Questionnaire (SRDQ) (Reynolds and Baker, 1988); Zung Depression Inventory – Mental 
Handicap Version (ZDI-MH) (Deb et al., 2001b, Helsel and Matson, 1988); Intellectual Disability Mood Scale 
(IDMS; Argus, Terry, Bramston e Dinsdale, 2004); Anxiety, Depression, and Mood Scale (ADAMS) 
(Esbensen et al., 2003); Mood, Interest & Pleasure Questionnaire (MIPQ) (Ross and Oliver, 2003); Glasgow 
Depression Scale for people with a Learning Disability (GDS-LD) (Cuthill et al., 2003). Noteworthy, none of 
them have an Italian translation. The Hamilton Depression Scale – Mental Handicap Version (HDS-MH), the 
Beck Depression Inventory (BDI) and the Zung Depression Inventory – Mental Handicap Version (ZDI-MH) 
are adaptations of the corresponding assessing instruments for the general population.  
The psychometric properties of the Self-Report Depression Questionnaire (SRDQ) have been tested by 
Esbensen, Seltzer, Greenberg e Benson (Esbensen et al., 2005), comparing the data of pre-existing studies. 
The validity and reliability resulted good, sometimes actually excellent.  
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The Intellectual Disability Mood Scale (IDMS) also showed good psychometric properties, although it has 
been tested almost exclusively in persons with mild ID. It is characterized by six dimensions: rage, confusion, 
depression, tiredness, tension and energy. These dimensions are evaluated through a 5-point Likert scale, 
presented to the evaluated persons as buckets filled with increasing levels of liquid. Thus, good abstractive and 
logical skills are required to complete it.  
The Anxiety, Depression, and Mood Scale (ADAMS) is usable with any ID level. It is constituted by 28 items 
to be scored on the basis of information obtained by someone who knows the person very well. Items are 
organized in 5 subscales: Manic/Hyperactive Behavior, Depressed Mood, Social Avoidance, General Anxiety, 
and Compulsive Behavior. The internal coherence of each subscale resulted satisfactory (Cronbach’s alpha 
ranging from .75 and .83), as well as test-retest reliability (correlational coefficients ranging from .72 to .83). 
The Mood, Interest & Pleasure Questionnaire (MIPQ) includes 25 items with a Likert-scale scoring, it is 
organized in two subscales for Mood and Interest and Pleasure; it can be used with persons with severe ID and 
LF-ASD. MIPQ has shown excellent internal coherence (.94) and good reliability. Both test-retest and inter-
rater, respectively .87 e .76. The concurrent validity has been demonstrated through the comparison with the 
Aberrant Behavior Checklist (ABC), mostly with the ABC subscales Lethargy and Social Withdrawal, 
interpreted as indices of good construct validity.  
A particularly promising tool is the Glasgow Depression Scale for people with a Learning Disability (GDS-
LD), whose peculiarity is the integration of information collected by both the PwID evaluated (mild to 
moderate ID) and caregivers and proxies. At this purpose the tool is divided in two parts comprehending 20 
and 16 items, respectively. The evaluation of the psychometric properties gave promising results.  
Noteworthy, none of the above cited assessing tools specifically developed for PwID refers to the categorical 
classification systems, ICD and DSM. There are many advantages in this approach, which is at most 
dimensional, mainly aimed to a clinical utility and, in the research perspective, addressing the issue of peculiar 
clinical presentations of MDs in ID. Moreover, few of them account for mania and its softer forms. Otherwise, 
the reference to a major classificatory system appears crucial in some ways. To correct frame patients 
according to commonly shared, univocal diagnostic categories has significant implications: improvement of 
the psychiatric diagnosis and administrative coherence with clinical needs, development and correct 
application of treatment guidelines with subsequent reduction of health care inequalities, expansion and 
improvement of research standards in this field. An optimal instrument should account for this aspect without 
losing the sensitivity and specificity toward the peculiarities of PDs in ID and LF-ASD.    
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CHAPTER 2 
 
MATERIALS AND METHODS 
2.1 Study design 
The present study has been designed as an observational, prospective, cross-sectional, multicentric, single arm 
study.  
The main objective of the study was the validation of the version for MDs (depressive and bipolar disorders) 
of the Systematic Psychopathological Assessment for persons with Intellectual and Developmental Disabilities 
(SPAIDD-M). A secondary aim was the identification of the prevalence and clinical features of MDs in 
subjects with ID and LF-ASD.  Primary outcomes were represented by measures of SPAIDD-M psychometric 
properties, including: content, face, construct and criterion validity, reliability, internal consistency (sensitivity 
and specificity), and test-retest reliability. Secondary outcomes consisted of prevalence rates of DDs and BDs 
in people with ID and LF-ASD as well as demographic, anamnestic, familial and clinical data associated with 
this comorbidity. Clinical data included course and other specificities of MDs in this population as well as 
response to psychopharmacological treatments. 
 
2.2 Participants, procedure and setting  
The study sample was composed of 233 adults, including 64 women and 169 men. Socio-demographic 
characteristics of the sample are shown in Table 2 (chapter 3). 
The study included individuals aged 16 years and older with a diagnosis of ID or LF-ASD according to the 
DSM-5 criteria ((APA), 2013). There were no exclusion criteria with the exception of the cut-off for age. The 
presence of co-occurring relevant genetic and medical issues was registered but was not considered a limitation 
for the participation to the study according to its naturalistic, non-interventional design. 
Study participants have been randomly or consecutively recruited among those attending the psychiatric 
services of the Research and Clinical Centre (CREA) of the San Sebastiano Foundation of the Misericordia di 
Firenze. The broad network of CREA throughout Italy was involved in the data collection. In fact, the present 
study is an appendix of a study protocol approved by the Ethical Committee of the University of Florence 
(number of the study protocol: CEAVC 14828), the “Autism and Psychopathology: Prevalence, Identification, 
and Symptoms Equivalence” study (APPrISE), made in collaboration with the Italian Society for 
Neurodevelopmental Disorders (SIDiN) and the Italian Foundation for Autism (FIA). APPrISE is aimed to 
evaluate the prevalence of psychiatric disorders in people with ASD and/or ID via the administration of 
SPAIDD-G and other psychopathological assessing instruments. At the time of the realization of the present 
study, the APPrISE network included around 60 participating centres across Italy. Clinicians and researchers 
recruited as evaluators are psychologists and psychiatrists: they received an initial training on the use of the 
assessing tools. The CREA team was available to give full and continuous support by mail and phone in case 
of doubts or difficulties. Some of the external evaluators (pertaining to 12 centres) of the APPrISE study 
accepted to include in the assessing sessions of some probands the administration of SPAIDD-M. They were 
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trained and supported also for this part of the study. This procedure may be considered a source of referral bias 
that will be discussed later. 
Thus, the inclusion of different centres provided the expansion of recruitment settings: outpatient services 
specifically addressed for ID and ASD persons, including psychiatric ambulatory for ID/ASD adults, 
residential facilities (from cluster centres to small apartments), rehabilitative services, and, at a lesser extent, 
families. The variety of recruitment settings was aimed to obtain data generalizable to the entire Italian ID/LF-
ASD population.  
The study has been conducted in agreement with the latest version of the Declaration of Helsinki, under the 
guiding principle of not violating participants’ ethical values and respecting the principles of autonomy, 
benefit, and privacy. The participation to the study did not influence the provision of ongoing treatments. All 
the candidates or their legal representatives signed an informed consent in which the observational, non-
interventional nature of the study was explained. The purposes of the study were directly elucidated to those 
participants able to express a consent, adapting the explanation to their cognitive skills, according to the 
principles expressed in the ONU convention on the rights for persons with disabilities regarding self-
determination and self-representativeness (Nations, 2016). According to the current legislation on Personal 
Data Protection, an informed consent that allowed the use of personal data had to be signed for each participant, 
and anonymity was guaranteed.  
The entire sample underwent to a complex anamnestic evaluation implying the collection of demographics, 
psychosocial, and clinical information via a semi-structured interview developed ad hoc for the present study. 
The interview included information regarding the physiological anamnesis with specific focus on early 
developmental events during pregnancy and in the first stages of life, also encompassing the achievement of 
developmental milestones. The personal and familial histories for medical and psychiatric issues were 
investigated. Information about previous psychopharmacological and non-pharmacological interventions was 
collected. The eventual psychiatric diagnoses formulated prior to the participation to the study were registered, 
in order to compare them with the diagnoses resulted from the overall assessing procedure of the study (the 
diagnosis obtained with SPAIDD-M and a final diagnosis integrating both clinical judgement and the outcomes 
of the standardized assessment).  
The probands had the possibility to participate to their own evaluation procedure and had the possibility to 
integrate proxy’s information, for example giving further explanations regarding feelings and thoughts. 
The assessments were conducted in a quiet, private room for the interview, which lasted approximately one to 
two hours for each participant. The assessment scheme was the following: (a) general interview for collecting 
demographic data; (b) clinical assessment; (c) administration of psychopathology assessment tools. 
The full study protocol was completed for 141 participants (the 68.4% of the sample), directly evaluated by 
the CREA team. The remaining 65 participants received variable combinations of the tools convenient to the 
external evaluators.  
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2.3 Assessment tools 
The study protocol included the following assessing instruments for the evaluation of mood disorders: 
- SPAIDD-M 1.2 
- DASH-II 
- DSM-5 criteria for Major Depressive Episode, Mania and Hypomania.  
 
SPAIDD-M 
The SPAIDD-M used for the final draft of this study was the 1.2 version. It is organized in three sections. 
Section A is constituted by 46 dichotomous questions regarding a variety of behaviors and symptoms (e.g. 
appetite, sleep, mood, etc.) possibly associated to MDs. Three different patterns and labels underline the mood 
polarity of symptoms and behaviors, in order to facilitate the evaluator in the formulation of questions. The 
last three items of the section refer to clinical specifiers (catatonic and psychotic symptoms). The instructions 
for the compilation of the instrument stress the fundamental concept that the SPAIDD-M explores the entire 
life-span, but behaviors and symptoms described in the questionnaire have to be present for circumscribed 
period/s in a significant different way from the baseline functioning of the proband. The evaluator is 
recommended to underline and repeat this concept and to help the informant/s in making differences with 
baseline. Noteworthy, 10 items (from 24 to 33) are considered overlapping between the depressive and manic 
polarities, according to the data from the literature.   
Section B is made of 10 items encompassing the chronological and course specifiers for the diagnosis and 
differentiation of DDs. A template for the registration of non-overlapping excitatory symptoms eventually 
present during depression is included for the diagnosis of MDE with mixed features. Given the difficulties in 
clearly detecting mixed features, the compilation of the mixed features template is considered optional. Section 
B explores the duration and qualitative criteria for MDE, persistent depressive disorder (PDD), premenstrual 
dysphoric disorder and substance/medication-induced depressive disorder or depressive disorder due to 
another medical condition (the two latter considered together). There are also questions regarding seasonal 
course pattern, psychotic and catatonic features of depression. The last question of the section investigates the 
severity of symptoms and related functional impairment comparing to baseline.  
Section C has a structure similar to section B and the 10 questions allow the chronological and severity 
differentiation among mania, hypomania and cyclothymic disorder. The specifiers encompassed are the 
seasonal pattern of the disease, psychotic and catatonic features, rapid cycling, relationship of symptoms with 
substances, medications or medical illnesses and mixed features. Similar to section B, an optional template for 
non-overlapping depressive symptoms presenting during (hypo)mania is provided.  
The score for each item is dichotomous (zero or one) according to the presence or absence of the 
symptom/behavior described. The 65 items are entered in a complex scoresheet specifically developed to adapt 
behavioral and symptoms equivalents to DSM-5 criteria for DDs and BDs. The scoresheet allows a definite 
categorical diagnosis among the following: MDD, PDD, premenstrual dysphoric disorder, 
substance/medication-induced depressive disorder or depressive disorder due to another medical condition 
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(organic depression), BD type I, BD type II, cyclothymic disorder, BD otherwise specified (short duration 
hypomania, hypomania with insufficient symptoms, hypomania without depression, short duration 
cyclothymia) and substance/medication-induced BDI or II or due to another medical condition (organic BDI 
and II). The scoresheet also provides a graphic representation of symptomatic dimensions based on the relative 
scores obtained for depression, (hypo)mania, mixed depression and mixed (hypo)mania. This is the first step 
toward the development of an instrument able to integrate both categorical and dimensional perspectives. 
Figure 1 represents two examples of the graphics produced along with the scoresheet. The graphics also give 
indications regarding the full meeting of the main clinical and course specifiers. The mean time for the 
administration of the SPAIDD-M was 30 minutes.  
 
Figure 1. Two examples of graphics produced with the SPAIDD-M 1.2 score sheet. 
 
 
 
DASH-II 
DASH-II is an 84-item screening instrument developed in 1991 and subsequently improved by using the DSM 
classification system and the authors’ past experience (Matson, 1995). It is mostly aimed to detect major 
psychiatric disorders in individuals with moderate-to-profound ID. The full description of the instrument and 
its psychometric properties have already been drawn in chapter 1.7. Each item describes a variety of symptoms 
and behaviors commonly found in individuals with lower cognitive abilities, including PBs. Their relevance 
is estimated by means of a combined score of their frequency, severity and duration. The symptoms are 
clustered to describe psychiatric syndromes and are considered clinically significant when individual clusters 
overcome a cut-off value.  
The validity of the subscales for depression and mania have been tested (Matson et al., 1999, Matson and 
Smiroldo, 1997) comparing to DSM criteria. The mean time for the administration was 20 to 30 minutes.  
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DSM-5 CRITERIA FOR MAJOR DEPRESSION AND (HYPO)MANIA 
The symptomatic criteria for the MDE, hypomanic and manic episode were evaluated by two clinical 
psychiatrists, expert in the psychiatric diagnosis in intellectually disabled and ASD persons. The use of DSM 
criteria by fully trained professionals in the field of ID would inevitably account for the suggestions and 
adaptations provided by Diagnostic Criteria for Learning Disability (DC-LD) (Psychiatrists, 2001) and 
Diagnostic Manual - Intellectual Disability (DM-ID-2) (Fletcher et al., 2016) developed by the American 
Psychiatric Association and the Royal College of Psychiatrists, respectively. This is important to be 
emphasized, as it is possible that the sensitivity of the clinical diagnosis could be different (probably higher) 
than in conventional psychiatric settings, but it could also have to be considered as a possible bias source. 
DSM-5 criteria have been chosen as the comparator for the validity of the SPAIDD-M diagnosis for the overall 
sample but mostly for persons with mild and moderate ID, since most literature suggested that DSM criteria 
are able to detect comorbid PDs in these subpopulations (Two separate validation procedure are provided). 
 
A special session for the evaluation of inter-rater reliability was performed. A clinical case was told to a group 
of different professionals usually working with ID and LF-ASD and including psychiatrists, psychologists, 
nurses and educators. They were asked to complete SPAIDD-M according to the information given. They were 
blind to the purpose of the assessing session and blind one to each other for the completion of SPAIDD-M. A 
CREA researcher compiled the respective scoresheets and a separate section of the database for the 
comparisons needed for inter-rater reliability testing.  
 
2.4. Development of SPAIDD-M 1.2 
At first, a systematic mapping of the literature regarding MDs in ID and LF-ASD was conducted in order to 
acquire complete information regarding the presentation and course peculiarities of depressive and bipolar 
illnesses in this population. The mapping also encompassed the evaluation of already existing assessing 
instruments for MDs and related studies to explore their strengths and weaknesses. The synthesis of this work 
can be found in chapters 1.6 and 1.7. 
A first version of SPAIDD-M was produced, SPAIDD-M 1.1. The main structure of the tool and items followed 
the conceptual and practical organization of the DM-ID 2 and DC-LD. The results of the literature research 
were used to expand items. A scoresheet and a database were developed. 
SPAIDD-M 1.1 version was a 35-item tool and included a list of mood symptoms and behavioral equivalents 
pertaining depression and (hypo)mania. It was simple and rapid to be used. The first 27 items regarded 
observable symptoms and behaviors, while the last 8 items allowed the diagnostic framing of MDD, Dysthymic 
Disorder, BD I and II, Cyclothymic Disorder according to chronological criteria and the specification of 
premenstrual symptoms and syndromic pictures related to substances, medications and general medical 
conditions.  
A pilot experimentation with 120 adults with ID recruited among those attending the residential and clinic-
rehabilitative facilities of the San Sebastiano Foundation in Florence was performed and the results were 
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presented in national and international conferences (Vannucchi et al., 2017b). All the participants underwent 
a complex anamnestic, cognitive and psychopathological evaluation, through the administration of structured 
and semi-structured assessing instruments (WAIS-III, ISTORIA, SPAIDD-G 1.8 version, SPAIDD-M 1.1; 26 
patients were also evaluated with DASH-II). SPAIDD-M 1.1 showed good psychometric properties. The 
internal consistency was high with a Chronbach’s alfa coefficient of 0,81. The Cohen’s k=0,76 demonstrated 
good inter-rater reliability. The concordance with the subscales for mood symptoms of the DASH-II was 98%. 
The overall prevalence of MDs was around 36%. MDD rate was near to 17%, BD type I and II had a 9.3% 
prevalence rates, respectively, cyclothymic disorder was 3.7%, dysthymic disorder 2.8% and premenstrual 
increase of the symptoms were identified in around the 2% of the sample. These rates resulted much higher 
than previously reported in the majority of studies. SPAIDD-M 1.1 was hypothesized to be much more 
sensitive in identifying atypical presentations and this result confirmed the experimental hypothesis that 
intellectual developmental disorder would be associated to higher vulnerability for the development of MDs. 
However, it is also possible that such high rates could be the result of low specificity of the tool. Moreover, 
other issues emerged:  
- A good face validity was limited to the symptomatic/behavioral items, whereas chronological and course 
specifiers’ items resulted complex and a possible source of bias. The full range of specifiers provided by DSM-
5 was not encompassed.  
- MDs diagnoses were based on overcoming the minimum cut-off number of symptoms for both depression 
and (hypo)mania established by DSM criteria. In the SPAIDD-M 1.1 the cut-off number was disrespectful to 
the actual correspondence of symptomatic and behavioral equivalents to DSM-5 criteria. In fact, it is possible 
that more than one behavior is related to one unique criterion. This limitation was a potential source of reduced 
specificity.  
- In the cluster system developed for DSM-IV-TR and then revised for DSM-5 by Michael First and colleagues 
(First, 2014, First et al., 2003) more symptoms and behaviors clustered with MDs, especially with depression. 
Some of these symptoms and behaviors had been ruled out by SPAIDD-M 1.1, in order to reduce the time 
required for the interview. These exclusions would be argued to affect the sensitivity, especially in those 
patients with lower communicative and cognitive skills and very limited behavioral repertoires.  
-    The differential diagnosis among different MDs was based on chronological items defining the illness 
course according to DSM conceptualization. This approach arose problems in the differential diagnosis 
between type I and II BD. Moreover, the BDs otherwise specified were not diagnosable, even if they represent 
a residual category often used in clinical practice and administrative registries. The lack of the residual category 
pertaining to the so-called soft bipolar spectrum seemed to potentially lead to underestimation of BDs in favour 
of DDs.   
- Some problems were found with the reliability of items related to reduced pleasure, feelings of guilt and 
racing thoughts, probably due to the difficulties to find reliable behavioral equivalents of those cognitive 
symptoms. 
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In order to improve the specificity and implement the content validity and reliability, SPAIDD-M 1.1 was 
revised. The revised version, SPAIDD-M 1.2, consisted in some face, conceptual and content changes. The 
face validity was revised twice as a first draft arose some perplexities and completion challenges by most 
external evaluators. The changes are summarized as follows: 
- The symptomatic/behavioral items’ section was implemented by the addition of items accounting for all the 
symptoms indicated in the fundamental clusters designed for DSM-IV-TR (First et al., 2003). Adaptations 
were provided according to the differences between DSM-IV-TR and DSM-5. In this process, the adaptation 
of the items continued integrating the suggestions of the literature regarding atypical manifestations and 
behavioral equivalents of MDs in PwID and LF-ASD. For example, irritable mood characterizing depression 
is usually considered a counterpolar symptom in persons with typical neurodevelopment as well as 
aggressiveness. The ID-related literature showed that these are commonly associated symptoms, sometimes 
prominent, in most cases of depression in PwID. Thus, we considered them as overlapping symptoms and 
possibly clustering with both depression and (hypo)mania. Moreover, the sentencing of some items was 
ameliorated in order to stress the underlying relationship with MDs. For example, the SPAIDD-G item 
generically related to sleep problems was decomposed in two items specifically addressing to insomnia and 
reduced need for sleep, respectively.    
- Each item was grouped with other items to univocally cluster with one DSM criterion according to its main 
psychopathological link with the criterion. This adaptation procedure may show some limitations, for example, 
in different patients, withdrawal may be linked to hypobulia, co-occurring anxiety or both, and the attribution 
of the behavior to a cluster or another could appear arbitrary. Therefore, we speculated that in presence of a 
full-blown mood syndrome, this limitation should have minor effects on the reliability of the diagnosis, while 
it could have some kind of impact in milder forms. Independently of the number of items clustering with one 
criterion, the positivity for the criterion was defined by the presence of at least one item of the group.  
- In order to differentiate hypomania and mania, a “severity item” that summarizes DSM-5 criterion C for 
mania was added.  The presence of psychotic symptoms during mania also indicated a BD type I diagnosis.  
- The sentencing of the chronological criteria for PDD, cyclothymic disorder and premenstrual dysphoric 
disorder was also refined along with a differential clustering of symptoms according to the adaptation of their 
specific DSM-5 criteria.  
- Further items encompassing important clinical and course specifiers were added or refined. SPAIDD-M 1.2 
included items for psychotic features, catatonic features, seasonal pattern, rapid cycles and mixed features. As 
described above, the mixed features specifier has been adapted by excluding those items/symptoms the 
literature demonstrated not to be counterpolar in persons with ID and LF-ASD.  
 
At the end of the experimentation of SPAIDD-M 1.2, some issues remain still open: 
- We were not able to find univocal and reliable equivalents for racing thoughts in mania, thus in this stage the 
related DSM criterion was ruled out with a possible impact on the underdiagnosis of BD type I and II. The 
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possibility of diagnosing BD otherwise specified, namely hypomania with insufficient symptoms, may help in 
reducing the underestimation of bipolar conditions.  
- The tool does not allow the differential diagnosis with schizophrenia spectrum disorders and some iatrogenic 
clinical pictures.  
- The attempt to produce behavioral equivalents of feelings of guilt, unworthiness and low self-esteem has 
been made but the reliability could be questionable.  
- The previous version of the SPAIDD-M was rapid and easy to be performed. This new version is longer, and 
this could affect the speed of administration and its applicability in clinical practice in general psychiatry 
settings.  Moreover, it requires a pre-existing knowledge of MDs, as well as the knowledge of DSM criteria. 
The lack of these prerequisites may potentially affect the correct administration of the instrument. This aspect 
becomes particularly challenging regarding the completion of the templates related to mixed features. Not only 
the identification of mixed states in this population is very difficult even for expert clinicians, but also, during 
the training and the following support phone sessions with external evaluators, some professionals struggled 
with the basic concepts. This is the reason why we decided to perform the analyses regarding mixed features 
only accounting for a part of the evaluations (175 participants), mainly those made by the psychiatrists of the 
CREA team. This problem obviously challenges the feasibility and the generalizability of this component of 
the evaluation.    
 
2.5 Statistical analyses 
The statistical analyses were carried out according to the following methods. 
For comparisons between groups, χ² test for categorical variables and ANOVA and F-variance test for 
continuous variables were used. For the analyses relative to the comparisons among three groups, the Scheffè 
test was considered.  The analyses involved many tests of statistical significance, raising the potential of type 
I and type II errors. Given the sample size and the number of comparisons, we reported as significant 
differences the results with p < .05. 
The evaluation of the psychometric properties of the tool involved different analyses. For the evaluation of 
internal consistency, we used a reliability test with the calculation of the Cronbach’ coefficient. The inter-
rater reliability was evaluated with a correlation analysis and the calculation of Cohen’s K coefficient. For the 
validity criterion, two ANOVA analyses were performed including the first the SPAIDD-M categorical 
diagnosis of MDE as the grouping factor, and the mean relative scores of the depressive items clustering the 9 
DSM-5 criteria for the MDE as well as total mean score for the MDE; the second included the categorical 
diagnosis of (hypo)mania made with the SPAIDD-M and the mean relative scores of equivalents clustering 
with DSM-5 criteria A and B, and the relative mean total score for the (hypo)manic episode. 
For the realization of the pattern matrix of the factorial analysis we used a principal component analysis, for 
the extraction, and oblimin with Kaiser normalization, for the rotation. 
Test-retest reliability was evaluated with Person’s and Spearman’s correlation analyses. 
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Two stepwise backward procedure logistic regression models were then used to identify the predictive value 
of the familial and psychiatric comorbidity features for the diagnosis of BD according to the SPAIDD-M and 
clinical diagnoses. Odds ratios with 95% confidence intervals were used for observed associations.  
SPSS 22.0 statistic pack for Windows has been utilized to create and update the database and for further 
statistical processing of data. 
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CHAPTER 3 
 
3. RESULTS 
3.1 Background features of the sample 
A total of 233 probands participated to the study, including 169 (72.5%) males and 64 females (27.5%) with a 
mean age of 41.00 years (SD 15.93). The distribution of ID levels was the following: 66 participants had mild 
ID or BIF (28.3%), 88 had moderate ID (37.8%), and 79 had severe or profound ID (33.9). 83 participants also 
had a diagnosis of ASD (35.6%). 
The socio-demographic features of the sample are summarized in Table 2. Comparisons of them according to 
3 ID levels were made.  
Table 2. Socio-demographic features and comparisons according to ID levels 
Demographic and socio-
economic features 
BIF/Mild 
ID 
N=66 
Moderate 
ID 
N=88 
Severe/Profound 
ID 
N=79 
χ² or F p 
Gender (M) N (%) 44 (66.7) 69 (78.4) 56 (70.9) 2.77 NS 
Age, Mean (sd) 38.09 
(15.18) 
41.47 
(15.55) 
42.92 (16.80) 1.73 NS 
BMI, Mean (sd) 23.05 
(6.73) 
23.66 
(12.86) 
22.36 (8.41) .27 NS 
Recruitment source N (%)  
Residential facilities 22 (33.3) 45 (51.1) 42 (53.2)  
 
7.22 
 
 
NS 
Rehabilitative centers  27 (40.9) 26 (29.5) 25 (31.6) 
Families 17 (25.8) 17 (19.3) 12 (15.2) 
  
Adopted N (%) 2 (3.5) 1 (1.6) 3 (4.7) .98 NS 
Invalidity pension N (%) 55 (98.2) 63 (98.4) 62 (96.9) .42 NS 
Employed N (%) 16 (28.1) 8 (3.1) 2 (3.1) 15.73 <.001 
Problems with justice N (%) 5 (8.8) 0 (0.0) 1 (1.7) 7.61 .022 
Provenance N (%)  
Urban, big city  16 (28.1) 22 (35.5) 13 (22.0)  
 
3.27 
 
 
NS 
Periphery, small city 36 (63.2) 33 (53.2) 38 (64.4) 
Rural 5 (8.8) 7 (11.3) 8 (13.6) 
Familial economic level N 
(%) 
 
Low income 10 (17.5) 4 (7.0) 14 (24.1)   
 95 
 
 
  No differences were detected regarding gender distribution, mean age and BMI. 
 Similarly, the three subgroups did not report significant differences in the other socio-demographic parameters 
explored except for occupational status and previous justice problems, resulting higher among BIF/Mild ID 
individuals. The achievement of higher educational levels was significantly different among the three 
subgroups with severe to profound ID individuals reporting shorter scholastic pathways despite no differences 
in educational supports. Differences in the distribution of the family economic status were evidenced.   
No differences emerged in the quality of familial relationships, whereas moderate to profound ID individuals 
showed significantly poorer social adjustment comparing to the other two subgroups.  
 
3.2 Medical, family and psychiatric history of the sample 
The comparisons regarding physiological and familial features according to ID levels are summarized in 
Table 3.  
The physiological parameters explored included age of the mother and father at birth, the anamnesis of 
pregnancy and delivery, early development including first physiological acts, psychomotor, autonomous 
locomotion and language development. The considered variables about pregnancy and delivery did not 
differentiate the three subgroups. The comparisons of physiological variables showed severe to profound ID 
to be associated to significantly higher rates of abnormalities in post-delivery physiological acts (42.4%) and 
delayed psychomotor, locomotion and language developments (76.3%, 76.9%, 92.3%, respectively). 
Medium income 36 (63.2) 47 (82.5) 31 (53.4)  
11.53 
 
.021 High income 11 (19.3) 6 (10.5) 13 (22.4) 
Educational Level N (%)  
None 1 (1.9) 4 (7.1) 11 (19.0)  
 
 
20.53 
 
 
 
.008 
Primary 7 (13.0) 7 (12.5) 12 (20.7) 
Secondary 22 (40.7) 25 (44.6) 9 (15.5) 
Tertiary 24 (44.4) 20 (35.7) 9 (15.5) 
Educational support 49 (87.5) 49 (86.0) 47 (85.5) .11 NS 
Quality of familial relationships N (%)  
Low 17 (30.9) 7 (12.1) 12 (21.4)  
 
6.11 
 
 
NS 
Medium 20 (36.4) 28 (48.3) 25 (44.6) 
High 18 (32.7) 23 (39.7) 19 (33.9) 
Friendships N (%)  
None 10 (17.5) 17 (28.8) 39 (65.0)  
 
34.71 
 
 
<.001 
Few 30 (52.6) 29 (49.2) 19 (31.7) 
Normal 17 (29.8) 13 (22.0) 2 (3.3) 
Romantic relationships N 
(%) 
8 (14.3) 9 (15.3) 1 (1.7) 7.38 .025 
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Table 3. Physiological and familial features of the sample and comparisons according to ID levels 
The comparisons regarding the familial load for medical illness, neuropsychiatric and psychiatric conditions 
did not evidence significant differences among the three ID subgroups considered. However, severe/profound 
ID individuals showed lower rates of familial psychiatric load (32.6% vs. 56.0% in BIF/mild ID and 45.8% in 
moderate ID, χ²=5.31), near to the statistical significance (p=.070). 
The main medical illnesses were compared among the three subgroups. These comparisons are shown in Table 
4. Specific genetic analyses had been performed in a relative minority of the patients, without significant 
Physiological features BIF/Mild ID 
N=66 
Moderate ID 
N=88 
Severe/Profound 
ID 
N=79 
χ² or F p 
Age of the mother at birth, Mean 
(sd) 
30.65 (7.30) 31.68 (5.15) 30.67 (6.24) .16 NS 
Age of the mother at birth, Mean 
(sd) 
35.41 (8.51) 31.63 (9.16) 34.20 (6.47) .99 NS 
Pregnancy N (%)  
Problematic course 9 (27.3) 5 (13.9) 7 (21.2) 1.90 NS 
At term 28 (84.8) 30 (83.3) 22 (66.7)  
 
4.56 
 
 
NS 
Preterm 3 (9.1) 5 (13.9) 8 (24.2) 
Post-term 2 (6.1) 1 (2.8) 3 (9.1) 
Delivery N (%)  
Eutocic 15 (46.9) 23 (63.9) 17 (51.5)  
 
 
10.45 
 
 
 
NS 
Dystocic 7 (21.9) 9 (25.0) 12 (36.4) 
Planned caesarean section 5 (15.6) 3 (8.3) 0 (0.0) 
Urgency caesarean section 5 (15.6) 1 (2.8) 4 (12.1) 
Physiological developmental variables N (%) 
First physiological acts (abnormal) 7 (21.9) 5 (13.9) 14 (42.4) 7.70 .021 
Breast feeding 21 (67.7) 25 (78.1) 21 (70.0) .94 NS 
Delayed psychomotor development  14 (40.0) 17 (45.9) 29 (76.3) 11.35 .003 
Delayed autonomous locomotion 17 (48.6) 16 (40.0) 30 (76.9) 11.80 .003 
Delay or absence of language 
development 
31 (88.6) 27 (69.2) 36 (92.3) 8.48 .014 
Familial history N (%) 
Familial history for 
neuropsychiatric disorders 
14 (29.2) 13 (30.2) 7 (16.3) 2.78 NS 
Familial ASD 3 (6.3) 2 (4.8) 2 (4.7) .15 NS 
Familial ID 11 (22.9) 6 (14.3) 6 (14.0) 1.66 NS 
Familial history for psychiatric 
disorders 
28 (56.0) 22 (45.8) 15 (32.6) 5.31 NS (.070) 
Familial history for medical illness 26 (61.9) 22 (51.2) 17 (48.6) 1.61 NS 
Familial autoimmune diseases 7 (15.9) 4 (9.3) 4 (11.4) .914 NS 
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differences among the three subgroups, and a specific genetic cause related to ID had been identified in 
proportions varying from 28.3% in BIF/mild ID participants to 17.6% of severe/profound ID.  
Table 4. Medical comorbidity features of the sample and comparisons according to ID levels 
 
The presence of epilepsy, gastrointestinal disturbances, diabetes, obesity, immunity disreactivity including 
allergies and autoimmune diseases, motor disability, cardiovascular diseases and sensory impairments was 
investigated. One or more medical illnesses were identified in the 72.3% of the overall sample, indicating a 
high medical burden in ID comparing to the general population and according to the mean age of the sample. 
The three subgroups did not show significant differences in the rates of general medical comorbidities, but 
differences were detected considering specific illnesses. The rates of epilepsy and motor disabilities showed 
increasing rates directly proportional to the severity of ID, with the highest rate of 36.2% and 37.7% in 
severe/profound ID individuals, respectively (χ²=15.81, p<.001 for epilepsy, χ²=9.46, p=.010). Gastrointestinal 
disturbances showed a similar trend not achieving statistical significance. Sensory impairments resulted more 
 
Medical health N (%) 
BIF/Mild ID 
N=66 
Moderate ID 
N=88 
Severe/Profound 
ID 
N=79 
χ² p 
Genetical analyses 18 (32.7) 24 (40.0) 18 (34.0) .77 NS 
Genetic syndrome ID-related 15 (28.3) 13 (21.7) 9 (17.6) 1.73 NS 
Specific genetic syndromes N (%) 
Down’s Syndrome 8 (15.1) 7 (12.1) 3 (6.0)  
 
 
 
 
 
 
 
22.34 
 
 
 
 
 
 
 
 
NS 
Rett’s Syndrome 0 (0.0) 0 (0.0) 1 (2.0) 
Prader-Willi Syndrome 1 (1.9) 0 (0.0) 1 (2.0) 
Williams’ Syndrome 1 (1.9) 0 (0.0) 0 (0.0) 
Cri du chat syndrome 0 (0.0) 0 (0.0) 2 (3.9) 
Klinefelter’s Syndrome 0 (0.0) 2 (3.4) 0 (0.0) 
Epileptic encephalopathy 0 (0.0) 1 (1.7) 0 (0.0) 
Neurometabolic disorder 0 (0.0) 0 (0.0) 1 (2.0) 
Other genetic conditions 5 (9.4) 3 (5.2) 1 (2.0) 
Medical illness N (%)  
General medical comorbities 38 (63.3) 53 (72.6) 55 (79.2) 10.45 NS 
Epilepsy 4 (6.7) 18 (25.4) 44 (36.2) 15.81 <.001 
Gastrointestinal disturbances  8 (13.3) 13 (18.8) 20 (29.0) 5.01 NS (.082) 
Diabetes 3 (5.0) 5 (4.4) 3 (4.3) .04 NS 
Obesity 11 (18.6) 16 (23.5) 7 (10.1) 4.38 NS 
Immunity dysreactivity 19 (39.6) 12 (21.4) 7 (14.0) 9.12 .010 
Motor disabilities 13 (21.7) 11 (15.7) 26 (37.7) 9.46 .009 
Cardiovascular diseases 6 (10.0) 7 (10.4) 8 (11.6) .09 NS 
Sensory impairments 2 (3.3) 3 (4.4) 10 (14.5) 7.20 .027 
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frequent in severe/profound ID, with 14.5% prevalence rate comparing to 3.3% and 4.4% in BIF/Mild ID and 
moderate ID subgroups (χ²=7.20, p=.027). By the contrary, immunity disreactivity showed a higher prevalence 
rate in BIF/mild ID (39.6%) comparing to decreasing rates in moderate and severe/profound ID (21.4% and 
14.0%, respectively; χ²=9.12, p=.010  
Table 5 summarizes the comparisons of psychiatric diagnoses and related variables according to ID levels. 
The comparisons have been performed considering the diagnoses made before the study (external diagnosis) 
and those resulted from the complex diagnostic study protocol (internal diagnosis). The first interesting result 
was that severe/profound ID individuals had significant lower rates of co-occurring psychiatric disorders 
according to the external diagnosis, based on as usual diagnostic process (χ²=22.18, p<.001). This difference 
was not confirmed by the study diagnostic protocol and internal clinical diagnosis (χ²=1.79, not significant), 
and severe/profound ID individuals showed rates similar to BIF/Mild ID and moderate ID subjects. The 
analysis of the degree of diagnostic concordance evidenced, as expected, the highest levels of concordance in 
BIF/mild ID subjects, whereas the rates of diagnostic divergence were similar in moderate and severe/profound 
ID probands (25.4% and 22.8%, respectively; χ²=11.85, p=.019). 
ASD showed similar rates across the three subgroups, ranging from 31.8% in BIF/mild ID and 39.2% in 
severe/profound ID individuals.  
The three subgroups did not show statistically significant differences in the prevalence of the majority of 
psychiatric disorders, specifically both depressive and bipolar disorders. Anxiety disorders showed the highest 
prevalence rates in BIF/mild ID according to both external and internal diagnosis, although the prevalence was 
doubled according to the latter diagnostic pathway (17.2% vs. 34.1%). Similarly, the prevalence of anxiety 
disorders resulted doubled in the moderate ID subgroup according to external and internal diagnosis (9.1% vs. 
22.6%), although the greatest effect of the diagnostic process affected the severe/profound ID group, with rates 
about 5-fold higher (from 1.3% to 7.1%). No differences emerged regarding the specific anxiety disorders. 
However, panic disorder showed higher rates in BIF/mild ID subjects compared to the two other subgroups, 
although not reaching the statistical significance (χ²=5.66, p=.059). 
Schizophrenia Spectrum Disorders (SSDs) showed higher rates in both BIF/mild ID and moderate ID 
compared to severe/profound ID according to the external diagnosis (χ²=9.81, p=.007). The internal diagnosis 
did not reveal this difference. Interestingly, most individuals in all the three subgroups were reframed from the 
so-called graft psychosis and behavioral abnormalities category to schizoaffective disorder. According to the 
internal diagnosis, the co-occurrence of another neurodevelopmental disorder showed an increasing prevalence 
gradient proportional to the increasing severity of ID, from 42.2% in BIF/mild ID, to 57.1% and 82.9% in 
moderate and severe/profound ID, respectively (χ²=13.53, p=.001). This significant gradient specifically 
regarded the prevalence rates of ASD (χ²=13.74, p=.001). 
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Table 5. Psychiatric comorbidity features of the sample, other related variables and treatments: 
comparisons according to ID levels 
 
Mental health N (%) 
BIF/Mild ID 
N=66 
Moderate ID 
N=88 
Severe/Profound ID 
N=79 
χ² or F p 
Psychiatric comorbidity  E 38 (60.3) 48 (62.3) 22 (28.2) 22.18 <.001 
Psychiatric comorbidity I 42 (64.6) 54 (69.2) 46 (59.0) 1.79 NS 
Diagnostic concordance external/internal diagnosis N (%) 
Complete divergence 4 (7.4) 16 (25.4) 13 (22.8)  
11.85 
 
.019 Partial concordance 15 (27.8) 21 (33.3) 10 (17.5) 
Psychiatric comorbidity N (%) 
ASD 21 (31.8) 31 (35.2) 31 (39.2) .87 NS 
Anxiety disorders E 11 (17.2) 7 (9.1) 1 (1.3) 11.25 .004 
I 15 (34.1) 12 (22.6) 2 (7.1) 7.0 .030 
Panic Disorder E 4 (6.3) 2 (2.6) 1 (1.3) 2.94 NS 
I 7 (15.9) 2 (3.8) 1 (3.6) 5.66 NS (.059) 
GAD E 4 (6.3) 5 (6.5) 0 (0.0) 5.20 NS (.074) 
I 7 (15.9) 6 (11.5) 0 (0.0) 4.72 NS 
OCD-related disorders E 8 (12.5) 6 (7.8) 3 (3.8) 3.68 NS 
I 7 (16.3) 5 (10.0) 3 (10.0) 1.03 NS 
Schizophrenia spectrum 
disorders 
E 10 (15.9) 9 (11.7) 1 (1.3) 9.81 .007 
I 3 (7.0) 8 (15.4) 1 (3.4) 3.58 NS 
Schizophrenia E 3 (4.7) 6 (7.8) 0 (0.0) 1.14 NS 
I 0 (0.0) 1 (1.9) 0 (0.0) 1.38 NS 
Schizoaffective disorder E 1 (1.6) 1 (1.3) 0 (0.0) 11.25 .004 
I 3 (7.0) 6 (11.5) 0 (0.0) 3.58 NS 
Graft psychosis and 
behavioral abnormalities 
E 9 (14.1) 4 (5.2) 2 (2.6) 7.79 .020 
I 0 (0.0) 0 (0.0) 0 (0.0)   
Eating disorders E 2 (3.1) 1 (1.3) 3 (3.8) .99 NS 
I 3 (7.0) 3 (6.1) 3 (10.7) 5.31 NS (.070) 
Anorexia E 2 (3.1) 0 (0.0) 0 (0.0) 4.89 NS 
I 2 (4.7) 0 (0.0) 0 (0.0) 3.64 NS 
Bulimia E 1 (1.6) 0 (0.0) 0 (0.0) 2.42 NS 
I 1 (2.3) 0 (0.0) 0 (0.0) 1.81 NS 
BED E 1 (1.6) 0 (0.0) 2 (2.6) 1.91 NS 
I 2 (4.7) 3 (6.1) 2 (7.1) .20 NS 
Depressive Disorders E 3 (4.7) 3 (3.9) 2 (2.6) .47 NS 
I 10 (15.4) 12 (15.6) 14 (18.4) .31 NS 
MDD E 3 (4.7) 3 (3.9) 0 (0.0) 3.50 NS 
I 8 (12.1) 10 (11.4) 12 (15.2) .59 NS 
PDD E 0 (0.0) 0 (0.0) 1 (1.3) 1.82 NS 
I 0 (0.0) 3 (3.9) 2 (2.6) 2.45 NS 
Bipolar Disorders E 9 (14.3) 9 (11.7) 7 (9.0) .97 NS 
I 16 (25.0) 26 (33.8) 19 (25.0) 1.89 NS 
BD I E 6 (9.4) 3 (3.9) 5 (6.5) 1.75 NS 
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I 12 (18.5) 11 (14.3) 11 (14.5) .58 NS 
BD II E 1 (1.6) 0 (0.0) 1 (1.3) 1.11 NS 
I 2 (3.1) 7 (9.1) 2 (2.6) 4.08 NS 
Cyclothymic Disorder E 0 (0.0) 0 (0.0) 0 (0.0)   
I 1 (1.5) 1(1.3) 0 (0.0) 1.10 NS 
BD otherwise specified E 2 (3.2) 5 (6.5) 1 (1.3) 3.04 NS 
I 1 (1.5) 6 (7.8) 5 (6.6) 2.91 NS 
Other ND E 22 (33.8) 28 (36.4) 26 (33.3) .18 NS 
I 19 (42.2) 32 (57.1) 29 (82.9) 13.53 .001 
ASD E 19 (29.2) 26 (33.8) 25 (32.1) .34 NS 
I 15 (33.3) 32 (57.1) 26 (74.3) 13.74 .001 
ADHD E 4 (6.3) 4 (5.2) 2 (2.6) 1.20 NS 
I 7 (16.3) 8 (14.8) 6 (19.4) .30 NS 
Impulse Control 
Disorders 
E 4 (6.3) 8 (10.4) 6 (7.7) .84 NS 
I 4 (9.3) 10 (20.0) 8 (27.6) 4.14 NS 
ODD E 2 (3.1) 4 (5.2) 3 (3.8) .40 NS 
I 4 (9.3) 6 (12.2) 6 (20.7) 2.03 NS 
Addiction-related 
Disorders 
E 3 (4.7) 1 (1.3) 0 (0.0) 4.49 NS 
I 4 (9.3) 1 (2.0) 0 (0.0) 4.61 NS 
Personality Disorders E 7 (10.9) 6 (7.8) 1 (1.3) 5.87 NS (.053) 
I 14 (32.6) 10 (19.6) 7 (25.0) 2.07 NS 
PDs Cluster A E 3 (4.7) 2 (2.6) 0 (0.0) 3.52 NS 
I 4 (9.3) 3 (6.0) 2 (7.1) .37 NS 
PDs Cluster B E 4 (6.3) 1 (1.3) 1 (1.3) 4.18 NS 
I 6 (14.0) 3 (6.0) 2 (7.1) 1.94 NS 
PDs Cluster C E 2 (3.1) 3 (3.9) 0 (0.0) 2.92 NS 
I 8 (18.6) 8 (16.3) 5 (17.9) .09 NS 
Treatments and related variables N (%) 
Psychiatric hospitalizations 12 (20.7) 10 (15.4) 3 (4.8) 6.74 .034 
Number of hospitalizations, Mean 
(SD) 
.52 (1.55) .57 (1.75) .19 (1.02) 1.19 NS 
Suicide attempts 7 (11.9) 1 (1.5) 0 (0.0) 12.61 .002 
Non-pharmacological 
treatments  
48 (81.4) 55 (79.7) 48 (76.2) .52 NS 
Psychotherapy 30 (50.8) 18 (26.1) 2 (3.2) 35.83 <.001 
Structured education 40 (67.8) 51 (73.9) 38 (60.3) 2.78 NS 
Behavioral therapy 12 (20.3) 29 (29.0) 22 (35.5) 3.43 NS 
Electroconvulsive Therapy 0 (0.0) 0 (0.0) 0 (0.0)   
Other treatments* 23 (39.7) 22 (31.9) 23 (36.5) .85 NS 
Psychopharmacological 
treatments 
34 (56.7) 52 (75.4) 50 (78.1) 8.09 .018 
Antidepressants (all) 18 (30.0) 18 (26.1) 14 (21,9) 1.07 NS 
SSRI 11 (18.3) 15 (21.7) 7 (10.9) 2.83 NS 
TCA 7 (11.7) 0 (0.0) 2 (3.1) 10.34 .006 
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*Other non-psychopharmacological treatments also include psychomotor and logopedic interventions, ergotherapy and similar 
treatments E: external diagnosis according to the diagnoses registered in the archives, medical or administrative records or reported 
by proxies. I: internal diagnosis combining the structured assessment and clinical judgment. ASD: Autism Spectrum Disorder; GAD: 
Generalized Anxiety Disorder; BED: Binge Eating Disorder; MDD: Major Depressive Disorder; PDD: Persistent Depressive 
Disorder; BD I: Bipolar Disorder type I; BD II: Bipolar Disorder type II; ND: Neurodevelopmental Disorders; ADHD: Attention-
Deficit/Hyperactivity Disorder; ODD: Oppositional-Defiant Disorder; PDs: Personality Disorders. 
SSRIs: Selective Serotonin Reuptake inhibitors; TCA: Tricyclic Antidepressants; FGA: First Generation Antipsychotics; SGA: 
Second Generation Antipsychotics; BDZ: Benzodiazepines; AD: antidepressants; AP: Antipsychotics; EPS: extrapyramidal effects 
 
  
The presence and mean number of psychiatric hospitalizations as well as a history of suicide attempts can be 
usually considered indirect indices of illness severity. In intellectually disabled persons, especially those with 
higher cognitive impairments, this consideration could not be fully appropriate. BIF/mild ID and moderate ID 
subjects had more frequently psychiatric hospitalizations than severe/profound ID (χ²=6.74, p=.034), although 
the mean number of hospitalizations did not differ across the three subgroups. 7 BIF/mild ID participants had 
committed a suicide attempt (11.9%), comparing to 1 with moderate ID (1.5%) and none with sever/profound 
ID.  
No significant differences emerged across the ID levels regarding non-pharmacological treatments with the 
exception of BIF/mild ID that were more frequently receiving, as expected on the basis of higher cognitive 
skills, psychotherapeutic support than the other subgroups (χ²=35.83, p<.001).  
All the three subgroups reported very large use of psychotropic medications, showing increasing rates from 
higher to lower ID levels (56.7% vs. 75.4% vs. 78.1%, in the three subgroups respectively; χ²=8.09, p=.018).  
No significant differences were detected regarding specific pharmacologic classes with the exception of 
Other antidepressants 6 (10.0) 6 (8.7) 6 (9.4) .07 NS 
Anticonvulsants 22 (36.7) 36 (52.2) 37 (57.8) 5.91 NS (.052) 
Lithium 6 (10.0) 5 (7.2) 0 (0.0) 6.24 .044 
Antipsychotics (all) 25 (41.7) 41 (59.4) 31 (33.2) 4.17 NS 
FGA 14 (23.3) 15 (21.7) 13 (33.2) .17 NS 
SGA 22 (36.7) 39 (56.5) 27 (42.2) 5.55 NS (.062) 
BDZ 17 (28.3) 26 (37.7) 26 (40.6) 2.21 NS 
Stimulants 2 (3.3) 1 (1.4) 0 (0.0) 2.26 NS 
Adverse psychiatric effects to 
antidepressants 
7 (38.9) 7 (41.2) 5 (35.7) .10 NS 
Irritability AD 5 (27.8) 5 (29.4) 3 (21.4) .27 NS 
(Hypo)manic switch AD 3 (16.7) 2 (11.8) 1 (7.1) .67 NS 
Mood instability AD 4 (22.2) 3 (17.6) 0 (0.0) 3.42 NS 
Resistance to AD 1 (5.6) 0 (0.0) 0 (0.0) 1.76 NS 
Adverse effects to 
antipsychotics 
15 (65.2) 22 (55.0) 16 (51.6) 1.05 NS 
Flattening/depressed mood AP 9 (40.9) 9 (22.5) 5 (16.1) 4.43 NS 
Akathisia AP 6 (27.3) 3 (7.5) 2 (6.5) 6.61 .037 
EPS AP 10 (45.5)  9 (22.5) 8 (25.8) 3.87 NS 
Metabolic effects and increased 
weight  
8 (34.8) 16 (40.0) 8 (25.8) 1.57 NS 
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anticonvulsants, employed less frequently in BIF/mild ID subjects, in contrary to lithium, showing higher rates 
in this subgroup compared to the other two. Second generation antipsychotics showed a prescription rate of 
56.5% in moderate ID subgroups, higher than the 42,2% of severe/profound ID and the 36.7% of BIF/mild ID 
participants. Noteworthy, the χ² statistics were only about the significance for anticonvulsants and 
antipsychotics.  
Among those ID patients reporting past or present assumption of antidepressants, the 38.8% (N=19) had 
suffered for their psychiatric adverse effects, namely antidepressant-induced irritability and activation (N=13, 
26.5%), (hypo)manic switches (N=6, 12.2%) and increased mood instability (N=7, 14.3%). Resistance to 
antidepressants was reported only for one patient (2.0%). The comparisons among the three ID subgroups did 
not show significant differences.  
53 of the 94 ID patients treated with antipsychotics (56.4%) reported adverse effects: affective flattening and 
antipsychotic-related depressed mood (N=23, 24.7%), akathisia (N=11, 11.8%), EPS (N=27, 29.0%) and 
weight gain or metabolic side effects (N=32, 34.0%). Only the rates of akathisia resulted significantly different 
across the three ID subgroups, being higher in BIF/mild ID (χ²=6.61, p=.037), but it is possible that in this 
group akathisia was more easily detectable.  
 
3.3 Psychometric properties of SPAIDD-M 1.2 
3.3.1 Internal Consistency 
The internal consistency of SPAIDD-M was evaluated via a reliability analysis including all the main 65 items 
of the tool. The Cronbach’ was .937. The analyses relative to each item evidenced very homogeneous values, 
ranging from .934 and .938. The Cronbach’ calculated for the 33 items related to mixed symptoms was lower, 
but acceptable (Cronbach’=.876). 
 
3.3.2 Inter-rater reliability 
As explained in the method section, the inter-rater reliability was tested via one special session in which 
different professionals (psychiatrists, psychologists and professional educators) independently completed the 
SPAIDD-M of a single clinical case. The comparison among the individual items and categorical diagnoses 
according to the SPAIDD-M score sheet expressed by different evaluators indicated an acceptable inter-rater 
reliability. This can be considered an indirect sign of homogeneity in the attribution of absence ì/presence to 
the items. The inter-rater reliability of SPAIDD-M as expressed by a Cohen’s K coefficient that resulted to 
range from .870 and .575, with a mean of .713  
 
3.3.3 Face validity 
The last version of the SPAIDD-M, more than the previous, was judged by most of the involved evaluators as 
sufficiently clear and easy to use. This judgment appears to be particularly related to the intelligibility of 
individual items of all the three section. The explanatory instruction document in attachment to the test, 
stressing the fundamental rules to the correct completion of the tool, has added further clarity. However, some 
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external evaluators found high difficulties for the completion of the mixed symptoms specifiers and 
symptomatic items, therefore we decided to consider for the related statistical analyses only those 
questionnaires directly verified by the CREA team or performed by expert psychiatrists. Indeed, some issues 
seemed to arise from actual difficulties in detecting specific counterpolar symptoms and behavioral equivalents 
in complex clinical pictures; however, it has been noted that some evaluators without a basic knowledge of 
mood disorders had some problems in understanding what they were asked to detect.  
It has to be considered that this is the first study attempting to the conceptualization and operationalization of 
mixed features in ID and LF-ASD individuals.    
 
3.3.4 Criterion validity 
The criterion validity of the items related to depression have been evaluated by means of the ANOVA analysis 
including the SPAIDD-M categorical diagnosis of MDE as the grouping factor, and the mean relative scores 
of the depressive items clustering the 9 DSM-5 criteria for the MDE as well as total mean score for the MDE. 
As shown in Table 6, all the relative scores for each criterion and the total score resulted higher in the SPAIDD-
M MDE diagnosed group. 
 
Table 6. ANOVA analysis of the variance for the criterion validity of MDE in SPAIDD-M 
MDE: patients resulted positive with a Major Depressive Episode according to the SPAIDD-M definition 
No: patients without the positivity for MDE 
 
 
DSM-5 MDE criteria:  
SPAIDD-M mean scores 
 
Mean (SD) 
 
F 
 
p 
Criterion 1 
Depressed mood  
No .14 (.17)  
155.96 
 
<.001 MDE .47 (.21) 
Criterion 2 
Diminished interest/pleasure 
No .12 (.14)  
153.17 
 
<.001 MDE .44 (.22) 
Criterion 3 
Weight/appetite alterations 
No .03 (.12)  
61.05 
 
<.001 MDE .28 (.29) 
Criterion 4 
Sleep disturbances 
No .06 (.18)  
83.94 
 
<.001 MDE .42 (.35) 
Criterion 5 
Psychomotor alterations 
No .21 (.23)  
105.02 
 
<.001 MDE .53 (.23) 
Criterion 6  
Fatigue/loos of energy 
No .05 (.21)  
121.00 
 
<.001 MDE .64 (.48) 
Criterion 7 
Worthlessness/guilt 
No .19 (.32)  
70.63 
 
<.001 MDE .57 (.35) 
Criterion 8 
Difficulty concentrating/doubt 
No .11 (.17)  
67.08 
 
<.001 MDE .39 (.29) 
Criterion 9 
Suicidality 
No .05 (.16)  
46.71 
 
<.001 MDE .30 (.32) 
Total mean score for MDE criteria No .12 (.08)  
353.144 
 
<.001 MDE .44 (.15) 
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The validity criterion for (hypo)mania was evaluated via the ANOVA analysis considering the categorical 
diagnosis of (hypo)mania made with the SPAIDD-M and the mean relative scores of equivalents clustering 
with DSM-5 criteria A and B, and the relative mean total score for the (hypo)manic episode. Similar to MDE, 
the relative scores for the (hypo)manic episode criteria and the mean total relative score for all the (hypo)manic 
equivalents resulted higher in the group of participants diagnosed with a (hypo)manic episode by SPAIDD-M. 
Details can be found in Table 7.  
 
 
 
Table 7. ANOVA analysis of the variance for the criterion validity of the (hypo)manic episode in 
SPAIDD-M 
Man: patients resulted positive with a (hypo)manic episode according to the SPAIDD-M definition 
No: patients without the positivity for a (hypo)manic episode 
 
 
 
 
For the factorial analysis of the full instrument, a discrimination analysis of four centroid groups’ functions 
was carried out and equal eigenvalues were calculated. These resulted to be as follows: 10.071, 2.654, 2.328 
and 2.066, corresponding respectively to the following explained variance percentages: 21.9, 5.8, 5.1 and 4.5. 
The four discriminating functions represent a considerable percentage of items variance, equal to 37.21. 
Sample adequacy, calculated through Kaiser-Meyer-Olkin Measure, resulted to of .84, with a statistical 
significance of < 0.0001 (Bartlett’s Test). The Wilks test showed the four discriminating functions to be 
statistically significant (p < 0.001) and to explain differences among items very well. Evaluations were 
therefore judged as collectable following four main standard discriminating functions, which seem to 
correspond to manic symptoms, depressive symptoms, non-mood related depressive symptoms, and last factor 
inversely correlated to anxiety (see Table 8). 
DSM-5 (hypo)manic episode criteria:  
SPAIDD-M mean scores 
 
Mean (SD) 
 
F 
 
p 
Criterion A 
 
No .31 (.27)  
202.43 
 
<.001 Man .86 (.16) 
Criterion B No .21 (.17)  
185.48 
 
<.001 Man .54 (.14) 
(Hypo)manic episode SPAIDD-M relative 
score 
No .24 (.18)  
244.74 
 
<.001 Man .64 (.12) 
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Table 8. Factor analysis pattern matrix on 
SPAIDD-M items 
Factor 1 
Manic 
Factor 2 
Depressive 
Factor 3 
Non-mood D 
Factor 4 
Vs-Anxiety 
SPAIDD-M Item 1: Depressed Mood ,045 ,433 ,295 -,230 
SPAIDD-M Item 2: Anhedonia ,159 ,322 ,342 -,382 
SPAIDD-M Item 3: Weight gain ,166 -,116 ,407 -,139 
SPAIDD-M Item 4: Insomnia ,448 ,107 ,153 -,081 
SPAIDD-M Item 5: Hypersomnia ,133 ,123 ,377 ,033 
SPAIDD-M Item 6: Psychomotor retardation  ,052 ,067 ,468 -,062 
SPAIDD-M Item 7: Loss of energy/fatigue ,279 ,282 ,404 -,209 
SPAIDD-M Item 8: Guilt ,263 -,199 ,227 -,345 
SPAIDD-M Item 9: Reduced participation ,312 ,322 ,285 -,214 
SPAIDD-M Item 10: Self-injury ,282 ,285 -,263 -,119 
SPAIDD-M Item 11: Tendency to cry ,314 -,102 -,154 -,281 
SPAIDD-M Item 12: Appetite alterations ,045 -,092 ,448 -,258 
SPAIDD-M Item 13: Somatization ,034 -,263 ,182 -,501 
SPAIDD-M Item 14: Indecision ,061 ,483 ,185 -,224 
SPAIDD-M Item 15: Avoidance -,049 ,083 ,084 -,512 
SPAIDD-M Item 16: Impaired abstractive thinking* -,089 ,020 ,710 ,122 
SPAIDD-M Item 17: Impaired memory* -,039 ,075 ,632 ,319 
SPAIDD-M Item 18: Affective flattening ,044 ,291 ,427 ,000 
SPAIDD-M Item 19: Retire at home -,018 ,198 ,221 -,562 
SPAIDD-M Item 20: Pica ,022 ,243 -,140 ,045 
SPAIDD-M Item 21: Anxiety ,204 ,157 -,137 -,502 
SPAIDD-M Item 22: Reduced social interaction -,028 ,771 ,030 -,008 
SPAIDD-M Item 23: Apathy ,081 ,730 ,064 ,149 
SPAIDD-M Item 24: Irritability ,596 ,173 -,060 -,249 
SPAIDD-M Item 25: Weight loss -,080 ,031 ,307 -,220 
SPAIDD-M Item 26: Psychomotor 
agitation/restlessness 
,553 ,199 -,039 -,243 
SPAIDD-M Item 27: Suicidality ,076 ,283 ,174 -,084 
SPAIDD-M Item 28: Aggressiveness  ,601 ,155 -,076 -,198 
SPAIDD-M Item 29: Affective lability ,512 -,013 ,022 -,226 
SPAIDD-M Item 30: Impaired judgment ,452 ,103 ,208 ,065 
SPAIDD-M Item 31: Substance abuse ,307 -,232 ,190 -,169 
SPAIDD-M Item 32: Distractibility ,463 ,099 ,284 ,254 
SPAIDD-M Item 33: Sexual activity alterations ,622 -,055 -,008 ,095 
SPAIDD-M Item 34: Euphoria ,640 ,004 -,046 ,166 
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SPAIDD-M Item 35: Purpose hyperactivity ,653 ,001 ,157 -,002 
SPAIDD-M Item 36: Grandiosity ,337 -,251 ,391 ,072 
SPAIDD-M Item 37: Pressured communication ,677 ,024 ,026 -,037 
SPAIDD-M Item 38: Purposeless hyperactivity ,512 ,366 ,137 ,259 
SPAIDD-M Item 39: Reduced need for sleep ,585 ,079 ,020 ,135 
SPAIDD-M Item 40: Defiant/antisocial behavior ,507 ,243 -,007 -,244 
SPAIDD-M Item 41: Disorganization ,180 ,464 ,397 ,065 
SPAIDD-M Item 42: Manipulation/exploitation ,508 -,132 -,026 -,174 
SPAIDD-M Item 43: Undiscriminating socialization ,467 -,274 ,083 ,394 
SPAIDD-M Item 44: Catatonia -,020 ,386 ,045 -,060 
SPAIDD-M Item 45: Hallucinations ,073 ,070 ,411 -,177 
SPAIDD-M Item 46: Delusion ,151 -,117 ,507 -,207 
 
3.3.5 Test-retest reliability 
The stability and precision of the SPAIDD-M construct across time has been tested via the replication of five 
SPAIDD-M questionnaires, one per each ID level, after two-to-three months from the first completion. For all 
the five proofs, we found very good test-retest reliability as the Pearson’s r and Kendall’s -b value ranged 
from .77 to .96 with a p<.001.  
 
3.3.6 Concurring validity 
The concurring validity was tested comparing at first the SPAIDD-M diagnoses for MDD, BD I, BD II and 
BD otherwise specified with the respective DSM-5 diagnoses, as shown in Table 9. The concurrent validity 
was high for MDD, BD I and BD II diagnoses as demonstrated by both Pearson’s r and Spearman’s  
coefficients >0.7, with p=<.001. The correlation resulted only moderate for BD otherwise specified. 
 
Table 9. Correlations of the SPAIDD-M and DSM-5 diagnoses 
Diagnosis Coefficient* Correlation value  p 
MDD r and  .636 <.001 
BD I r and  .929 <.001 
BD II r and  .791 <.001 
BD otherwise 
specified 
r and  .368 <.001 
* Pearson’s r and Spearman’s  
 
A further correlation test was performed between the DASH-II subscales for depression and mania and the 
diagnoses of MDE and (hypo)manic episode. In this analysis, the correlation between the diagnosis of MDE 
and the DASH-II depression subscale was moderate (Pearson’s r=.310 and Spearman’s =.474 p <.001), The 
correlation for the (hypo)manic episode and the DASH-II mania subscale was instead low  according to the 
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Pearson correlation test (Pearson’s r=.283, p<.001) and moderate using Spearman’s test (Spearman’s =.480, 
p<.001).  
 
3.4 Mood Disorders in intellectually disabled persons: associated socio-demographic, familial, medical 
and psychiatric comorbidity features 
In our sample ID individuals with a clinical diagnosis of MD resulted younger than no-MD probands, even if 
the statistical significance was not reached (p=.074). No differences emerged between the MD and no-MD 
subjects regarding gender distribution and mean BMI. The χ² statistics relative to the recruitment source 
evidenced the homogeneity of the sample, as no significant differences were detected. However, it has to be 
noted that individuals with MD had been slightly more recruited from families, especially in ambulatory 
services, where the evaluation of psychiatric issues and behavioral disturbances is routinely executed (see 
Table 10). 
Table 10. Significant demographic, familial, medical and psychiatric features: comparisons according 
to the clinical diagnosis of Mood Disorders 
Features 
N (%) 
No-MD 
N=121 
MD 
N=96 
χ² or F P OR [95% CI] 
Demographic features 
Gender (M) 33 (15.2) 30 (31.3) .41 NS 1.21 [.67-2.18] 
Age, Mean (SD 41.96 
(16.94) 
39.76 (15.25) 13.22 NS (.074) 5.63 [1.86-16.99] 
BMI, Mean (SD) 21.02 (8.16) 25.39 (11.35) .02 NS 2.97 [.91-9.72] 
Recruitment source 
Residential facilities 54 (44.6) 45 (46.9)  
 
3.76 
. 
 
NS 
 
Rehabilitative centers  47 (38.8) 27 (28.1) 
Families 20 (16.5) 24 (25.0) 
Familial comorbidity 
Familial NDs* 14 (22.2) 20 (29.9) .98 NS 1.49 [.68-3.29] 
Familial psychiatric disorder* 26 (36.1) 38 (55.9) 5.52 .019 2.24 [1.14-4.42] 
Familial DDs  8 (11.3) 15 (22.7) 3.22 NS (.073) 2.32 [.91-5.90] 
Familial medical illness* 30 (54.5.) 34 (55.7) .02 NS 1.05 [.50-2.18] 
Medical comorbidity** 70 (66.7) 68 (76.4) 2.23 NS 1.62 [.86-3.06] 
ID-related genetic syndrome 23 (27.4) 12 (16.2) 2.84 NS (.092) .51 [.24-1.12] 
Motor disability 33 (31.4) 15 (17.0) 5.30 .021 .45 [.22-.90] 
Axis I psychiatric 
comorbidity°° 
23 (39.7) 39 (62.9) 6.49 .011 2.58 [1.24-5.39] 
OCD-related disorders 2 (3.4) 13 (20.3) 8.21 .004 7.27 [1.56-33.75] 
SSDs 10 (16.7) 2 (3.1) 6.50 .011 1.16 [.03-.77] 
Schizoaffective disorder 9 (15.0) 0 (0.0) 10.20 .001  
BED 1 (1.7) 6 (9.7) 3.45 NS (.063) 6.11 [.71-52.37] 
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* The comparisons relative to the familial occurrence of the following specific neurodevelopmental disorders, psychiatric disorders 
and medical illnesses are not reported as far as not significant differences were detected: ID, ASD, ADHD, specific learning 
disorders and epilepsy; BDs, SSDs, anxiety disorders, OCD-related disorders, Substance-related disorders, somatic symptom 
disorders, personality disorders, ICD; autoimmunity diseases, allergies, sensory impairments, diabetes, obesity, cardiovascular 
diseases, motoric disability. 
** The comparisons relative to the following medical comorbidities are not reported as far as not significant differences were 
detected: epilepsy, allergies, gastrointestinal disturbances, obesity, cardiovascular diseases, respiratory diseases, sensory 
impairments. 
° The comparisons relative to the specific psychiatric adverse effects of antidepressants (irritability, (hypo)manic switch, mood 
instability, resistance) and specific adverse effects of antipsychotics (affective flattening and depressed mood, akathisia, EPS, 
metabolic effects) are not reported as far as not significant differences were detected.  
°°The analysis of Axis I comorbidity does not include NDs and MDs. The comparisons relative to the following psychiatric disorders 
are not reported as far as not significant differences were detected: anxiety disorders, panic disorder, GAD, schizophrenia, EDs, 
anorexia, bulimia, NDs, ASD, specific learning disorders, conduct disorder, cluster A and B personality disorders  
 
MD diagnosis was significantly associated to the presence of family members with at least one comorbid 
psychiatric disorder (55.9% vs. 36.1%, χ²= 5.52 p=.019), but no specific psychiatric disorder have been found 
as significantly more associated to MD comparing to no-MD probands; the rate of familial DDs was actually 
doubled in MD participants but not significant (see Table 10). 
ADHD 5 (8.3) 16 (23.5) 5.37 .021 3.39 [1.16-9-90] 
ICDs 4 (6.9) 18 (28.1) 9.28 .002 5.28 [1.67-16.73] 
ODD 2 (3.4) 14 (22.2) 9.28 .002 8.00 [1.73-36.96] 
Substance-related disorder 0 (0.0) 5 (8.1) 4.88 .027  
Axis II psychiatric 
comorbidity 
8 (13.6) 23 (36.5) 8.47 .004 3-67 [1.48-9.06] 
Cluster C personality disorder 5 (8.5) 16 (26.2) 6.55 .010 3.84 [1.31-11.30] 
Severity related variables 
Attempted suicide 1 (1.0) 7 (8.0) 5.42 .020 8.38 [1.01-69.56] 
Hospitalizations 5 (5.2) 18 (21.4) 10.75 .001 5.02 [1.77-14.20] 
Number of hospitalizations, 
Mean (SD) 
.12 (.83) .70 (1.82) 24.65 <.001  
Psychopharmacological 
treatments 
51 (51.0) 81 (91.0) 35.79 <.001 9.73 [4.26-22.21] 
SSRI antidepressants 6 (6.0) 27 (30.3) 19.35 <.001 6.82 [2.66-17.48] 
Tricyclic antidepressants 3 (3.0) 6 (6.7) 1.45 NS 2.34 [.57-9.64] 
Other antidepressants 3 (3.0) 15 (16.9) 10.49 .001 6.55 [1.83-23.48] 
Anticonvulsants 31 (31.0) 60 (67.4) 25.01 <.001 4.61 [2.49-8.50] 
Lithium 2 (2.0) 9 (10.1) 5.65 .017 5.51 [1.16-26.24] 
FGA 8 (8.0) 35 (39.3) 26.29 <.001 7.45 [3.22-17.24] 
SGA 24 (24.0) 63 (70.8) 41.49 <.001 7.67 [4.02-14.66] 
BDZ 19 (19.0) 49 (55.1) 26.58 <.001 5.22 [2.72-10.02] 
Psychiatric adverse effects of 
antidepressants° 
2 (16.7) 17 (45.9) 3.27 NS (.070) 4.25 [.82-22.13] 
Adverse effects of 
antipsychotics° 
12 (48.0) 38 (57.6) .67 NS 1.47 [.58-3.70] 
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The only significantly different medical comorbidity in the two groups was the presence of motor disabilities, 
also including a certain number of patients with cerebral palsy: motor disabilities had higher rates in no-MD 
individuals of the sample. Even the presence of an ascertained genetic syndrome related to ID showed a similar, 
but not significant trend. It has to be noticed that, comparing to the overall numerosity of the sample, the total 
number of genetic syndromes is relatively lower and mostly represented by trisomy 21 that is well-known to 
have mild association with psychiatric vulnerability (see Table 10). 
 The classes of psychotropic medications were compared between the two groups: all but tricyclic 
antidepressants showed higher rates in the MD group. MD was associated to higher risk of adverse effects of 
antidepressants and antipsychotics, although the statistical significance was not achieved in both cases (near 
for antidepressants, p=.070) (see Table 10). 
We found MD to be associated to significantly higher rates of comorbid Axis I psychiatric disorders (OR=2.58, 
p=.011): the specific disorders showing significant differential occurrence in MD subjects included OCD-
related disorders (p=.004), ADHD (p=.021), impulse control disorders and specifically oppositional-defiant 
disorder (p=-002), substance-related disorders (p=.027) and binge eating disorder (p=.063). By the contrary, 
in the no-MD group higher rates of schizophrenia spectrum disorders were found (p=.001) and it was expected 
as the presence of some SSDs represent an exclusionary criterion for the diagnosis of MD. On the other hand, 
the two groups did not show significantly different rates of personality disorders, exception given for cluster 
C personality disorders, reporting higher rates in MDs. These results evidenced MDs to be associated to a 
greater burden of psychiatric illness (see Table 10). This was confirmed by the significantly higher rates of 
attempted suicides, hospitalizations and their higher mean number, but also the higher mean raw scores of 
almost all the DASH-II psychopathological dimensions, not only mania and depression (detailed in Table 11).  
 
Table 11. Psychopathological burden associated to mood disorders: comparisons of DASH-II raw 
scores according to the clinical diagnosis 
 
 
 
 
 
 
 
 
 
 
  
 
 
DASH-II psychopathological 
dimension, Mean (SD) 
No-MD 
N=121 
MD 
N=96 
F p 
Anxiety 6.86 (8.16) 10.50 (10.63) 12.70 .010 
Depression 9.31 (8.59) 23.90 (13.05) 16.11 <.001 
Impulse Control 13.13 (12.37) 27.73 (17.08) 18.96 <.001 
Stereotypies/Tics 7.36 (7.14) 12.55 (9.19) 8.29 <.001 
Organic disturbances 6.52 (6.47) 14.77 (8.15) 7.53 <.001 
Schizophrenia  3.60 (6.08) 5.63 (4.54) .39 .015 
PDD/Autism 9.10 (8.68) 15.14 (10.73) 8.15 <.001 
Mania 6.95 (6.86) 16.64 (9.36) 17.98 <.001 
Eating issues 1.65 (3.19) 3. 80 (4.66) 10.75 <.001 
Self-injurious behaviors 1.15 (2.39) 3.06 (5.10) 26.81 .001 
Elimination issues .64 (2.24) .83 (2.30) 1.00 NS 
Sleep disturbances 1.01 (2.25) 4.22 (4.59) 45.76 <.001 
Sexual disorders .67 (1.99) 2.14 (3.68) 31.32 .001 
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3.5 Mood disorders: clinical and course features associated to low-functioning Autism Spectrum 
Disorder 
Another interesting point to explore was the relationship between MDs and ASD in individuals with ID. 
Including the overall sample, we made comparisons of clinical diagnoses of MDs and associated clinical 
features, starting from the co-occurrence of ASD. The relative χ² statistics are shown in Table 12.  
 
Table 12: Clinical and course features of clinically diagnosed mood disorders: comparisons on the 
basis of the co-occurrence of autism spectrum disorder 
No-ASD: subjects without the diagnosis of autism spectrum disorder; ASD: subjects with the diagnosis of autism 
spectrum disorder;  MDs: Mood Disorders; DDs: Depressive Disorders; MDD: Major Depressive Disorder; PDD: 
Persistent Depressive Disorder; BDs: Bipolar Disorders; BD I: Bipolar Disorder type I; BD II: Bipolar Disorder type II; 
MDE: Major Depressive Episode; AP: antipsychotic. 
Diagnosis 
N (%) 
No-ASD 
N=150 
ASD 
N=83 
χ² p OR [95% CI] 
MDs 48 (35.6) 48 (58.5) 10.92 .001 2.56 [1.46-4.49] 
DDs 19 (14.0) 17 (20.7) 1.70 NS 1.61 [.78-3.31] 
MDD 16 (10.7) 14 (16.9) 1.83 NS 1.70 [.78-3.68] 
PDD 2 (1.5) 3 (3.7) 1.09 NS 2.54 [.42-15.56] 
BDs 20 (22.2) 31 (37.8) 6.13 .013 2.13 [1.16-3.89] 
BD I 15 (11.0) 19 (23.2) 5.73 .017 2.43 [1.16-5.11] 
BD II  5 (3.7) 6 (7.3) 1.42 NS 2.07 [.61-7.01] 
Cyclothymic Disorder 1 (0.7) 1 (1.2) .13 NS 1.67 [.10-27.01] 
BD otherwise specified 8 (5.9) 4 (4.9) .10 NS .82 [.24-2.82] 
Clinical and course features 
MDE with mixed features 16 (10.7) 21 (25.3) 8.57 .003 2.84 [1.39-5.81] 
MDE with catatonic features 0 (0.0) 11 (13.3) 20.87 <.001  
MDE with psychotic features 22 (14.7) 13 (15.7) .04 NS 1.08 [.51-2.28] 
MDE with seasonal pattern 12 (8.0) 22 (26.5) 14.69 <.001 4.15 [1.93-8.92] 
Euphoric (hypo)mania 23 (15.3) 18 (21.7) 1.49 NS 1.53 [.77-3.04] 
Dysphoric (hypo)mania 21 (14.0) 26 (31.3) 9.96 .002 2.80 [1.46-5.39] 
(Hypo)mania with mixed 
features 
18 (12.0) 25 (30.1) 11.70 .001 3.16 [1.60-6.24] 
(Hypo)mania with catatonic 
features 
0 (0.0) 3 (3.6) 5.49 .019  
(Hypo)mania with psychotic 
features 
21 (14.0) 13 (15.7) .12 NS 1.14 [.54-2.42] 
(Hypo)mania with seasonal 
pattern 
11 (7.3) 12 (14.5) 3.05) NS (.081) 2.14 [.90-5.08] 
Rapid cycling BD course 18 (12.0) 18 (21.7) 3.84 .050 2.03 [.99-4.16] 
Affective flattening/depressed 
mood under AP treatment 
5 (11.6) 18 (36.0) 7.38 .007 4.28 [1.43-12.80] 
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Comparing to subjects without an ASD diagnosis (no-ASD), the ASD group showed significantly higher rates 
of overall MDs (OR=2.56, p=.001) and specifically of BDs (OR= 2.13, p=.013) and BD I (OR=2.43, p=.017). 
No differences emerged regarding all DDs and soft bipolar diagnoses.  
The presentation of MDE in ASD individuals resulted more frequently associated to mixed and catatonic 
features, as well as to a seasonal pattern. The related statistics were significant. Similarly, the diagnosis of 
ASD was also associated to higher prevalence of the same features during the excitatory phases. Moreover, 
(hypo)mania was significantly more frequently characterized by dysphoria, while euphoria did not differ 
between ASD and no-ASD participants. Finally, ASD patients reported a doubled risk to show a rapid cycling 
course of bipolar illness.      
No differences between the two groups were evidenced regarding the development of psychiatric adverse 
effects of antidepressants, whereas ASD individuals reported significantly higher rates of antipsychotic-
induced affective flattening and depressed mood, but not akathisia, EPS and metabolic side effects.  
 
3.6 Depressive and Bipolar Disorders: prevalence rates according to SPAIDD-M diagnosis and 
comparisons of different diagnostic definitions 
SPAIDD-M resulted positive for the diagnosis of a MD in 110 participants (47.2%), 59 (25.3%) had a DD and 
70 (30.0%) had a BD. The comparisons of the rates in the three ID subgroups did not reveal significant 
differences. Table 13 summarizes the χ² statistics for the three ID subgroups of all the DDs and BDs-related 
diagnoses. The three subgroups showed no statistically significant difference in the rate for all the DD and BD-
related SPAIDD-M diagnoses.  
Table 13. Depressive and Bipolar Disorders: comparisons of SPAIDD-M rates according to ID levels 
MDD: Major Depressive Disorder; PDD: Persistent Depressive Disorder; BD I: Bipolar Disorder type I; BD II: Bipolar 
Disorder type II; GMC: General Medical Condition  
Scheffè test performed for all the comparisons did not evidence statistically significant differences. 
 
Diagnoses N (%) 
BIF/Mild ID 
N=66 
Moderate ID 
N=88 
Severe/Profound ID 
N=79 
χ² p 
Overall Mood Disorders  28 (42.4) 46 (52.3) 36 (45.6) 1.60 NS 
Depressive Disorders 12 (18.2) 25 (28.4) 22 (27.8) 2.49 NS 
MDD 10 (15.2) 21 (23.9) 16 (20.3) 1.78 NS 
PDD 3 (4.5) 6 (6.8) 5 (6.3) .37 NS 
Dysphoric Premenstrual 
Disorder 
0 (0.0) 0 (0.0) 0 (0.0)   
DD due to GMC or drugs 2 (3.1) 1 (1.1) 1 (1.3) .97 NS 
Bipolar Disorders 20 (30.3) 27 (30.7) 23 (29.1) .05 NS 
BD I 13 (19.7) 12 (13.6) 9 (11.4) 2.09 NS 
BD II 2 (3.0) 6 (6.8) 3 (3.8) 1.43 NS 
Cyclothymic Disorder  1 (1.5) 1 (1.1) 0 (0.0) 1.10 NS 
BD otherwise specified 2 (3.0) 5 (5.7) 7 (8.9) 2.19 NS 
BD due to GMC or drugs 1 (1.5) 1 (1.1) 0 (0.0) 1.10 NS 
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141 patients completed the full study protocol and the diagnoses of DDs and BDs were made according to 
different definitions, namely via the application of DSM-5 criteria for MDD, BD I, BD II and BD otherwise 
specified, the SPAIDD-M evaluation and a clinical expert diagnosis integrating all the anamnestic, 
observational and assessment information. Table 14 summarizes the χ² statistics for all MD diagnoses 
according to three ID levels.  
Table 14. Depressive and Bipolar Disorders: diagnoses according to different definitions and ID levels 
MDD: Major Depressive Disorder; PDD: Persistent Depressive Disorder; DD: Depressive Disorders; BD I: Bipolar 
Disorder type I; BD II: Bipolar Disorder type II; GMC: General Medical Condition 
Scheffè test performed for all the comparisons did not evidence statistically significant differences. 
 
For all the diagnoses, it can be identified a diagnostic trend indicating higher rates per diagnosis obtained with 
the SPAIDD-M assessment comparing to the application of adapted DSM-5 criteria and the final clinical 
diagnosis. This effect seemed to be more pronounced for DDs than BD ones. For example, the prevalence rate 
of MDD in moderate ID subjects resulted 26.1% and 34.8% according to DSM.5 criteria and SPAIDD-M 
respectively, whereas the clinical judgement evidenced a prevalence rate 17.4%. It is possible that the high 
load of antipsychotic treatments and their psychiatric side effects as well as the high prevalence of SSDs in the 
sample might have influenced the evaluation, especially reducing the specificity of SPAIDD-M results.  
 
 
Diagnoses N (%) 
BIF/Mild ID 
N=47 
Moderate ID 
N=46 
Severe/Profound ID 
N=48 
χ² p 
MDD DSM-5 5 (10.6) 12 (26.1) 9 (18.8) 3.69 NS 
SPAIDD-M 8 (17.0) 16 (34.8) 9 (18.8) 4.97 NS (.083) 
Clinical 6 (12.8) 8 (17.4) 9 (18.8) .68 NS 
PDD SPAIDD-M 3 (6.4) 2 (4.3) 0 (0.0) 2.96 NS 
Clinical 0 (0.0) 1 (2.2) 0 (0.0) 2.08 NS 
DD GMC and drug-
related 
SPAIDD-M 0 (0.0) 1 (2.2) 1 (2.1) 1.00 NS 
Clinical 0 (0.0) 1 (2.5) 1 (2.9) 1.05 NS 
BD I DSM-5 10 (21.3) 9 (19.6) 6 (12.5) 1.41 NS 
SPAIDD-M 11 (23.4) 9 (19.6) 6 (12.5) 1.94 NS 
Clinical 10 (21.3) 8 (17.4) 6 (12.5) 1.30 NS 
BD II DSM-5 2 (4.3) 3 (6.5) 2 (4.2) .35 NS 
SPAIDD-M 2 (4.3) 4 (8.7) 2 (4.2) 1.17 NS 
Clinical 2 (4.3) 4 (8.7) 2 (4.2) 1.17 NS 
Cyclothymic 
Disorder 
SPAIDD-M 1 (2.1) 0 (0.0) 0 (0.0) 2.01 NS 
Clinical 1 (2.1) 0 (0.0) 0 (0.0) 2.01 NS 
BD otherwise 
Specified 
DSM-5 5 (10.6) 2 (4.3) 0 (0.0) 5.75 NS (.056) 
SPAIDD-M 2 (4.3) 2 (4.3) 4 (8.3) .96 NS 
Clinical 1 (2.1) 3 (6.5) 2 (4.2) 1.10 NS 
BD GMC or drug-
related 
SPAIDD-M 1 (2.2) 1 (2.2) 0 (0.0) 1.04 NS 
Clinical 1 (2.6) 1 (2.5) 0 (0.0) .63 NS 
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Table 15. Demographic and socio-economic features in individuals with intellectual disability and co-
occurring mood disorders: comparisons between Depressive and Bipolar Disorders according to 
SPAIDD-M definition 
Demographic and socio-economic 
features 
Depressive 
Disorders 
N=47 
Bipolar 
Disorders 
N=63 
χ² or F p OR [95% CI] 
Gender (M) N (%) 36 (76.6) 44 (69.8) .62 NS  
Age, Mean (sd) 41.94 (15.10) 37.49 (14.95) .02 NS  
BMI, Mean (sd) 23.77 (5.03) 27.39 (12.74) 3.1 NS (.082)  
ID levels N (%)  
Mild 10 (21.3) 18 (28.6)  
 
.77 
 
 
NS 
 
Moderate 21 (44.7) 25 (39.7) 
Severe 16 (34.0) 20 (31.7) 
Recruitment source N (%) 
Residential facilities 26 (55.3) 27 (42.9)  
 
3.94 
 
 
NS 
 
Rehabilitative centers  9 (19.1) 23 (36.5) 
Families 12 (25.5) 13 (20.6) 
 
Adopted N (%) 1 (2.4) 3 (5.8) .62 NS 2.45 [.25-24.46] 
Invalidity pension N (%) 39 (97.5) 49 (94.2) .58 NS .42 [.04-4.19] 
Employed N (%) 2 (4.9) 7 (13.5) 1.93 NS 3.03 [.60-15.47] 
Problems with justice N (%) 1 (2.6) 1 (2.0) .27 NS .79 [.05-13.08] 
Provenance N (%) 
Urban, big city  20 (48.8) 14 (28.0)  
 
5.01 
 
 
NS 
 
Periphery, small city 16 (39.0) 31 (62.0) 
Rural 5 (12.2) 5 (10.0) 
Familial economic level N (%) 
Low income 8 (21.6) 9 (18.4)  
 
1.99 
 
 
NS 
 
Medium income 25 (67.6) 29 (59.2) 
High income 4 (10.8) 11 (22.4) 
Educational Level N (%) 
None 8 (20.5) 3 (6.8)  
 
 
4.97 
 
 
 
NS 
 
Primary 2 (5.1) 4 (9.1) 
Secondary 19 (48.7) 24 (54.5) 
Tertiary 29 (23.1) 13 (29.5) 
Educational support 30 (78.4) 37 (84.1) .36 NS 1.41 [.46-4.33] 
Quality of familial relationships N (%) 
Low 11 (29.7) 16 (34.0)  
 
.94 
 
 
NS 
 
Medium 18 (48.6) 18 (38.3) 
High 8 (21.6) 13 (27.7) 
Friendships N (%) 
None 20 (51.3) 19 (38.8)  
 
1.72 
 
 
NS 
 
Few 17 (43.6) 25 (51.0) 
Normal 2 (5.1) 5 (10.2) 
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3.7 Socio-demographic and clinical differences between Depressive and Bipolar patients with 
Intellectual Disability 
The dependent variable used for the analyses was the diagnosis of DDs and BDs according to the SPAIDD-M 
definition. The participants included in these analyses were 110.  
No differences emerged regarding gender and mean age of depressive and bipolar ID patients, whereas the 
mean BMI was slightly different in the two groups, although not achieving the statistical significance (χ²=3.1, 
p=.082). None of the other socio-demographic variables explored differentiated between the two diagnoses. 
The results are detailed in Table 15.  
The χ² tests concerning pregnancy and delivery showed that BDs patients with ID more frequently than DDs 
patients use medications during pregnancy and its course with the presentation of a variety of problematic 
issues (for example miscarriage risk, placenta previa etc.) (χ²=4.10, p=.043; χ²=4.77, p=.029, respectively).  
The comparisons of the physiological parameters after birth and achievement of developmental milestones did 
not differ between the two groups rather for the delay of the development of autonomous locomotion, more 
prevalent in the DDs group. All the χ² tests are detailed in Table 16.  
No medical illness but obesity showed statistically significant differences in DDs and BDs probands, including 
the prevalence of ID-related genetic syndromes as well as immunity dysreactive disorders. BDs individuals 
had significantly higher prevalence of obesity, with an OR=4.50 (χ²=7.05, p=.008). Table 16 summarizes also 
the comparisons regarding medical and familial features associated to DDs and BDs diagnoses.  
The familial co-occurrence of neuropsychiatric and psychiatric conditions among family member of the 
probands was also explored. DDs subjects showed a prevalence rate of familial ASD of 9.1% comparing to 
none of BDs participants. By the contrary, comparing to DDs, BDs subjects showed significantly higher rates 
for overall familial psychiatric comorbidity (OR=2.68, χ²=4.24, p=.039), and specifically a higher familial load 
for BD and personality disorders (32.6% vs. 3.3%, OR=14.00 in both cases). BD was also associated to slightly 
higher prevalence rates of familial psychotic and eating disorders but not reaching the statistical significance.   
   
Table 16. Physiological, medical and familial features in individuals with intellectual disability and co-
occurring mood disorders: comparisons between Depressive and Bipolar Disorders according to 
SPAIDD-M definition 
Physiological features  
N (%) 
Depressive 
Disorders 
N=47 
Bipolar 
Disorders 
N=63 
χ² p OR [95% CI] 
Pregnancy 
Use of medications 1 (3.7) 6 (22.2) 4.10 .043 7.43 [.83-66.62] 
Problematic course 3 (9.7) 10 (32.3) 4.77 .029 4.44 [1.09-18-18] 
At term  25 (86.2) 24 (77.4)  
 
.82 
 
 
NS 
 
Preterm 2 (6.9) 4 (12.9) 
Post-term 2 (6.9) 3 (9.7) 
Delivery  
Eutocic 19 (61.3) 15 (50.0)    
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*First physiological acts, breast feeding, psychomotor milestones achievement, and delay of the language development 
not reported as far as not significant differences were detected.  
** Immunity dysreactivity includes autoimmunity diseases and allergies. 
*** The comparisons relative to the following psychiatric disorders in first-degree family members are not reported as 
far as not significant differences were detected: Anxiety disorders, Obsessive-Compulsive and related disorders, 
Trauma and stress-related disorders, Addiction-related disorders, Somatic Symptom and related disorders, Impulse 
Control disorders.   
ASD: Autism Spectrum Disorder; ID: Intellectual Disability; DDs: Depressive Disorders; BDs: Bipolar Disorders. 
 
Table 17 shows the comparisons of psychiatric comorbidity according to the clinical evaluation made during 
the present study. The clinical diagnosis of DDs was confirmed in the 68.2% of the subjects resulted positive 
to DDs at the SPAIDD-M evaluation, whereas the 3.2% of the SPAIDD-M/BDs patients received a final 
diagnosis of DDs, namely an MDD diagnosis. By the contrary, the 11.4% of the patients with a SPAIDD-M 
diagnosis of DDs, were reframed as clinically bipolar: the 6.8% as BD I, the 9.1% as BDII and the 2.3% as 
BD otherwise specified.  
Dystocic 9 (29.0) 9 (30.0)  
 
3.46 
 
 
NS 
Planned caesarean section 0 (0.0) 3 (10.0) 
Urgency caesarean section 3 (9.7) 3 (10.0) 
Physiological developmental variables N (%)* 
Delayed locomotion 22 (68.8) 16 (43.2) 4.51 .034 .35 [.13-.93] 
Medical comorbidity N (%) 
Genetic syndrome related to ID 5 (12.8) 7 (15.9) .16 NS 1.29 [.37-4.44] 
Overall medical comorbidities 34 (81) 40 (69.0) 1.82 NS .52 [.20-1.35] 
Epilepsy 12 (28.6) 10 (17.5) 1.70 NS .53 [.20-1.38] 
Gastrointestinal disturbances 9 (21.4) 8 (14.0) .93 NS .60 [.21-1.71] 
Diabetes 1 (2.4) 3 (5.3) .52 NS 2.28 [.23-22.70] 
Obesity 4 (9.5) 18 (32.1) 7.05 .008 4.50 [1.39-14.54]  
Cardiovascular disorders 4 (9.8) 4 (7.0) .24 NS .70 [.16-2-97] 
Immunity dysreactivity** 9 (23.1) 14 (29.2) .41 NS 1.37 [.52-3.52] 
Motoric disability 6 (14.3) 8 (14.0) .001 NS .98 [.31-3.07] 
Sensory impairments 2 (4.8) 5 (8.8) .59 NS 1.92 [.36-10.43] 
Familial history N (%) 
Familial history for 
neuropsychiatric disorders 
10 (30.3) 12 (27.9) .05 NS .89 [.33-2.41] 
Familial ASD 3 (9.1) 0 (0.0) 3.98 .046  
Familial ID 7 (21.2) 9 (21.4) .001 NS 1.01 [.33-3.08] 
Familial history for medical illness 14 (46.7) 24 (61.5) 1.52 NS 1.83 [.70-4.80] 
Familial autoimmune diseases 2 (6.7) 6 (15.4) 1.26 NS 2.55 [.48-13.63] 
Familial history for psychiatric 
disorders*** 
13 (41.9) 29 (65.9) 4.24 .039 2.68 [1.04-6.90] 
Familial DDs 4 (13.3) 11 (58.4) 1.62 NS 2.23 [.64-7.85] 
Familial BDs 1 (3.3) 14 (32.6) 9.25 .002 14.00 [1.73-113.53] 
Familial Psychotic Disorders 2 (6.7) 9 (20.9) 2.81 NS (.094) 3.71 [.74-18.57] 
Familial Personality Disorders 1 (3.3) 14 (32.6) 9.25 .002 14.00 [1.73-113.53] 
Familial ED 2 6.7) 0 (0.0) 2.95 NS (.086)  
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Table 17. Clinically diagnosed psychiatric comorbidity in individuals with intellectual disability and co-
occurring mood disorders: comparisons between Depressive and Bipolar Disorders according to 
SPAIDD-M definition 
*The dependent variable was the diagnosis of BD according to SPAIDD-M. 
DDs: Depressive Disorders; BDs: Bipolar Disorders; MDD: Major Depressive Disorder; PDD: Persistent Depressive 
Disorder; BD I: Bipolar Disorder type I; BD II: Bipolar Disorder type II; ASD: Autism Spectrum Disorder; ADHD: 
Attention-Deficit/Hyperactivity Disorder; GAD: Generalized Anxiety Disorder; OCD: Obsessive-Compulsive Disorder; 
SSDs: Schizophrenia Spectrum Disorders; Eds: Eating Disorders; BED: Binge Eating Disorder; ICDs: Impulse Control 
Disorders; ODD: Oppositional-Defiant Disorder; PDs: Personality Disorders 
 
Psychiatric comorbidity 
N (%) 
Depressive 
Disorders 
N=47 
Bipolar 
Disorders 
N=63 
χ² p OR [95% CI]* 
DDs 30 (68.2) 2 (3.2) 51.52 <.001 .02 [.00-.07] 
MDD 28 (59.6) 2 (3.2) 43.17 <.001 .02 [.01-10] 
PDD 5 (11.4) 0 (0.0) 7.39 .007  
BDs 5 (11.4) 55 (88.7) 62.68 <.001 61.29 [18.12-207.33] 
BD I 3 (6.8) 31 (50.0) 22.03 <.001 13.67 [3.82-48.84] 
BD II 1 (9.1) 10 (16.1) 5.31 .021 8.27 [1.02-67.19] 
Cyclothymic Disorder 0 (0.0) 2 (3.2) 1.45 NS  
BD otherwise specified 1 (2.3) 11 (17.7) 6.13 .013 9.28 [1.15-74.76] 
Neurodevelopmental disord.  17 (51.5) 32 (64.3) 1.28 NS 1.67 [.68-4.09] 
ASD 16 (48.5) 28 (56.0) .45 NS 1.35 [.56-3.27] 
ADHD 2 (7.1) 16 (32.7) 6.47 .011 6.30 [1.33-29.91] 
Anxiety Disorders 9 (37.5) 9 (18.8) 3.00  NS (.083) .39 [.13-1.16] 
Panic disorder 3 (6.4) 3 (4.8) .14 NS .73 [.14-3.81] 
GAD 6 (25.0) 2 (4.3) 6.84 .009 .13 [.03-.72] 
OCD-related disorders 2 (8.3) 11 (22.4) 2.19 NS 3.18 [.65-15.70] 
SSDs 8 (29.6) 3 (6.3) 7.55 .006 .16 [.04-.66] 
Schizophrenia 1 (3.79 0 (0.0) 1.77 NS  
Schizoaffective disorder 7 (25.9) 2 (4.3) 7.54 .006 .13 [.02-.67] 
EDs 0 (0.0) 8 (17.0) 4.60 .032  
Anorexia 0 (0.0) 2 (4.3) 1.05 NS  
Bulimia 0 (0.0) 1 (2.1) .52 NS  
BED 0 (0.0) 7 (14.9)  3.97 .046  
ICDs 2 (8.0) 16 (33.3) 5.60 .017 5.75 [1.20-27.49] 
ODD 2 (8.0) 12 (25.5) 3.20 NS (.074) 3.94 [.81-19.27] 
Conduct disorders 1 (4.0) 0 (0.0) 1.91 NS  
Substance-related disorders 0 (0.0) 4 (8.5) 2.16 NS  
Personality disorders 5 (20.8) 23 (47.9) 4.94 .026 3.50 [1.12-10.89] 
Cluster A PDs 3 (12.5) 5 (10.6) .06 NS .83 [.18-3.83] 
Cluster B PDs 1 (4.2) 7 (14.9) 1.83 NS 4.03 [.47-34.80] 
Cluster C PDs 4 (17.4) 15 (31.9) 1.65 NS 2.23 [.64-7.70] 
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The SPADD-M DDs and BDs diagnoses were not significantly associated to different clinical diagnoses of 
most neurodevelopmental and psychiatric disorders with some exceptions. ADHD was more common in the 
BDs group (32.7% vs. 7.1%, χ²=6.47, p=.011), as well as BED (14.9% vs. 0.0%, χ²=3.97, p=.046), overall 
personality disorders (47.9% vs. 20.8%, χ²=4.94, p=.026), and impulse control disorders (33.3% vs. 8.0%, 
χ²=5.60, p=.017). Among the impulse control disorders, no differences were evidenced, but the prevalence rate 
of oppositional-defiant disorder was slightly higher in bipolar than depressive patients (25.5% vs. 8.0%). 
Anxiety disorders resulted more prevalent in DDs individuals, especially GAD (25.0% vs. 4.3%, χ²=6.84, 
p=.009). SSD clinical diagnoses showed significantly higher rates among DDs subjects (29.6% vs. 6.3%, 
χ²=7.55, p=.006), supporting the hypothesis that a significant proportion of probands resulted positive for DDs 
at the SPAIDD-M evaluation showed large clinical overlap with SSDs, mostly with schizoaffective disorder 
depressive subtype. This effect could be far less extended for SPAIDD-M bipolar diagnoses.   
Two multiple logistic regression analyses were performed to identify the significant variables independently 
associated to the SPAIDD-M diagnosis of BD and those variables associated to the clinical diagnosis of BD. 
The results are reported in Tables 18 and 19, respectively. 
 
Table 18. Multiple Logistic Regression backward procedure of familial and psychiatric comorbidity 
features on SPAIDD-M BD diagnosis in 110 persons with ID and MD. 
Variables  F Wald p OR [95% CI] 
Familial comorbidity for 
psychiatric disorders 
3.12 6.864 .009 22.71 [2.20-234.81] 
GAD - 2.10 3.0162 .075 .12 [.01-1.24] 
BED 21.83 .000 .999  
ADHD 2.87 5.32 .021 17.57 [1.54-200.95] 
Wald=5.863, df 1 p=.015 
Variables not in equation: Familial comorbidity for ASD, bipolar disorders and personality disorders, clinical diagnosis 
of SSDs, impulse control disorders and personality disorders 
 
The first regression model, applied with backward procedure, found the presence of psychiatric comorbidity 
in family members together with the co-occurrence of BD and ADHD, independently predictive of the 
positivity SPAIDD-M diagnosis for BD. On the other hand, the co-occurrence of GAD seemed not to predict 
the belonging to the BDS group but to DDs. Specific disorders in family members, namely ASD, BD and 
personality disorders, as well as the diagnosis of co-occurring psychotic spectrum, impulse control and 
personality disorders were excluded from the regression model. 
The multiple logistic regression model relative to the clinical diagnosis of BDs in the subsample of probands 
with a MDs diagnosis, gave similar results. However, it was found that the presence of ASD in family members 
was significantly not predictive to belong to the BD group, whereas BED was excluded by the model (see 
Table 19).   
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Table 19. Multiple Logistic Regression backward procedure of familial and psychiatric comorbidity 
features on clinical BD diagnosis in 96 persons with ID and MD. 
Variables  T Wald p OR [95% CI] 
Familial comorbidity for 
psychiatric disorders 
3.44 1.22 .005 31.04 [2.86-336.88] 
Familial comorbidity for ASD -23.95 .000 1.000 .000 
GAD - 3.14 4.681 .030 .04 [.00-.74] 
ADHD 1.62 2.46 .117 5.05 [.67-38.17] 
Wald=6.609, df 1 p=.010 
Variables not in equation: Familial comorbidity for bipolar disorders and personality disorders, clinical diagnosis of SSDs, 
impulse control disorders, BED, and personality disorders 
 
As shown in Table 20, DDs an BDs SPAIDD-M diagnoses were associated to similar rates and mean number 
of psychiatric hospitalizations, as well as similar rates of suicide attempts. The rates of hospitalizations, around 
25%, were relatively low considering the high prevalence of BD type I and the severe burden of medical and 
psychiatric comorbidity. The use of psychotropic medication was comparable between the two groups too, 
overcoming in both cases the 90%. No differences were identified relatively to the use of all antidepressant 
classes, also if the use of SSRIs was about one third lower in BD patients. By the contrary, the diagnosis of 
BDs was associated to higher rates of the use of TCAs (p=.028), mostly trimipramine, and other antidepressants 
(p=.079), mostly NASSAs, for the treatment of co-occurring anxiety symptoms.  As expected, the use of 
lithium salts was far more associated to BDs diagnosis (OR=6.86), even if the rate was only the 14.0%. The 
diagnosis of BDs was also associated to a significantly larger use of antipsychotics, both FGAs (OR=3.26, 
p=.071), SGAs (OR=8.45, p=.004), benzodiazepines (OR=3.11, p=.078) and other sedative medications 
(OR=15.00, p=.001).  
Among the 39 patients past or currently taking antidepressants (39.0% of SPAIDD-M MDs diagnosed 
subjects), 18 had experienced the psychiatric adverse effects of antidepressants. The rates of these adverse 
effects resulted higher in the BDs group but the statistical significance was not achieved (54.4% vs. 37.5%). 
Considering the specific adverse effects, the χ² statistics did not identify significant differences in the 
prevalence of antidepressant-induced irritability and activation symptoms, nor resistance to antidepressants. 
The SPAIDD-M BDs diagnosis was associated to significantly higher rates of (hypo)manic switch under 
antidepressant treatment (χ²=4.19, p=.041). The induction of mood instability was more frequent in BDs than 
in DDs subjects but it was only near to the statistical significance.  
The 80% of MDs subjects diagnosed via SPAIDD-M, reported antipsychotics side effects, but no differences 
were identified between DDs and BDs. Antipsychotic-induced akathisia was reported only in BDs patients 
(χ²=5.50, p=.019).  
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Table 20. Psychopharmacological treatments and indirect severity indices in individuals with 
intellectual disability and co-occurring mood disorders: comparisons between Depressive and Bipolar 
Disorders according to SPAIDD-M definition 
SSRIs: Selective Serotonin Reuptake inhibitors; TCA: Tricyclic Antidepressants; FGA: First Generation Antipsychotics; SGA: Second 
Generation Antipsychotics; BDZ: Benzodiazepines; AD: antidepressants; AP: Antipsychotics; EPS: extrapyramidal effects 
   
 
 
 
 
 
 
Clinical features 
N (%) 
Depressive 
Disorders 
N=47 
Bipolar 
Disorders 
N=63 
χ² or F p OR [95% CI] 
Psychiatric hospitalizations 11 (26.2) 12 (23.5) .08 NS .87 [.34-2.23] 
Number of psychiatric 
hospitalizations, Mean (SD) 
.74 (1.78) .90 (2.18) .60 NS  
Suicide attempts 3 (7.0) 4 (7.3) .003 NS 1.05 [.22-4.94] 
Psychopharmacological 
treatments 
40 (93.0) 52 (91.2) .11 NS .78 [.18-3.46] 
SSRIs 15 (34.9) 13 (22.8) 1.77 NS .55 [.23-1.33] 
TCAs 0 (0.0) 6 (10.5) 4.82 .028  
Other antidepressants 3 (7.0) 11 (19.3) 3.09 NS (.079) 3.19 [.83-12.24] 
Anticonvulsants 27 (62.8) 41 (71.9) .94 NS 1.52 [.65-3.54] 
Lithium  1 (2.3) 8 (14.0) 4.10 .043 6.86 [.82-57.09] 
FGAs 12 (27.9) 26 (45.6) 3.26 NS (.071) 2.17 [.93-5.05] 
SGAs 25 (58.1) 48 (84.2) 8.45 .004 3.84 [1.51-9.78] 
BDZ 18 (41.9) 34 (59.6) 3.11  NS (.078) 2.05 [.92-4.59] 
Other sedatives 1 (2.3) 15 (26.3) 10.50 .001 15.00 [1.90-118.75] 
Psychiatric adverse effects with 
antidepressants 
6 (37.5) 12 (54.5) 1.08 NS 2.00 [.54-7.45] 
Irritability AD 3 (18.8) 10 (45.5) 2.94 NS (.087) 3.61 [.80-16.35] 
(Hypo)manic switch 0 (0.0) 5 (22.7) 4.19 .041  
Mood instability AD 2 (12.5) 5 (22.7) .65 NS 2.06 [.35-12.28] 
Resistance to AD 1 (6.3) 0 (0.0) 1.41 NS  
Adverse effects with 
antipsychotics 
15 (55.6) 32 (64.0) .53 NS 1.42 [.55-3.69] 
AP affective flattening/depressed 
mood  
5 (18.5) 17 (34.0) 2.06 NS 2.27 [.73-7.04] 
AP akathisia 0 (0.0) 9 (18.0) 5.50 .019  
AP EPS 8 (29.6) 17 (34.0) .15 NS 1.22 [.45-3.37] 
AP metabolic effects/weight gain 8 (29.6) 19 (38.0)  .54 NS 1.46 [.55-3.97] 
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3.8 Clinical and course features of Major Depressive Episodes and Depressive Disorders in persons with 
ID.  
As shown in Table 21, the χ² statistics comparing DDs and BDs in regards to the specifiers for the MDE, 
including the MDE related to a general medical condition or the assumptions of substances and medications, 
the presence during the episode of catatonic, psychotic and mixed features, and the seasonal pattern of 
depressive episodes, did not reveal any statistical difference, with the exception of the former specifier (episode 
CMG or drug-related), and plus, none of the DDs patients had reported this condition. This difference was not 
confirmed repeating the statistics considering the final clinical diagnoses of DDs and BDs (MDE GMC/drug 
related: 8.6% in DDs vs. 8.2% in BDs, χ²=.004, ns).  
As already noted, the high prevalence of psychotic symptoms in the SPAIDD-M DDs group might be related 
to the high prevalence of depressive syndromic pictures in patients clinically reframed as belonging the SSDs 
category. However, although with a consistent reshaping of the rate, the two groups of MDs did not differ for 
the presence of psychosis during MDE even considering the final clinical diagnoses (MDE with psychotic 
features: 20.0% in DDs vs. 27.7% in BDs, χ²=.73, ns). 
 
 
Table 21. Clinical features of major depressive episode in individuals with intellectual disability and 
co-occurring mood disorders: comparisons between Depressive and Bipolar Disorders according to 
SPAIDD-M definition 
 
 
 
To the best of our knowledge, this is the first study accounting for mixed features of affective episodes in 
intellectually disabled persons. The prevalence of MDE with mixed features in the overall sample was 21.7%. 
Noteworthy, we included in these analyses only those participants in which the completion of the relative 
SPAIDD-M section had been verified by the CREA team to improve the clinical validity. Unexpectedly, we 
did not find significant differences between DDs and BDs in the prevalence rates of mixed features during 
MDE, according to both the SPAIDD-M and the clinical diagnoses. Although not significant, we found that 
the rate of mixed depressive features was higher in DDs than in BDs patients, reaching a rate of 50%. The 
comparisons regarding individual, non-overlapping, excitatory symptoms during MDE did non evidence 
Clinical features 
N (%) 
Depressive 
Disorders 
N=47 
Bipolar 
Disorders 
N=63 
χ² P OR [95% CI] 
GMC/drug-related MDE 0 (0.0) 5 (7.9) 3.91 .048 .55 [.47-.66] 
Catatonic features 4 (8.5) 6 (9.5) .03 NS 1.13 [.30-1.26] 
Psychotic features 16 (34.0) 17 (27.0) .64 NS .72 [.32-1.63] 
Seasonal pattern 9 (19.1) 20 (31.7) 2.20 NS 1.96 [.80-4.83] 
Mixed features 17 (36.2) 19 (30.2) .44 NS .76 [.34-1.70] 
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significant differences between the two diagnostic groups. The relative total score means for mixed symptoms 
were comparable in DDs and BDs ID probands. The results are summarized in Table 22. 
 
 
Table 22: Mixed features during MDE: comparisons between Depressive and Bipolar Disorders 
according to SPAIDD-M definition 
MDE: Major Depressive Episode 
 
3.9 Clinical and course features of (hypo)manic episodes and Bipolar Disorders in persons with ID.  
Among the 70 participants with a SPAIDD-M test positive for a bipolar spectrum disorder, two had 
experienced (hypo)manic episodes only related to a general medical condition, medications or drugs (2.9%). 
Catatonic features resulted lower than expected, as they were reported during (hypo)mania only in one patient 
(1.4%). A seasonal pattern of the excitatory syndromic picture had been identified in the 21.4% of the sample. 
Psychotic and mixed features during the excitatory phases characterized the 27.1% and 44.3% of the bipolar 
ID patients, respectively. The 22.9% of the BDs sample had a rapid cycling course.  
A clinical diagnosis of BD was confirmed in 61 probands. The frequencies of the above mentioned descriptive 
clinical features resulted similar: the CMG/drug related episode was reported in the 3.3%, catatonic features 
in the 1.6%, a seasonal pattern characterized the 23.0% of the sample. Manic episodes with psychotic features 
Clinical features 
N (%) 
Depressive 
Disorders 
N=29 
Bipolar 
Disorders 
N=54 
χ² p OR [95% CI] 
Mixed features SPAIDD-M 14 (48.3) 16 (29.6) 2.84 NS (.092) .45 [.18-1.15] 
Clinical 11 (50.0) 14 (28.6) 3.06  NS (.080) .40 [.14-1.13] 
Non-overlapping SPAIDD-M behavioral equivalents of manic symptoms during MDE  
Euphoria 2 (6.9) 4 (7.4) .007 NS 1.08 [.19-6.28] 
Increased energy 1 (3.4) 2 (3.7) .004 NS 1.08 [.09-12.41] 
Grandiosity 3 (10.3) 2 (3.7) 1.47 NS .33 [.05-2.12] 
Pressured communication 6 (20.7) 16 (29.6) .77 NS 1.61 [.55-4.7] 
Purposeless hyperactivity 5 (17.2) 15 (27.8) 1.15 NS 1.85 [.60-5.73] 
Reduced need for sleep 2 (6.9) 3 (5.6) .06 NS .79 [.13-5.05] 
Defiant/antisocial behavior  21 (72.4) 31 (57.4) 1.82 NS .51 [.19-1.36] 
Disorganization 12 (41.4) 13 (24.1) 2.68  NS .45 [.17-1.18] 
Manipulation/exploitation 11 (37.9) 16 (29.6) .59 NS .69 [.27-1.78] 
Hyper-social behavior 3 (10.3) 6 (11.1) 1.08 NS 1.08 [.25-4.69] 
Relative total score 
(hypo)manic features during 
MDE, Mean (SD) 
.23 (.15) .20 (.19) 2.10 NS  
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were reported in the 29.5% of the cases, whereas (hypo)mania with mixed features had been experienced by 
the 21.7% of the sample. The rates of rapid cycling increased to about 30% in  BD clinically diagnosed patients.  
Table 23 summarizes the comparisons regarding clinical and course features of the affective illness in different 
types of BD. Soft bipolar diagnoses included BD II and BD otherwise specified. The two groups showed 
similar distributions of gender, age and BMI scores. The presence of psychotic features emerged as 
significantly different between the two groups, not only during the excitatory phases (by definition), but also 
during the depressive ones (47.1% vs. 2.8%). BD type I was also associated to higher rates of dysphoria, 
characterizing the (hypo)manic episodes almost invariably (97.1%), and higher rates of seasonal pattern for 
the depressive phases (41.2% vs. 22.2%). No differences were detected regarding the prevalence rates of MDE 
with mixed features, while (hypo)mania with mixed features was more prevalent in soft BDs (30.6% in BD I 
vs. 58.8% in soft BDs). The results were all replicated using the clinical diagnoses of BD instead of SPAIDD-
M diagnoses.  
 
 
Table 23. Clinical features and course of Bipolar Disorders in individuals with intellectual disability: 
comparisons between Bipolar Disorder type I and soft bipolar spectrum disorders according to 
SPAIDD-M definition* 
* The analyses repeated according to the final clinical diagnosis of BDs resulted statistically significant the same, with the exception 
of mixed features during (hypo)mania, GMC/drug-related MDE, and seasonal pattern of MDE 
  
 
Clinical features BD I 
N=36 
Soft BD 
N=34 
χ² or F p OR [95% CI] 
Age, Mean (SD) 36.47 (15.02) 40.64 (15.07) .002 NS  
Gender, M 10 (29.4) 10 (27.8) .02 NS 1.08 [.38-3.06] 
BMI, Mean (SD) 26.41 (6.07) 27.22 (15.97) .93 NS  
Clinical features of (hypo)manic episode N (%) 
GMC/drug-related (hypo)manic 
episode 
0 (0.0) 2 (5.6) 1.94 NS  
Catatonic features 1 (2.9) 0 (0.0) 1.07 NS  
Psychotic features 19 (55.9) 0 (0.0) 27.61 <.001  
Seasonal pattern 9 (26.5) 6 (16.7) 1.00 NS 1.80 [.56-5.75] 
Rapid cycling 10 (29.4) 6 (16.7) 1.61 NS 2.08 [.66-6.55] 
Mixed features 11 (30.6) 20 (58.8) 5.66 .017 3.25 [1.21-8.70] 
Euphoric (hypo)mania 23 (67.6) 18 (50.0) 2.24 NS 2.09 [.79-5.52] 
Dysphoric (hypo)mania 33 (97.1) 13 (36.1) 28.83 <.001 58.39 [7.13-477.96] 
Clinical features of MDE N (%) 
GMC/drug-related MDE 3 (8.8) 2 (51.4) .28 NS 1.65 [.26-10.51] 
Catatonic features 4 (11.8) 2 (5.6) .86 NS 2.27 [.39-13.27] 
Psychotic features 16 (47.1) 1 (2.8) 18.65 <.001 31.11 [3.82-253.74] 
Seasonal pattern 14 (41.2) 6 (16.7) 5.15 .023 3.50 [1.15-10.63] 
Mixed features 11 (32.4) 8 (22.2) .91 NS 1.67 [.58-4.85] 
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The comparisons of rates of non-overlapping mixed symptoms and behavioral equivalents during (hypo)mania 
were made.  Table 24 reports those mixed symptoms whose χ² statistics resulted statistically significant or 
near the significance. (Hypo)manic mixed states in BDI seemed to be associated more frequently than soft 
BDs to insomnia (p=.075), reduced participation to usually appreciated activities (p=.001), self-injurious 
behavior (p=.066), avoidance of social situations or specific stimuli and persons (p=.016), affective flattening 
(p=.068), anxiety symptoms (p=.001) and reduced social responsiveness (p=.081). The same comparisons 
according to the clinical diagnosis evidenced that insomnia, affective flattening, self-injury and reduced social 
interactions did not result significant anymore.   
 
 
Table 24: Mixed features during (hypo)mania: comparisons between Bipolar Disorder type I and soft 
bipolar spectrum disorders according to SPAIDD-M definition* 
* The analyses repeated according to the final clinical diagnosis of BDs resulted statistically significant the same, with 
the exception of: insomnia, self-injury, affective flattening, and reduced social interaction.  
**The comparisons relative to the following depressive symptoms and equivalents appearing during mania are not 
reported as far as not significant differences were detected: depressed mood, reduced pleasure and interest, weight gain, 
hypersomnia, psychomotor retardation, reduced energy and fatigue, guilt feelings, easiness to cry, altered appetite, 
somatizations, indecisiveness and doubt, abstractive thinking decline, memory issues, reduced drive to leave home, 
pica, apathy.  
 
 
 
 
 
 
 
 
 
 
 
Clinical features 
N (%) 
BD I 
N=36 
Soft BD 
N=34 
χ² p OR [95% CI] 
Non-overlapping SPAIDD-M behavioral equivalents of depressive equivalents during (hypo)mania*  
Insomnia 12 (35.3) 6 (16.7) 3.18 NS (.075) 2.73 [.89-8.39] 
Reduced participation 18 (52.9) 6 (16.7) 10.21 .001 5.63 [1.86-16.99] 
Self-injury 11 (32.4) 5 (13.9) 3.38 NS (.066) 2.97 [.91-9.72] 
Avoidant behavior 9 (26.5) 2 (5.6) 5.78 .016 6.12 [1.22-30.83] 
Affective flattening 3 (8.8) 0 (0.0) 3.32 NS (.068)  
Anxiety 22 (64.7) 9 (25.0) 11.17 .001 5.50 [1.96-15.43] 
Reduced social interactions  8 (23.4) 3 (8.3) 3.05 NS (.081) 3.39 [.82-14.04] 
Relative total score depressive 
features during (hypo)mania, 
Mean (SD) 
.19 (.13) .07 (.11) 2.46 <.001  
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CHAPTER 4 
 
4. DISCUSSION 
4.1 Characteristics of the sample 
The primary aim of the present study was to evaluate the psychometric properties of the SPAIDD-M, a tool 
for the diagnosis of depressive and bipolar disorders in persons with ID and LF-ASD, based on adaptation of 
DSM-5 diagnostic criteria. To this purpose, 233 persons with ID of different severity level were randomly or 
consecutively recruited to undergo an assessment protocol including the SPAIDD-M. As shown in Tables 2, 
3, 4, and 5, participants were grouped according to the following three ID levels, 1. BIF and mild ID; 2. 
moderate ID; 3. severe and profound ID, in order to facilitate the check of sample homogeneity for socio-
demographic, physiological, familial, medical and psychiatric background characteristics. . All the among-
groups comparisons demonstrated high homogeneity of the sample. The distributions of gender, age and BMI 
were similar across the groups as well as the main socio-economic features. As expected, BIF/mild ID 
individuals showed higher social adjustment, educational level, and occupational experiences. They also 
included a higher number of offenders, even if to a lesser extent in comparison to most of rates in the literature 
(Lindsay et al., 2013). Regarding the personal physiological anamnesis,  the group with severe/profound ID 
showed higher rates of abnormalities in the first physiological acts after birth and delay in psychomotor, 
locomotion and language development as well as higher rates of sensory impairments, motor disabilities, 
epilepsy and gastrointestinal disturbances, which are comparable to those reported in previous studies (Kwok 
and Cheung, 2007). It has to be noted that immunity-related problems, including allergies and autoimmune 
diseases, resulted significantly more common in the BIF/mild ID group. The relationship between immunity 
dysregulation, mostly at the CNS level, and the development of a variety of neurodevelopmental and 
psychiatric disorders is a field in expansion. For example, immunity-mediated processes, genetic and 
epigenetic correlates have been implicated in the etiopathogenesis of ASD (Ashwood and Van de Water, 2004). 
It is possible that, early severe events may impact the neurodevelopment at a level that macroscopic anatomical 
alterations and severe disruption of most cognitive and motor functions subside most forms of moderate to 
profound ID. By the contrary, it is possible that milder forms of cognitive impairments, frequently without the 
detection of imaging abnormalities, may have a more subtle and functional underpinning. The involvement of 
SNC and general immunity dysregulation at this level is one of the most intriguing hypotheses.    
 The sample representativeness of the population with ID and LF-ASD resulted to be quite low. In fact, the 
sample shows a preponderance of participants with moderate-to severe ID while this portion is the lowest in 
the real-world population. The sample also shows higher percentages of mental health issues and psychotropic 
medication. Nevertheless, having a sample representative of the real population with ID and LF-ASD was not 
foreseen in the study design and not relevant for the study aim, since the SPAIDD-M is addressed to persons 
with high insight and communication impairment. The study design included a random/consecutive sample as 
meant to be an unbiased representation of the population with ID/LF-ASD attending a clinical service qualified 
for psychopathological assessment. It was considered a fair way to select a sample from a larger population 
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since every member of the population with that specific assessment need has an equal chance of getting 
selected.  
A sampling bias linked to this last point refers to the sources of recruitment: half of participants with moderate-
to-profound ID were recruited in residential facilities, whereas a similar percentage of those with BIF/mild ID 
were enrolled in rehabilitative centers and clinics specialized in evaluation of mental health issues in persons 
with ID and LF-ASD. 
In the overall sample entering the study the prevalence rate of co-occurrent psychiatric disorders is 50%, 
confirmed by internal diagnostic orientation, and the use of psychotropics drugs is around the 70%, particularly 
anticonvulsants and antipsychotics (around 50% for both). It has to be noted that many patients were under 
polypharmacy, including add-on treatments with mood stabilizers, multiple antipsychotics, benzodiazepines, 
and antidepressants, which was not explained by specific diagnostic formulation, not even completed yet at 
the recruitment time. Unfortunately the association of several compounds is quite common in non-specialized 
clinical settings and can result from urgency-based management strategies, inattentive prescribing, lack of 
follow-up of medication use, , wide-spread recourse to off-label prescriptions, lack of specifically addressed 
evidence-based guidelines , and pressuring to prescription by clients, family members or staff members, who 
are often insufficiently informed or trained on advantages and risks of drugs use (Bertelli et al., 2018). 
Of course medication issues are in general strictly related to diagnostic issues, which are very frequent   in 
non-specialized contexts, especially in reference to persons with higher cognitive and communication 
impairment (Bertelli, 2015, Bertelli et al., 2015, Costello and Bouras, 2006, Matson and Russell, 1994, Moss 
et al., 2000, Reiss and Szyszko, 1983). These diagnostic issues are confirmed also by our study findings, with 
study entry overall psychiatric comorbidity being significantly higher in participants with BIF-to-moderate ID 
than in those of severe-to-profound degree (see Table 5). Indeed, after the deep appropriate assessment 
foreseen by the study protocol, these differences resulted to be no more statistically significant, with prevalence 
rates of overall psychiatric comorbidity being similar across the three groups. Diagnostic issues for study entry 
data were corroborated by results of the detailed analysis of discrepancies between entry and final diagnoses, 
which show partial or complete mismatch not only for around 40% of participants with severe/profound ID, 
but also for around 50% of those with moderate ID.       
 
4.2 Psychometric properties of SPAIDD-M 1.2 
The SPAIDD-M final version (1.2) showed a fair face validity as indicated by most of the evaluators as well 
as, indirectly, by its good psychometric properties. Reliabilities between different evaluators and across time 
resulted to be more than acceptable. The former, calculated through Cohen’s K coefficient, was never lower 
than .575, with a mean coefficient of .713, confirming that, in the complex, the error variance related to the 
attribution of the scores and the subjectivity of evaluators was poorly significant. Similarly, the stability over 
time of the attribution of the scores resulted to be very good, as shown by Pearson’s r and Kendall’s -b 
correlation coefficients being never lower than .77. 
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 Another psychometric property considered was the internal consistency of the tool. All the 65 items relative 
to symptoms and behavioral equivalents as well as chronological, clinical and course specifiers, resulted to be 
highly interrelated, as demonstrated by the high value of the Cronbach’ score (.937). The 33 items relative 
to mixed features showed a lower but equally good consistency (Cronbach’=.876). 
The criterion validity for the major depressive and (hypo)manic episodes was evaluated by two ANOVA 
analyses comparing the means of SPAIDD-M general and area scores with the clinical overall and specific 
scores, based on DSM-5 criteria. This method evidenced an excellent criterion validity for all the 9 criteria of 
the MDE defined in SPAIDD-M as well as for the total mean score. This result was replicated for the 
(hypo)manic episode for which we considered DSM-5 criteria A and B and the total mean score. We decided 
not to include mixed features in this analysis as the difficulties met by a certain number of evaluators in the 
completion of this part of the tool and the lack of previous research to reference to, challenged the full 
operationalizability of this construct. Further research on larger samples is surely needed on these common but 
neglected clinical presentations. Thus, it has to be noted that results relative to mixed features and expressed 
below have to be considered as a first explorative research attempt. 
Subsequently, we performed a factorial analysis to identify the number and type of factors explaining the 
variance of the full instrument. The first four main factors resulting from the factorial analysis explains the 
37.21% of the variance in the tool and appeared to explain the differences among items. The first factor, 
explaining alone around the 20% of the variance was characterized by almost all the items pertaining to 
(hypo)mania. Here are included not only the “full-blown” (hypo)manic symptoms and equivalents, but also a 
number of those we had considered as overlapping with depression in ID. Excluding irritability, psychomotor 
agitation and restlessness, aggressiveness, and impaired judgement, the items relative to affective lability and 
substance abuse seemed to actually belong to the excitatory dimension. As far as this analysis confirmed the 
strength of the manic construct proposed in SPAIDD-M, some hypotheses could arise. Indeed, according to 
one of the initial hypotheses that mood episodes in ID may have an atypical presentation including the 
association with behavioral problems, this factor actually includes a variety of PBs such as aggressiveness, 
substance abuse and addiction-related behaviors, hypersexual behaviors, defiant and antisocial conducts, 
manipulation and exploitation especially directed to peers, and excessive research of social interactions. Other 
symptoms and equivalents, formally pertaining to the depressive cluster, belong to this factor, specifically 
insomnia, reduced participation to activities previously appreciated and tendency to cry. Noteworthy, these 
latter items were frequently reported by evaluators as occurring during the (hypo)manic episode and they often 
characterized mixed manic phases. Considering the association to this factor to affective lability, it could be 
speculated a “multistage” link between emotional dysregulation often characterizing the basal functioning of 
persons with neurodevelopmental disorders and BDs, but also its pathoplastic effect on the presentation of the 
episode assuming a mixicity figure (Mazefsky et al., 2013, Purper-Ouakil et al., 2017, Shaw et al., 2014, 
Vannucchi et al., 2019a). 
The second factor, explaining around the 6% of the variance, account for depressed mood and reduced pleasure 
and interests: thus, it can be identified as the “depressive factor”. It also includes apathy as well as symptomatic 
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and behavioral equivalence as well as increase of indecision, rigidity and adhesion to routines, reduced 
participation and refuse of social interactions. Importantly, it also includes the item relative to catatonic 
symptoms and disorganization of language and behavior. It has to be noted that the evaluation of catatonia in 
SPAIDD-M does not include the symptoms of excited catatonia, but only a limited number of more 
characteristic signs, such as posturing and waxy flexibility.  
The third factor explains the 5% of the variance and has been identified as a “non-mood related depressive 
factor” as it includes a variety of symptoms and behaviors belonging to depression but unrelated to depressive 
mood. It is composed by symptoms and equivalents pertaining to energies and psychomotor activity 
disturbances, neurovegetative symptoms regarding appetite and sleep, cognitive and memory worsening, 
perceptual and though abnormalities. As in the case of the manic factor, here we can find grandiosity and 
disorganization which are among the mixed symptoms more frequently reported during depression in patients 
with mixed depressive episodes. It is very suggestive that the main construct of depression can be decomposed 
in two factors with almost equal weight: this finding may suggest that, at least in persons with ID, the weight 
given to the presence of depressed mood to make the diagnosis, should be reconsidered. 
Th fourth factor accounts for the 4.5% of the variance. This factor is inversely correlated to most anxiety and 
related symptoms and behavioral equivalents, and it includes excessive research for social interaction and 
impairment of memory. It is possible to interpret this factor as a secondary manic-related factor or impulsivity-
related. 
The last psychometric property we evaluated was the concurrent validity. We used two different procedures to 
make this evaluation, but it has to be considered that the lack of a fully comparable tool, validated in Italian 
language, and allowing the diagnosis and differential diagnosis of MDs in the ID population, reduced our 
opportunities to have an irreproachable validation. 
The first procedure provided the correlation of the SPAIDD-M main diagnoses (MDD, BD I; BD II and BD 
otherwise specified) with the corresponding DSM-5 based diagnoses. We excluded persistent depressive and 
cyclothymic disorders given their low rates in the sample. Other confounding factors were considered, such as 
the difficulties to clinically distinguish in this sample mild long-lasting dysthymic pictures from antipsychotic-
induced depressive-oriented mood alterations. On the other hand, in a population with a high level of basic 
emotional dysregulation the diagnosis of cyclothymia strictu senso could be questionable. The correlation 
among SPAIDD-M and DSM-5 diagnoses resulted very strong and strong for BD I and BD II (r>0.7). The 
correlation value of the MDD diagnosis was little bit lower, at the highest limit of moderate correlation range. 
This could be due to the fact that a number of persons diagnosed by SPAIDD-M as having MDD, were 
reframed as having BD otherwise specified or schizoaffective disorder, depressive type. The diagnosis of BD 
otherwise specified was that with the lowest correlation value, anyway considered a moderate correlation.  
The second procedure, carried out to check the concurrent validity of the SPAIDD-M, involved the correlation 
of SPAIDD-M diagnoses of depressive and (hypo)manic episodes with the DASH-II subscales for depression 
and mania, respectively. Although Pearson’s and Spearman’s coefficients resulted to be both statistically 
significant, the Spearman’s one was higher. In the interpretation of these latter results, it has to be kept in mind 
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that whereas SPAIDD-M provides a lifetime evaluation, DASH-II is aimed to evaluate a brief period before 
the assessment. Moreover, the DASH-II is mostly addressed to lower levels of ID: as a consequence, the 
behaviors and symptoms investigated in the DASH-II items are very sensitive and specific for this 
subpopulation, but they could not be considered fully appropriate to investigate psychopathology higher 
functioning subjects. In this perspective and as demonstrated above, SPAIDD-M can give reliable results 
independently from the severity of ID. By the contrary, DASH-II has the advantage it can be easily used as a 
follow-up measure and it gives estimation of the severity and impact on adaptation of the symptoms and 
behaviors. 
 
4.3 Mood Disorders in persons with intellectual disability and low-functioning autism spectrum disorder. 
The prevalence rate of the final clinical diagnosis of overall MDs in our sample was 44.2%. This rate is much 
higher comparing to the rates around 5% for DDs and 2.5% for BDs found in the literature relative to large ID 
population-based studies (Cooper et al., 2007a, Deb et al., 2001a). A recent metanalysis about the prevalence 
of co-occurring mental health diagnoses in the autism population and including one hundred studies reported 
prevalence rates for DDs and BDs of 11% and 5%, respectively (Lai et al., 2019). Nonetheless, this rate can 
be considered aligned to the results of studies performed in clinical settings (Charlot et al., 2007a). In our 
sample, the clinical diagnosis of MDs was not associated to differences in main demographic features. Most 
differences were identified regarding familial and personal psychiatric comorbidity. In fact, MDs were 
associated to higher rates of overall psychiatric comorbidities in family members. Although the rates for 
individual psychiatric categories in relatives were all higher in the MDs group comparing to the group without 
MD, none reached the statistical significance. For example, the OR for familial DDs was 2.24. Familial BDs 
(not reported in Table 10) rated 22.7% in MDs participants, about doubled comparing to the 11.3% of the 
comparison group. These data are in agreement with the current literature regarding the general population as 
well as ASD (Bolton et al., 1998, DeLong, 1994, DeLong, 2004, Piven and Palmer, 1999, Song et al., 2015, 
Vandeleur et al., 2014), whereas systematic data regarding the familial psychiatric load in individuals with ID 
are substantially lacking. It is possible that the high prevalence of MDs in the sample as well as the high 
morbidity of the comparison non-MDs group may have contributed to the non-achievement of the statistical 
significance.  
According to the literature regarding the general population, MDs probands in our sample showed prevalence 
rates of co-occurring psychiatric disorders higher than no-MDs individuals, with an OR=2.58 (p=.011). MDs 
in this population seemed to be associated to ADHD, OCD, ODD, substance abuse disorders and BED. This 
pattern of comorbidities is well-known in average IQ children (Masi et al., 2006a, Donfrancesco et al., 2011, 
Masi et al., 2006b, Hazell, 2010, Sonneville et al., 2015), but also in adults, at least for BED and addiction 
(Maremmani et al., 2006, Vannucchi et al., 2014b). This result stresses the concept of how actual 
developmental and emotional levels may have a pathoplastic effect on the expression of PDs in adults, whose 
clinical picture and management complexities may resemble those found in children more than the pathways 
typical of their average IQ peers (Bertelli, 2015, Bouras and Drummond, 1992). The higher load of further 
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psychopathology related to the co-occurrence of MDs in ID was also confirmed by the higher mean raw scores 
of almost all the DASH-II psychopathological dimensions. The prevalence of personality disorders and 
specifically those of the cluster C was also higher in individuals with MDs. No data are available in ID and 
LF-ASD population to compare our data accounting for the co-occurrence of MDs. Moreover, it has to be 
considered that the construct of personality disorders is extensively criticized by most researchers and 
clinicians depending on the idea that the full structuration of personality requires a complete emotional 
development. Thus, it could be more correct, as for young adolescents, to cautiously speak about personality 
traits and organization. Further specific studies would be needed to address the large overlapping areas between 
true pathological personality traits and the “normal” rigidity and neurovegetative over-reactivity as well as 
tendency to isolation characterizing persons with ID and LF-ASD. Nonetheless, both of the groups should 
have suffered for these limitations and it is interesting that MDs would be associated to basic anxiety and 
anankastic traits in such a population. 
As expected, MDs were associated to much higher load of psychotropic drugs: the presence of any MD leads 
to a 9-fold increase of the probability to assume psychotropics of all psychopharmacological classes. By the 
contrary, no significant differences emerged regarding the side effects of medications between the two groups, 
although MDs subjects had a 4-fold higher risk to develop psychiatric adverse effects under antidepressant 
treatment. This is not surprising considering the high prevalence of BDs in our sample. By the contrary, that 
these results did not achieve the statistical significance could be attribute to the fact that all the use of 
psychotropics was widespread in the overall sample, independently from the diagnosis, and ID individuals are 
known to be more vulnerable than the general population to side effects (Bertelli et al., 2018).  
When examining the clinical features of MDs in ASD subjects of our sample, comparing to the non-ASD 
subjects, we found ASD to be associated to higher prevalence of overall MD diagnoses and specifically BD I. 
ASD was also associated to mixed features of both MDE and (hypo)manic episodes, dysphoric mania, 
catatonia, seasonal pattern and rapid cycling course (Lai et al., 2011, Lainhart and Folstein, 1994, Vannucchi 
et al., 2019b). As regards the response to psychotropics, the ASD diagnosis was significantly associated to the 
development of affective flattening and depressed mood. This is a very important aspect as far as it may 
contribute to the misdiagnosis of BD forms in ASD as SSDs (Skeppar et al., 2013). Although our data are not 
sufficient to state ASD to be an additional risk factor for the development of MDs at all, it can be hypothesized 
the association of ASD with a bipolar diathesis. The phenotype of BD in ASD was characterized by higher 
severity indices including the prevalence of type I forms, mixed states and rapid cycling. It is possible that the 
severe emotional dysregulation characterizing most of the ASD patients at high risk to develop MDs may 
mediate this peculiar and complex pattern of affective manifestations (Joshi et al., 2018). 
 
4.4 Depressive and Bipolar Disorders in Intellectual Disability and Low-Functioning Autism Spectrum 
Disorder 
In our overall sample, as for the general psychiatric comorbidity, the prevalence rates of MDs and specific 
DDs and BDs diagnoses according to the SPAIDD-M assessment did not differ across the three ID groups. 
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This is important as it confirmed the suggestions of some researchers that even lower functioning ID persons 
may suffer for the complete span of affective disorders (Cooper et al., 2018, Fletcher et al., 2016, Hurley, 2006, 
Sovner and Hurley, 1983). The repetition of the comparative analyses on the subsample regarding those 
participants who had completed the full study protocol, and considering different definitions of DDs and BDs 
(SPAIDD-M, adapted DSM-5 criteria, and clinical procedure) confirmed this finding. The comparison of the 
prevalence rates per specific MD diagnosis evidenced a diagnostic trend across the different diagnostic 
procedure. As expected, we found the higher rates with SPAIDD-M assessment: indeed, as far as it equates 
typical affective symptoms to behavioral equivalents and although a rigidly DSM-5 based structure, it resulted 
highly sensitive and also inclusive of very atypical syndromic presentations. It can be questionable that such a 
sensitivity could lead to over-inclusiveness. Differently from what suggested by previous research, we found 
higher rates via the application of DSM criteria than with the clinical diagnostic procedure (Cooper et al., 
2018). This discrepancy with the literature could be justified by the fact that, given the main purpose of the 
study to cross-validate SPAIDD-M with DSM-5 criteria, as explained in the method section, the application 
of DSM-5 criteria extensively took into account the adaptations and examples of DM-ID-2 (Fletcher et al., 
2016). It seems plausible that this enlargement may have improved the diagnostic sensitivity. The rates resulted 
from the clinical diagnostic procedure were highly superimposable to those of both SPAIDD-M and DSM-5, 
rather for DDs. It has been already suggested that a considerable number of those participants with a SPAIDD-
M assessment positive for DDs had been reframed as has schizoaffective or cluster A personality disorders. 
Moreover, given the large use of antipsychotics in our sample, it resulted very hard to differentiate a primary 
DD from syndromic pictures secondary to use of such medications. The reduced potential for differential 
diagnosis with the above-mentioned conditions, represents one of the major limitations of the current version 
of SPAIDD-M. However, it has to be considered that the SPAIDD-package tools are thought to be used 
“surgically” in combination one each other, just in order to overcome these diagnostic issues.  
Multiple statistical analyses were made on the subsample of the 110 participants diagnosed as having MDs 
with the SPAIDD-M, with the aim to identify differential clinical profiles of DDs and BDs. Depressive and 
bipolar patients did not result different regarding socio-demographic and most physiological variables. Even 
the medical comorbidities had similar rates between the two groups, rather obesity, significantly associated to 
BDs. This result might be the resultant of multiple factors interacting one each other: in fact, the BDs diagnosis 
was associated to the co-occurrence of BED and larger use of antipsychotic medications. Although the 
comparison of antipsychotic-induced weight gain and metabolic side effects did not achieve the statistical 
significance, BDs subjects appeared at higher risk than DDs. BDs were associated to higher prevalence of 
overall mental health disorders among in relatives, specifically and according to the expectations of BD and 
personality disorders, but also psychotic and eating disorders although the statistical significance was not 
reached. Coherently with the comorbidity profiles of different MDs in the general population, we found DDs 
to be associated to comorbid anxiety disorders (Charlot et al., 2007b, Fletcher et al., 2016, Hurley et al., 2003, 
Marston et al., 1997), mostly GAD, whereas BD presented a complex pattern of comorbidities including 
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ADHD, eating disorders, impulse control disorders and dysfunctional personality organizations (Hazell, 2010, 
Masi et al., 2006b, Mavromatis, 2000, Sonneville et al., 2015).  
As mentioned above, it seems to exist a relationship between affective disorders, eating dyscontrol and ADHD. 
In our study this relationship seems to be mainly related to a bipolar diathesis as far as demonstrated by the 
regression model (see Table 18), indicating that the belonging to the SPAIDD-M defined BDs group was 
predicted by the co-occurrence of BED and ADHD as well as the higher familial load for mental health issues. 
By the contrary, the co-occurrence of GAD predicted the diagnosis of DDs. When considering the clinical 
diagnosis of MDs rather than the SPAIDD-M assessment, the diagnosis of BD was predicted by ADHD and 
family history for psychiatric disorders, whereas DDs were predicted by GAD and the presence of family 
members with ASD (see Table 19). It can be cautiously speculated that there would be a continuity among 
different neurodevelopmental disorders and that the co-occurrence of psychiatric disorders should be 
interpreted through a neurodevelopmental perspective: differential pathways of central nervous system 
development, through differences in prevailing cognitive, executive and subcortical dysfunctions, may carry 
out a significant pathoplastic effect subsiding differential clinical, psychiatric and behavioral phenotypes in 
adults with ID. Familial predisposition, thus differential genetic underpinnings, may have a weight in 
determining both the developmental pathways as well as the comorbidity patterns of neurodevelopmental and 
psychiatric disorders. In this perspective, the affective dimension and MDs diagnoses should be better 
explained as a continuum rather than separated entities. This hypothesis might be cautiously confirmed by the 
evidence in our study that DDs and BDs did not show significant differences in most clinical illness-related 
variables considered in this sample. For example, no differences emerged in the clinical and course specifiers 
of the MDE between the two diagnostic groups.  
Noteworthy, DDs and BDs were not associated to differences in the prevalence of mixed depressive episodes 
and the type of counterpolar symptoms. Indeed, mixicity was very common in both the diagnostic groups, far 
higher than the rates reported in the general population (Vieta and Valenti, 2013). Even considering that mixed 
features are poorly operationalized in the ID population and the results of our study have absolutely to be 
considered inconclusive concerning this point, some considerations can be made. On one hand, our results 
gave a confirmation to the widespread impression of clinicians and experts that mood episodes in ID, as well 
as in other neurodevelopmental disorders, actually have more frequently mixed clinical presentations 
(Felstrom et al., 2005, Reid and Naylor, 1976, Ruedrich, 1993). This unrecognized aspect may lead to over-
representation or accentuation of aggressiveness, self-injury, impulsivity and oppositional-defiance during 
major affective episodes, particularly depression: this might be a potential source of misdiagnosis and it may 
be related to inconsistent psychopharmacological strategies. On the other hand, our result challenges the 
concept of “mixed features specifier” as conceived in DSM-5: at least in the ID population with MDs, mixed 
features seem to represent a core feature of the illness more than a mere specifier, and in highly unstable 
patients it could appear artificial and hard the distinction between opposite polarity episodes as far as in most 
cases depression and excitement are present at the same in time with various intensity or rapidly alternating. 
A result further supporting this hypothesis was derived by the comparisons of clinical and course features of 
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BD I with soft bipolar spectrum disorders. No clinical and course differences were identified, rather for 
psychotic symptoms to be associated by definition to BD I. However, the analysis regarding the type of 
depressive and mixed equivalents present during the manic episode comparing to hypomania (see Table 24), 
revealed that anxiety symptoms, self-injury, reduced interests and participation to activities, and social 
withdrawal were more common during mania. This result could suggest the validity of the constructs of the 
full-blown mixed episode and affective illness characterized by mixed episodes as a specific phenotype of MD, 
as they were conceived in the classical literature (Kraepelin, 1896, Weygandt, 1899). In the continuity 
hypothesis mixicity could also be considered a severity index. Certainly, these are speculations based on a 
pioneer and inconclusive work; further research on larger samples are needed to explore in depth this topic.  
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CHAPTER 5 
 
LIMITATIONS OF THE STUDY 
Several limitations have to be taken into account in the interpretation of the present study and concerns regard 
both the main and the secondary objectives. 
The method employed for the validation of SPAIDD-M, particularly the procedure relative to test the 
concurrent validity, suffered for the lack of a full comparable tool validated in Italian language. Thus, definite 
conclusions about its sensitivity and specificity could not be drawn. Moreover, both the application of adapted 
DSM-5 criteria for DDs and BDs and the clinical diagnoses have not followed a blinding procedure and this 
represents an important methodological weakness. On the other hand, the administration of the study protocol 
and the final diagnostic conclusion have been relied on fully trained psychiatrists with a specific expertise in 
the ID field. Considering the literature evidencing the great difficulties of the psychiatric diagnostic process in 
persons with ID, mostly those with greater cognitive and communication impairments, this can be considered 
at some extent a strength.  
Another possible reason of debate could be represented by concept of behavioral equivalence itself and its 
relationship with psychiatric syndromes, observed behaviors and problem behaviors. In chapter 1 the concerns 
at this regard have been extensively discussed, but here it is necessary to mention that it could be arguable a 
large related selection bias. Indeed, the study was mainly aimed to validate a diagnostic tool, thus we tried to 
recruit a sample including proportional numbers of subjects with low and high risk to be diagnosed as having 
a MD. Nonetheless, it could be argued that such a recruitment procedure selected those individuals who were 
already known to have complex behavioral disturbances and to experience mental health issues, as confirmed 
by the data. The resulting demonstration that behavioral equivalents are a reliable mean to diagnose psychiatric 
disorders in persons with ID, mostly those with lower functioning, would be argued to be tautological. 
However, it has to be noted that at the beginning of the study only the 28% of the participants with severe to 
profound ID had received a psychiatric diagnosis and only for this subgroup the rate was doubled at the end of 
the study achieving a prevalence level similar to those reported for the other ID groups. This observation, 
together with the parallel use of adapted DSM-5 criteria and the fact that behavioral equivalents were 
accurately clustered with other types of “more classical” affective-related symptoms to describe complex 
syndromic entities, partially overcome this concern.  
A related issue would be that the appearance of behavioal problems might be related to stressful events, thus 
it could be difficult in some cases to qualify a behavior as reactive or actually related to a psychiatric condition. 
Actually, the study did not provide the environmental assessment and behavioral analysis usually performed 
to settle such an issue in clinical practice. Though, the lifetime design of the tool and the evidence that no 
differences were detected between participants with and without MDs regarding a variety of social, 
relationship, educational, and economic information collected, suggest that this issue would be considered 
negligible. 
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If anything, the possible selection bias conditioned by the main purpose of the study, as well as the referral 
bias related to the recruitment settings, affected the generalizability of the data to the overall ID and LF-ASD 
population. The prevalence rates of DDs and BDs, as well as comorbid psychiatric disorders, are related to a 
clinical population of persons attending specific clinical and rehabilitative services or living in residencies 
addressed to meet the complex needs of more severely impaired ID subjects. This is an indirect severity index 
mostly for BIF and mild ID individuals. Unfortunately, an attempt to extend the recruitment to different 
settings was made via the involvement of multiple partners across the Italian country (e.g. associations of 
families), but the adhesions resulted very sparse; by the contrary, both the clinicians and the proxies of 
intellectually disabled persons with mental health or behavioral issues were highly motivated to participate in 
order to receive a diagnostic refinement.  
Even an informant bias has to be kept in mind, shared by any assessing tool using proxies to collect 
information. The informant bias would not probably influence the rates of disorders: indeed, the bias was 
bidirectional as some proxy tend to exaggerate the relevance, severity or duration of symptoms and behaviors 
explored by the tool, while others may show an opposite tendency toward minimization or may have 
difficulties in remembering or making chronological positioning of the symptoms. 
One of the major weakness of the SPAIDD-M, already discussed along the manuscript, was represented by it 
does not provide the possibility to definitely make a differential diagnosis between primary affective disorders, 
schizophrenia spectrum disorders and some iatrogenic clinical pictures including affective manifestations 
related to side effects of psychotropics, mainly antipsychotics. More specifically, the tool resulted positive for 
depression and mania in many cases we subsequently clinically diagnosed as schizophrenia and schizoaffective 
disorder. Contrary to the expectations, major issue did not arise with the differential diagnosis between SSDs 
mainly characterized by positive symptoms and BD I, but mostly between clinical pictures with prevailing 
negative symptoms and mild long-lasting forms of DDs. Similarly, DDs were poorly distinguished from those 
iatrogenic clinical pictures related to the side effects of long-duration antipsychotic treatments. However, the 
latter aspect would not be completely attributable to some weaknesses of the instrument, but perhaps to the 
poor awareness of most clinicians about the full range of such side-effects and their behavioral correlates or 
the difficulties in obtaining such a complex information by proxies.  
Given all the discussed limitations, our study has some important strengths. The numerosity of the sample was 
adequate to evaluate the psychometric properties of the tool, even if the optimal number to achieve the goal of 
full validation would have been 300 participants. The dimension of our sample, in comparisons with clinical 
samples usually utilized in this field, appeared far acceptable to draw indications regarding the main features 
and associated characteristics of MDs in adults with ID and LF-ASD. The diagnostic methodology including 
the comparative use of adapted DSM-5 criteria and another specifically addressed tool, the DASH-II, made 
the results sufficiently robust.    
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CHAPTER 6 
 
CONCLUSIONS 
The present study was aimed to validate a new tool for the diagnosis of depressive and bipolar disorders in 
adults with ID and LF-ASD, the SPAIDD-M. The tool was based on the criteria provided by the current 
classifications of mental disorders (DSM-5), but the formulation of the items and descriptions of clinical 
features were integrated with adaptations for persons with ID taken from DM-ID-2 and DC-LD as well as with 
the results of a systematic mapping of the literature regarding the peculiar and atypical manifestations of mood 
disorders in this population. The tool was a dichotomous-answer questionnaire to be administered to proxies 
or care givers. It was based on indication of behavioral changes (in quantity or quality) from the baseline and 
other observable symptoms across time with a significant impact on personal functioning. The theoretical 
frame was represented by the concept of behavioral equivalents, particularly useful for the psychiatric 
diagnosis in those persons with lower cognitive abilities and severe language and communication impairments. 
SPAIDD-M, 1.2 version, beyond the good psychometric properties, demonstrated to fairly describe depressive 
and bipolar disorders in intellectually disabled individuals, and to discriminate different affective disorders 
from each other, independently from the ID level. Indeed, when comparing the prevalence rates between 
different ID levels, we found similar percentages across the ID range, which supports the hypothesis that ID 
persons may suffer from the whole span of mood disorders. Findings of previous studies showing lower 
prevalence rates in persons with ID compared to the general population, especially in moderate-to-profound 
ID degree, would be explained through methodological issues and assessment procedures. Moreover, the 
factorial analysis of SPAIDD-M 1.2 items indicated that behavioral equivalents clustered with other observable 
symptoms, describing coherently two manic and two depressive dimensions. Thus, our results support the use 
of behavioral equivalence as an effective integration to the psychiatric diagnostic process. 
In our sample the prevalence rates of DDs and BDs resulted to be much higher than in the general population 
with ID and LF-ASD, this could be attributed to the peculiarities of the study design and results cannot be 
extended to the all ID population. By the contrary, our sample allowed to delineate demographic, anamnestic, 
familial and clinical variables associated to MDs. We found MDs to be associated to higher family history of 
all psychiatric disorders, particularly of MDs. In line with literature on the general population, we found MDs 
in people with ID to be significantly associated to a variety of psychiatric comorbidities. The comorbidity 
patterns are quite similar to those found in children average IQ and in young adolescents with MDs more than 
in adults, confirming that the developmental level may significantly impact on the presentation and trajectory 
of co-occurring mental health issues. We found ADHD, impulse control and binge eating to be associated to 
bipolar presentations, whereas anxiety disorders were more commonly associated to depressive ones. LF-ASD 
was associated to higher rates of all MDs, especially BD I, and to symptomatic peculiarities, such as catatonic 
and mixed features. In a perspective of neurodevelopmental vulnerability, persons with LF-ASD with high 
baseline levels of emotional dysregulation may be regarded as the persons within the autism spectrum with 
highest risk to develop severe bipolar illness.  
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We found few differences of clinical and course phenotypization between DDs and BDs, although the small 
sample size, which is probably insufficient to draw definite conclusions on this point. DDs and BDs resulted 
to be both characterized by high rates of catatonia, psychotic features and seasonal pattern. Moreover, around 
23% of BD patients showed a rapid cycling course of the illness. All these features, which represent clinical 
specifiers, may be interpreted as indices of severity, although there are other probable explanations, such as a 
pathoplastic effect of the basal neurodevelopmental condition on the expression of co-occurring disorders. As 
far as our knowledge, this is the first study attempting the operationalization of mixed features in the 
presentations of MDs in adults with ID and LF-ASD. In both DDs and BDs mixed features are much more 
common in ID (up to around 50%) than in the general population, and the construct of the full-blown mixed 
episode could depict a high number of clinical pictures than the current DSM categories. This prominence of 
mixed features in adults with ID and LF-ASD could be interpreted as a result of a complex mood vulnerability 
linked to the neurodevelopmental alterations and can offer a base for future studies on the utility of a separated 
model of MDs in respect to a unified one.    
Further research with larger samples is needed to identify the actual prevalence and to better delineate specific 
features of MDs in the general population with ID and LF-ASD.  
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